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Abstract 
 
Smchd1 (Structural Maintenance of Chromosomes Hinge Domain containing 1), a 
previously uncharacterised gene, was identified during an N-ethyl-nitrosourea (ENU) 
mutagenesis screen in mice, which was designed to identify modifiers of epigenetic 
reprogramming. The mutant allele of Smchd1 is named MommeD1 (Modifier of murine 
metastable epialleles, D1) and results in significantly reduced Smchd1 transcript levels, due 
to nonsense mediated mRNA decay. Accumulating studies have revealed that Smchd1 plays 
a critical role in X inactivation, as well as regulating a subset of clustered autosomal genes 
which are subject to monoallelic expression (e.g. imprinted genes and the clustered 
protocadherin genes). Loss of SMCHD1 function is also implicated in Facioscapulohumeral 
Muscular Dystrophy Type 2 (FSHD2) in humans. 
 
The clustered protocadherin (Pcdh) genes are expressed in a random combinatorial 
monoallelic manner and encode cell surface adhesion proteins. The enormous diversity of 
the protocadherins extracellular domain, which is displayed on the surface of neurons is 
sufficient to confer each with an individual identity. It has been proposed that this individual 
identity is critical for forming the cellular connections and interactions necessary to develop 
complex neuronal networks. Several studies have suggested that the clustered Pcdh genes 
may play a critical role in autism and schizophrenia. 
 
In this project, neural stem cells (NSCs) were used to perform qRT-PCR in bulk cells and at 
the single cell level to analyse expression of the clustered Pcdh genes, as well as conducting 
Transcriptome-seq and MBD-seq (methyl-CpG binding domain (MBD)). Results showed 
that the expression of most clustered Pcdha and Pcdhb isoforms were up-regulated in 
iii | P a g e  
 
Smchd1MommeD1/MommeD1 NSCs, and at the individual cell level, more Smchd1MommeD1/MommeD1 
NSCs expressed more individual Pcdha and b isoforms per cell than was found in Smchd1+/+ 
NSCs.  
 
Attempts were made to isolate single Purkinje cells from the cerebella of Smchd1+/+ and 
Smchd1MommeD1/MommeD1 male mice, and analyse the expression of clustered Pcdh genes by 
single cell qRT-PCR. Unfortunately, the methods used to isolate single Purkinje cells 
required further optimisation and no definitive results were obtained from this analysis to 
date. However, the analysis of dendritic morphology of Purkinje cells was successful, which 
showed a “loss of self-avoidance” in the dendrites of Smchd1MommeD1/MommeD1 compared to 
Smchd1+/+ Purkinje cells.  
 
The restricted expression pattern of PCDHA isoforms was not altered to any great extent 
after knockdown or knockout of SMCHD1 (in combination with the loss of some DNA 
methylation) in human neuroblastoma cell lines SK-N-SH and SH-SH5Y. This finding 
indicates that once the pattern of PCDHA isoform expression has been chosen and 
epigenetically stabilised in the presence of SMCHD1, the subsequent loss of SMCHD1 is not 
sufficient to totally disrupt the pattern, even in combination with the loss of DNA 
methylation. 
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Chapter 1 Introduction 
 
Smchd1, a previously uncharacterised gene, was identified during an ENU mutagenesis 
screen in mice that was designed to identify modifiers of epigenetic reprogramming (Blewitt 
et al., 2005). Smchd1 is an epigenetic modifier of position effect variegation in mammals. 
The mutant allele of Smchd1 identified in the screen was named MommeD1. Female mouse 
embryos homozygous for the Smchd1MommeD1 mutant allele (i.e. Smchd1MommeD1/MommeD1) 
displayed lethality during mid-gestation development (at approximately E9.5-E11.5), but 
homozygous mutant male mice often survived to adulthood on the FVB/n background. This 
suggested that Smchd1 could be involved in X chromosome inactivation (XCI) and 
subsequent studies demonstrated that the Smchd1 protein, which was concentrated on the 
inactive X chromosome (Xi), was critical for the DNA methylation of Xi CpG islands (CGI) 
and for the long-term silencing of most Xi genes (Blewitt et al., 2008, Gendrel et al., 2013, 
Mould et al., 2013). This critical requirement during XCI explained the female 
Smchd1MommeD1/MommeD1 specific embryo lethality.  
 
While Smchd1MommeD1/MommeD1 males on a FVB/n background could survive to adulthood, 
backcrossing the mutant allele onto the C57Bl/6J background revealed that the male 
homozygous mutant mice displayed perinatal lethality. This suggested that Smchd1 had a 
wider conserved function affecting the expression of autosomal loci, rather than functioning 
only during XCI. Subsequent studies (Gendrel et al., 2013, Mould et al., 2013, Chen et al., 
2015) demonstrated that Smchd1 was involved in regulating autosomal gene expression, in 
particular with clustered genes subject to monoallelic expression (e.g. imprinted genes and 
the clustered protocadherin (Pcdh) genes), but possibly also with gene clusters not reported to 
be monoallelically expressed (e.g. the Hox gene clusters).  
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The clustered Pcdh genes encode a family of cell surface localised proteins that are expressed 
in a random combinatorial monoallelic manner generating enormous diversity on the surface 
of individual neurons (Kaneko et al., 2006, Hirano et al., 2012). It has been proposed that 
protocadherin diversity may be critical for determining cellular identity, connection and 
interaction, and that it may contribute to the formation of complex neuronal networks 
(Yoshimura and Callaway, 2005, Perin et al., 2011, Ohtsuki et al., 2012). Several studies 
have suggested that the clustered Pcdh genes may play roles in autism (Anitha et al., 2013), 
schizophrenia (Lachman et al., 2008, Pedrosa et al., 2008,  Schizophrenia Working Group of 
the Psychiatric Genomics Consortium, 2014) and fetal alcohol spectrum disorders (Laufer et 
al., 2015), but the molecular mechanisms which involve the clustered Pcdh gene function that 
underlies these disorders, are poorly understood.  
 
This project focused on studying the contribution of Smchd1 in the epigenetic mechanism 
that controls the random combinatorial monoallelic expression of clustered Pcdh genes. 
 
1.1 Epigenetics 
 
Epigenetics refers to “any potentially stable and, ideally, heritable change in gene expression 
or cellular phenotype that occurs without changes in Watson-Crick base-pairing of DNA” 
(quote from (Goldberg et al., 2007)). Epigenetic modifications either enhance or repress gene 
expression and, therefore, alter the phenotype of a cell, tissue or even the whole organism. In 
eukaryotes, DNA methylation and post-translational histone modifications are the two main 
types of epigenetic modification which regulate gene expression. Abnormal epigenetic 
modifications are evident in tumorigenesis (Byler et al., 2014) and some inherited disease 
syndromes (e.g. imprinting disorders) (Cooper et al., 2005, Gicquel et al., 2005).  
Chapter 1 Introduction 
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1.1.1 DNA methylation 
 
DNA methylation of the 5 position of cytosine, a heritable epigenetic mark, is catalysed by 
DNA methyltransferases (DNMTs) (Bestor et al., 1988, Yoder and Bestor, 1998, Okamato et 
al., 1998, Bestor, 2000, Cheng and Blumenthal, 2008). Normally, the cytosines that are 
methylated are followed by a guanine and termed CpG dinucleotides. In mammals, 98% of 
DNA methylation occurs in the CpG dinucleotide in somatic cells, whereas a quarter of all 
DNA methylation takes place in non-CpG dinucleotides in embryonic stem cells (ESCs) 
(Lister et al., 2009). A genomic region containing a high density of CpG dinucleotides is 
called a CGI. CGIs generally lie near the transcriptional start site of genes and play key roles 
in maintaining the transcriptional silence of the associated gene. Most CGIs are protected 
from DNA methylation unless the associated gene is epigenetically silenced (Shen et al., 
2007).  
 
There are three main types of DNMTs: DNMT1, DNMT2 and DNMT3 (Bestor et al., 1988, 
Yoder and Bestor, 1998, Okamato et al., 1998, Bestor, 2000, Cheng and Blumenthal, 2008). 
DNMT1 has weak activity as a de novo DNA methylation enzyme but prefers to methylate 
hemi-methylated DNA during the cells replication phase. It is considered a maintenance 
DNMT that is responsible for maintaining the pattern of DNA methylation from parent to 
daughter cells after DNA replication (Probst et al., 2009). Mouse models, which are deleted 
for Dnmt1, are embryonic lethal at about embryonic day 9 (E9) (Li et al., 1992, Li, 2002). 
DNMT2 has an homologous structure to that of other DNMT family members, and has weak 
de novo DNA methylation activity, but it has a higher affinity for methylating cytosine-38 in 
the anticodon loop of transfer RNA than DNA (Goll et al., 2006). Three DNMT3 isoforms 
have been identified: DNMT3a, DNMT3b and DNMT3l. DNMT3a and DNMT3b 
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preferentially methylate unmethylated CpG dinucleotides and thus, are involved in de novo 
DNA methylation during development (Okano et al., 1999). Dnmt3a knockout mice die by 
about four weeks of age, while mice lacking Dnmt3b die between E14.5 to E18.5 (Okano et 
al., 1999, Li, 2002). DNMT3l possesses a similar structure to DNMT3a and DNMT3b, and 
serves to raise the affinity between the de novo methyltransferases and S-adenosyl-L-
methionine (SAM), the donor of the methyl group (Kareta et al., 2006). This function leads to 
enhanced DNA methylation in vivo, however, DNMT3l does not have any catalytic activity 
by itself. Consequently, DNMT1 mainly acts as an enzyme for DNA methylation 
maintenance after DNA replication, while both DNMT3a and DNMT3b normally perform de 
novo DNA methylation during development. However, there is increasing evidence to 
suggest that DNMT1 is also required for de novo methylation (Egger et al., 2006), and that 
DNMT3a and DNMT3b can contribute to maintaining DNA methylation levels after DNA 
replication (Riggs and Xiong, 2004). 
 
1.1.2 Histone Modification 
 
The core component of chromatin is termed the nucleosome. It consists of a core histone 
octamer around which 146 base pairs of DNA are wound in a left-handed superhelix. The 
core histone octamer composes two each of histone H2A, H2B, H3 and H4 (Luger et al., 
1997, Delcuve et al., 2009, Davey et al., 2002). Another histone, H1, which is structurally 
different from other histones, acts as a link between nucleosomes to help form the higher 
order structure of chromatin (Brown et al., 2006). 
 
Post-translational histone modifications, particularly within the histone tail, are crucial 
epigenetic marks governing gene expression or repression (Zheng and Hayes, 2003, Delcuve 
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et al., 2009). These histone modifications consist of small chemical modifications (e.g. an 
acetyl group, a methyl group and a phosphate group) or the addition of larger peptides (e.g. 
ubiquitination and sumoylation). 
 
Acetylation of lysine located in the histone tail plays a critical role during transcription and is 
highly dynamic (Xhemalce et al., 2011). This process is mainly controlled by histone 
acetyltransferases (transferring an acetyl group) and histone deacetylases (removing an acetyl 
group) (Xhemalce et al., 2011). By adding or removing an acetyl group, the positive charge 
of the lysine can either be neutralised or restored. These alterations to the charge have a great 
impact on the interaction between histones and DNA, thus affecting DNA expression. 
 
Histone phosphorylation is also highly dynamic. It normally occurs on tyrosine, serine and 
threonine residues within in the N-terminal histone tails (Xhemalce et al., 2011). The 
modification is controlled by kinases and phosphatases, which insert or remove a phosphate, 
respectively (Oki et al., 2007). This modification changes the charge of the histone and 
impacts upon the stability of the chromatin structure. Most histone phosphorylation takes 
place in the N-terminal tails, however there are exceptions such as the H3Y41 phosphorylated 
site (Dawson et al., 2009). 
 
Histone methylation takes place either on arginine or lysine residues. At least 24 potential 
methylation sites have been found in histones (Zheng and Hayes, 2003). The degree of 
histone methylation (i.e. mono-, di- or tri-methylation) and the amino acid within the histone 
that is methylated have different effects on gene expression, including both transcriptional 
activation (Steger et al., 2008, Izzo and Schneider, 2010) and repression (Ebert et al., 2006). 
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Histone methylation had been considered a stable histone modification until several new 
potential demethylation pathways were discovered (Yamane et al., 2006, Xiang et al., 2007).  
The histone modifications mentioned above are all associated with transferring a relatively 
small chemical group to the amino acid chain. In contrast, ubiquitin is a larger covalently 
linked molecule (i.e. a 76 amino acid polypeptide). Ubiquitination is the process whereby 
ubiquitin is covalently attached to specific lysine residues within the histone through a series 
of reactions catalyzed by three enzymes (E1 activating, E2 conjugating and E3 ligating 
enzymes) (Hershko and Ciechanover, 1998). Complexes of these enzymes determine both the 
degree of ubiquitination and the substrate specificity. Two sites in H2A and H2B have been 
extensively characterised. They are H2AK119ub1, which is related to gene silencing (Wang 
et al., 2004), and H2BK123ub1, which is important for transcriptional initiation and 
elongation (Lee et al., 2007, Kim et al., 2009). The inverse process of this modification (i.e. 
removal of the ubiquitin) is catalysed by de-ubiquitinating enzymes and plays an important 
role in both activating and silencing gene expression. 
 
Sumoylation, similar to ubiquitination, is a covalently attached ubiquitin-like molecule that is 
bound to histone lysine residues (Seeler and Dejean, 2003). It has been found in histones 
H2A, H2B, H3 and H4, and is associated with repressing gene expression (Shiio and 
Eisenman, 2003, Nathan et al., 2006). 
 
1.2 Monoallelic expression 
 
In diploid eukaryotes, every individual cell contains two copies of each autosomal gene, one 
paternally inherited and the other maternally inherited. Each pair of genes are known as 
alleles and normally both alleles have an equal chance of being transcribed. However, in 
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some cases only one of the alleles is transcribed, while the other is epigenetically silenced. 
This phenomenon is termed monoallelic expression. Monoallelic expression can be divided 
into two classes. The first class is deterministic monoallelic expression, also called genomic 
imprinting, which is dependent upon the parental origin of the allele. The remaining class is 
random monoallelic expression, which can be separated into two subgroups, random XCI and 
autosomal random monoallelic expression.  
 
1.2.1 Genomic Imprinting 
 
During gametogenesis, the alleles of some genes are marked for exclusive 
expression/repression by being differentially marked on the maternally or paternally inherited 
allele. This phenomenon is called genomic imprinting (Cattanach and Kirk, 2004, Tomizawa 
and Sasaki, 2012). In humans, abnormal genomic imprinting underlies numerous 
neurological and developmental disorders (Amor and Halliday, 2008), and loss-of-imprinting 
is also commonly identified in cancer (Feinberg et al., 2006). 
 
In 1991, the first imprinted gene, insulin-like growth factor 2 (Igf2r), was identified (Barlow 
et al., 1991). This was followed by the identification of the H19-Igf2 gene pair as being 
reciprocally imprinted (Bartolomei et al., 1991, DeChiara et al., 1991). Since then, 
approximately 150 imprinted genes have been identified to date, in the mouse (Williamson et 
al., 2013). Fewer imprinted genes have been definitively identified in humans, since not all 
genes have been tested (Weksberg, 2010). Imprinted genes are often found in clusters rather 
than being uniformly distributed throughout the genome. Imprinting control regions (ICRs) 
govern the differential expression of the clustered imprinted genes. Differential DNA 
methylation and other chromatin modifications at the ICR are responsible for directing the 
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differential expression of the parental alleles in genomic imprinting. For example, an ICR is 
located between H19 and Igf2 genes. On the maternal allele, insulator CCCTC-binding factor 
(Ctcf) binds to the unmethylated ICR, which blocks the physical interaction between the 
enhancer and Igf2 promoter. This results in H19 gene expression. In contrast, on the paternal 
allele, the methylated ICR region prevents Ctcf binding, which facilitates the promoter of 
Igf2 to interact with the enhancer and leads to Igf2 expression (Hark et al., 2000).  
 
At present, all identified ICRs are also called differentially methylated regions (DMRs) 
(Radford et al., 2011). The differential methylation of the DMRs is inherited from the 
gametes (Edwards and Ferguson-Smith, 2007, Radford et al., 2011) and is essential for the 
correct expression of the imprinted genes, through the formation of higher order chromatin 
structure. Additionally, many proteins have been implicated in the parent-of-origin 
expression of imprinted genes. For example, specificity protein 1 (SP1), nuclear respiratory 
factor 1 (NRF-1), Yin-Yang1 (YY1) and methyl CpG binding protein 2 (MeCP2) are 
regulatory proteins that interact with DNaseI HS regions at the Small nuclear 
ribonucleoprotein-associated protein N (SNRPN) locus (Rodriguez-Jato et al., 2005, 
Rodriguez-Jato et al., 2013). Loss of Smchd1/SMCHD1 can also cause some imprinted genes 
within imprinted gene clusters to become biallelically expressed (e.g. certain genes within the 
Snrpn and Igf2r imprinted gene clusters) (Mould et al., 2013, Gendrel et al., 2013). 
 
Moreover, long non-coding RNA (lncRNA) is another major player that has been involved in 
regulating gene expression in well-characterised imprinted gene clusters (e.g. lncRNAs such 
as H19, IPW, Snrpn, MEG3, Kcnq1ot1, Airn, Nespas, Ube3a-ATS, IG-DMReRNAs (Kanduri, 
2015, Massah et al., 2015)). DNA methylation, chromatin structure, regulatory proteins and 
lncRNA have all been identified in the molecular mechanisms that control allelic gene 
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expression of imprinted genes, however the specific details of the interactions involved are 
still unclear.  
1.2.2 Autosomal random monoallelic expression 
 
Random monoallelic expression is different from genomic imprinting in that it is not 
determined by the parental origin of the alleles, rather the allele to be expressed is chosen at 
random during development. Random monoallelic expression of genes is often called allelic 
exclusion or stochastic expression. Well known autosomal genes subject to random 
monoallelic expression are for the most part involved in the immune (e.g. immune cell 
receptor genes) and nervous systems (e.g. olfactory genes and clustered Pcdh genes) (Chess, 
2012, Massah et al., 2015).  
 
 Monoallelic expression of the antigen receptor genes in immune cells is established as a 
consequence of variable-diversity-joining (V-D-J) recombination. V-D-J recombination 
events that result in the expression of a functional protein are preserved, while the other allele 
is rendered silent, to prevent individual cells having multiple specificities. Many epigenetic 
processes are involved in regulating the monoallelic DNA rearrangement of a single antigen 
receptor gene allele, while suppressing recombination and expression of the other. 
Asynchronous replication (i.e. replication of the two alleles at a different time point during 
the cell cycle) might be a potential early epigenetic marker (Mostoslavsky et al., 2001, 
Farago et al., 2012). Moreover, subnuclear localisation (i.e. one allele lying central within the 
nucleus and the other allele close to nuclear periphery along with heterochromatin), histone 
modifications (i.e. H3K4me3) and the level of DNA methylation in the promoter region are 
also important in the choice of which allele will be destined for monoallelic rearrangement 
and expression (Levin-Klein and Bergman, 2014).  
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The second group of genes that are stochastically and monoallelically expressed are the 
olfactory receptor (Olfr) genes (Chess et al., 1994). There are more than 1000 Olfr genes 
located in clusters throughout the mouse genome (Zhang and Firestein, 2002) and around 400 
genes in the human genome (Olender et al., 2008). They encode odorant receptors that are 
expressed in the cilia of olfactory sensory neurons in the nose (Buck and Axel, 1991) to 
detect different odorants (Buck and Axel, 1991, Malnic et al., 2004). Each individual sensory 
neuron expresses only one Olfr gene from one allele. Unlike the immune receptor, this 
process is epigenetically regulated rather than being achieved through DNA rearrangement 
(Eggan et al., 2004). The detailed mechanism underlying this stochastic and monoallelic 
expression of Olfr genes remains unknown, but long-range chromatin interaction between 
promoters and enhancers (Markenscoff-Papadimitriou et al., 2014), transient expression of 
Lsd1 (Lyons et al., 2013) and nuclear architecture (Clowney et al., 2012, Armelin-Correa et 
al., 2014) (Yoon et al., 2015) are all implicated in regulating the promoter choice. In addition, 
the single neuron maintains the monoallelic Olfr gene expression by a feedback loop, which 
also inhibits the other Olfr genes from being expressed (Lyons et al., 2013).  
 
The clustered Pcdh genes are another group of genes that display a distinct type of random 
monoallelic expression (a detailed description of the clustered Pcdh genes and their 
expression pattern is provided later in this chapter). 
 
Recent technological developments (e.g. SNP microarrays and genome-wide sequencing) 
have also identified the extensive and apparently random monoallelic expression of 
individual genes spread across both human (Gimelbrant et al., 2007) and mouse (Zwemer et 
al., 2012) genomes. Little is currently known about the mechanism behind this form of 
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monoallelic expression. Indeed, it is not known whether this is the result of a concerted 
mechanism driving monoallelic expression or merely the end result of a polymorphic 
genome. 
 
1.2.3 X chromosome inactivation 
 
Male and female mammals have different numbers of X chromosomes, and as a result, 
females (XX) carry double the dose of X-linked genes compare to males (XY). The Y 
chromosome is a gene-poor chromosome and mainly contains genes for sperm production 
and maleness. In contrast, the X chromosome comprises approximately 1000 genes required 
for normal cell and embryonic development in both males and females. The difference in X-
linked gene dosage between males and females must be balanced, otherwise it would lead to 
poor cell differentiation and embryonic lethality (Takagi and Abe, 1990). To solve the 
imbalance for X-linked genes between different sexes, female mammals have evolved a 
specific process of dosage compensation, termed X chromosome inactivation (XCI) (Lyon, 
1961). 
 
The process of XCI is quite complex and has been studied mainly in mice. During 
perimplantation development (i.e. from the 2-cell to 16-cell morula stage), the paternal X 
chromosome is preferentially inactivated in mice. This is also known as imprinted XCI. At 
the initial stage of blastocyst formation, this imprinted paternal XCI is maintained in cells 
that will contribute to the extra-embryonic tissues, but the paternal X chromosome is re-
activated in epiblast cells, which then undergo random XCI in the embryo proper (Okamoto 
et al., 2004, Mak et al., 2004).  
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The master cis-regulatory region for XCI is called the X inactivation centre (Xic). The Xic 
expresses a number of lncRNA transcripts that regulate XCI. The two best characterised 
lncRNAs located in Xic are termed the “X-inactive specific transcript” (Xist) (Brockdorff et 
al., 1991, Borsani et al., 1991, Brown et al., 1991) and the “Xist antisense RNA transcript” 
(Tsix) (Lee et al., 1999). Other genes located in the Xic encode many different lncRNA 
transcripts, which work with Xist or Tsix to regulate the XCI (Yue et al., 2015, Massah et al., 
2015, Monfort et al., 2015).  
 
The process of random XCI consists of the following events: (1) counting the number of X 
chromosomes, (2) randomly choosing one of them become the inactive X chromosome (Xi) 
and the other to become the active X chromosome (Xa), (3) silencing the genes along the 
length of the Xi and (4) the subsequent maintenance of XCI after cell division. The counting 
step ensures that there is only one Xa per diploid autosomal set of chromosomes in a cell. The 
exact molecular mechanism underlying counting remains unknown, however it has been 
proposed that the X-pairing region and binding of CTCF protein to the pairing region play 
critical roles in this step (Augui et al., 2007, Kung et al., 2015). During the XCI, Xist lncRNA 
is expressed from the allele on the Xi and spreads to coat on the entire Xi (Borsani et al., 
1991, Brown et al., 1991, Penny et al., 1996). To do this, it requires many other specialised 
factors (such as Xpr, Jpx, RepA, Ftx and Spen) and proteins (Polycomb repressive complex2 
(PRC2), Rnf12, YY1, heterochromatin protein 1 (HP1), Rbm15, Wtap, Hnrnpk, SHARP, 
HDAC3 and SMRT), many of which either regulate Xist expression or interact directly with 
Xist RNA transcript (Yue et al., 2015, Massah et al., 2015, Minajigi et al., 2015, Moindrot et 
al., 2015, Monfort et al., 2015, Chu et al., 2015, McHugh et al., 2015, Jonkers et al., 2009). 
Other loci, some of which encode lncRNA (e.g. Xite, Tsx, Linx, Dxpas34) also located in Xic, 
are involved in regulating Tsix expression (Yue et al., 2015, Massah et al., 2015). Tsix 
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negatively regulates the expression of Xist by inducing changes in histone modification (Sado 
et al., 2005, Sun et al., 2006) or/and inhibiting the PRC2 complex targeting the Xist locus 
(Zhao et al., 2008), (Ohhata et al., 2015). A recent publication has reported that Tsix lncRNA 
may function to protect the Xa by actively repressing Xist expression from the allele on the 
Xa rather than being involved in the initiation of random XCI (Gayen et al., 2015). Another 
antisense transcript encoded within the Xist gene (i.g. Xist activating RNA or XistAR) that is 
expressed from the Xi has recently been identified (Sarkar et al., 2015). Unlike Tsix lncRNA, 
it is proposed that XistAR lncRNA drives Xist expression. 
 
1.3 Smchd1 
 
Smchd1 was first identified as a regulator of murine metastable epialleles in an ENU 
mutagenesis screen in mice, which was designed to identify new modifiers of epigenetic 
reprogramming (Blewitt et al., 2005). The ENU-induced nonsense mutant allele of the 
Smchd1 named MommeD1 results in significantly reduced Smchd1 expression levels due to 
nonsense mediated mRNA decay (Blewitt et al., 2008). The Smchd1 gene was named after 
the predicted protein it encodes and contains a conserved C-terminal SMC hinge domain, 
which is characteristic of SMC hinge proteins (Hirano, 2005). Members of the SMC family 
normally form heterodimers in protein complexes which play a critical role in DNA repair, 
chromosome condensation and cohesion (Hirano, 2006). In contrast, recent publications 
demonstrate that Smchd1 most likely forms homodimers in protein complexes (Brideau et al., 
2015, Chen et al., 2015) Although the predicted Smchd1 protein has an ATPase domain, it is 
much more similar to the gyrase, histidine kinase and MutL (GHKL) superfamily than the 
ATP binding cassette-type ATPase which is characteristic of the SMC protein family (Iyer et 
al., 2008). This structure implies that the Smchd1 protein probably functions in an ATP-
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dependent manner. The demonstration that GHKL ATPase of Smchd1 hydrolyses ATP 
supports this implication (Brideau et al., 2015). 
 
Additional studies have revealed that Smchd1 plays a critical role in X inactivation (Blewitt et 
al., 2008, Gendrel et al., 2013, Mould et al., 2013), as well as regulating a subset of 
autosomal genes subject to monoallelic expression (Gendrel et al., 2013, Mould et al., 2013). 
In functional studies, loss of Smchd1 is associated with accelerating hematopoietic cancers in 
tumour prone mouse models (San Leong et al., 2013). It has also been reported that 
SMCHD1 protein accumulates at DNA damage sites (Coker and Brockdorff, 2014) and the 
plant homologue of Smchd1 is involved in the non-homologous end joining DNA repair 
pathway (Tang et al., 2014).  
 
In humans, the SMCHD1 heterozygous mutation is responsible for the rare form of muscular 
weakness syndrome Facioscapulohumeral Muscular Dystrophy 2 (FSHD2) (Lemmers et al., 
2012, Larsen et al., 2014, Lemmers et al., 2014). The heterozygous mutation of SMCHD1 
causes the D4Z4 microsatellite array to become hypomethylated. This causes the DUX4 
retrogene that is implanted in the array to become variegated in its expression in skeletal 
muscle (Lemmers et al., 2012). Further investigation has shown that SMCHD1 mutations 
enhance disease severity in the more common form of Facioscapulohumeral Muscular 
Dystrophy, termed FSHD1 (Sacconi et al., 2013, Larsen et al., 2014). Additionally, patients 
with variants in the FAT1 gene develop FSHD-like symptoms without a decrease in D4Z4 
copy number (FSHD1) or SMCHD1 variants (FSHD2) (Puppo et al., 2015), which indicates 
that the nature of this disorder may be more complex than originally thought. Nevertheless, it 
is considered to be a powerful model to investigate epigenetic regulation and gene expression 
in human disease. 
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1.3.1 Smchd1 and X chromosome inactivation 
 
Accumulating evidence has demonstrated a critical role for Smchd1 in XCI (Blewitt et al., 
2008, Gendrel et al., 2013, Mould et al., 2013, Gendrel et al., 2012). Smchd1MommeD1/MommeD1 
female embryos fail during mid-gestation development, whereas Smchd1MommeD1/MommeD1 
male can survive to become fertile adults (Blewitt et al., 2005). Detailed studies have 
revealed that, in female mutant embryos, many X-linked genes either escaped XCI shortly 
after the initiation of silencing or failed to maintain XCI (Blewitt et al., 2008). This failure of 
XCI was associated with the failure of CGI methylation that is normally associated with 
genes on the Xi (Blewitt et al., 2008). Genome-wide analysis demonstrated that, in addition 
to X-linked genes, the transcript levels of gene categories related with apoptosis, 
development and biosynthetic pathways were significantly altered in female 
Smchd1MommeD1/MommeD1 embryos at E9.5 (Mould et al., 2013). This observation is consistent 
with the female embryos failing at that stage. Interestingly, in the Smchd1MommeD1/MommeD1 
embryos, chromosome-wide analysis revealed that not all X-linked genes escaped XCI, and 
those which did escape inactivation tended to be located in clusters (Gendrel et al., 2013). 
Additionally, it was shown that genes on the Xi can be classified as either Smchd1-dependent 
or Smchd1-independent for methylation of their CGI. Smchd1-independent CGI methylation 
occurs rapidly after the initiation of XCI, whereas Smchd1-dependent methylation occurs late 
event in XCI (Gendrel et al., 2012). Therefore, Smchd1 is fundamental for DNA methylation 
and the silencing of some genes on the Xi, and is therefore considered to be involved in the 
maintenance and/or completion of XCI. A further study hypothesised that the Smchd1 protein 
is associated with Xist lncRNA and interacts with the HP1-binding protein (HBiX1 or Lrif1) 
at H3K9Me3 decorated domains. This results in the formation of a compact chromatin 
structure (Nozawa et al., 2013, Brideau et al., 2015). If this is correct, Smchd1 is more likely 
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to be involved in establishing higher-order chromatin structure throughout the Xi, rather than 
being directly involved in regulating the expression of Xi genes. 
 
1.3.2 Smchd1 and autosomal gene expression 
 
As mentioned above, Smchd1MommeD1/MommeD1 males survive to become fertile adults on the 
FVB/n genetic background. However, when bred onto the C57BL6/J background, the male 
homozygous mutants displayed perinatal lethality (San Leong et al., 2013, Blewitt et al., 
2005). This implies that Smchd1 may have a wider epigenetic function than just being 
involved in XCI and it may also function in regulating the expression of autosomal gene loci. 
Two groups (Gendrel et al., 2013, Mould et al., 2013) have identified gene clusters in mice 
which are normally known to be subject to genomic imprinting and show increased transcript 
levels in both male and female Smchd1MommeD1/MommeD1 embryos. The most significantly 
disrupted gene cluster in Smchd1MommeD1/MommeD1 mice is the Snrpn imprinted gene cluster 
(Gendrel et al., 2013, Mould et al., 2013). Mutations that affect the allelic expression of genes 
in this cluster are responsible for Angelman (OMIM 105830) and Parader-Willi syndromes 
(OMIM 176270). Detailed analysis of the expression and epigenetic profile of genes within 
the Snrpn cluster revealed that Smchd1 function is critical for silencing the maternal allele of 
a subset of genes, including Ndn, Magel2, Mkrn3 and Peg12 (Gendrel et al., 2013, Mould et 
al., 2013). As a result the affected genes become biallelically expressed. Another imprinted 
gene cluster which is influenced by the Smchd1MommeD1 mutation is the Igf2r imprinted gene 
cluster (Mould et al., 2013). At this locus loss of Smchd1 function also results in biallelic 
expression of the disrupted gene (e.g. Slc22a3). In both clusters (i.e. the Snrpn and Igf2r 
imprinted gene clusters) the disruption in Smchd1MommeD1/MommeD1 mutants is not due to 
disruption of the differential methylation that marks the ICR, however DNA methylation 
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levels at loci remote from the ICR are affected. This suggests that, at these imprinted gene 
clusters, Smchd1 is functioning to either maintain and/or complete the silencing of genes 
which are linked to the ICR. This is similar to its role in XCI, where Smchd1 only functions 
late in the epigenetic cascade, which ultimately results in stable silencing of X-linked genes. 
Using a different approach, another group has shown that the imprinted gene cluster 
associated with Beckwith-Wiedemann and Silver-Russell syndromes (including the genes 
H19, KCNQ1, CDKN1C) is dysregulated in SMCHD1 knockdown SH-SY5Y cells and 
HEK293 cells (Massah et al., 2014), which suggests that Smchd1/SMCHD1 might function 
in further imprinted gene clusters. 
 
Another autosomal gene cluster which is subject to monoallelic expression and is also 
disrupted in Smchd1 mutants, is the clustered Pcdh gene locus (Gendrel et al., 2013, Mould et 
al., 2013). The clustered Pcdh genes are normally expressed in a random combinatorial 
monoallelic manner in neurons. In Smchd1MommeD1/MommeD1 mutants, there is disrupted 
expression of Pcdha and Pcdhb genes, in particular, although Pcdhg shows some disruption 
(Gendrel et al., 2013, Mould et al., 2013). It has been shown that CGI methylation, 
CTCF/cohesion and Smchd1 are all involved the mechanism of controlling clustered Pcdh 
expression (Guo et al., 2012, Chen et al., 2015), however the precise molecular mechanism is 
still unclear. 
 
1.4 Clustered Protocadherins  
 
The protocadherins are a group of cell surface adhesion molecules whose expression has been 
characterised predominantly in mammalian neurons. They are divided into (a) the clustered 
Pcdh genes, located in a cluster at a single site on chromosome 18 (in mouse) or chromosome 
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5 (in human) and (b) the non-clustered Pcdh genes that are individual genes spread 
throughout the genome. The clustered Pcdh genes are further sub-divided into three groups 
Pcdha, Pcdhb and Pcdhg, which encode more than 50 different isoforms (Wu and Maniatis, 
1999, Wu et al., 2001). The Pcdha and Pcdhg genes each contain four exons, where one of 
many alternative first exons is spliced onto the three common exons. In mice, there are 12 
variable and 2 constant alternative Pcdha first exons, and 19 variable and 3 constant 
alternative Pcdhg first exons (Figure 1). Humans have 13 variable and 2 constant alternative 
PCDHA first exons, and 19 variable and 3 constant alternative PCDHG first exons 
(PCDHGB8 is a pseudogene). Each of the Pcdhb genes (22 genes in mice and 16 genes and 3 
pseudogenes in humans) has only a single exon. The variable exons of the Pcdha and Pcdhg 
gene clusters encode highly homologous yet different extracellular domains, a 
transmembrane domain and a short variable cytoplasmic domain. Their shared constant exons 
encode the rest of an identical cytoplasmic domain. Each Pcdhb isoform only contains an 
extracellular domain, a transmembrane domain and a short cytoplasmic domain (Sugino et al., 
2000).  
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Figure 1. Mouse clustered Pcdh genes.  
Image from the UCSC Genome Browser showing the mouse clustered Pcdh locus. Each Pcdha and Pcdhg gene contains four exons (one of 
many alternative variable first exons is spliced to the three common exons), whereas the Pcdhb genes all have a single exon. 
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1.4.1 Random combinatorial monoallelic gene expression of the clustered Pcdhs and 
neuronal function. 
 
It is proposed that the clustered Pcdh genes encode the unique molecular identity carried by 
each individual neuron, which is necessary for the formation of a complex neural network in 
mammals (and in higher eukaryotes) (Tasic et al., 2002, Wang et al., 2002a). In Drosophila 
this role is performed by the Dscam (homolog of Down syndrome cell adhesion molecule) 
genes, which also encode a group of cell surface molecules involved in cell recognition 
(Hemani and Soller, 2012). Both the clustered Pcdh genes and the Dscam genes encode a 
large number of isoforms using a relatively small number of exons. The diversity of isoforms 
generated from these gene clusters is the result of alternative promoter choice or stochastic 
splicing of their pre-mRNA, respectively (Esumi et al., 2005, Hemani and Soller, 2012). This 
contrasts with the immunoglobulin (Ig) and T-cell receptor (TCR) gene clusters, which, while 
generally similar in structure, produce vast variability in the antibody and the TCR catalog by 
mutation and somatic DNA recombination.  
 
Double in situ hybridisation experiments have shown that different neurons express different 
combinations of the clustered Pcdh isoforms (Kohmura et al., 1998). Additionally, single cell 
RT-PCR analyses have shown that each single Purkinje cell expresses a limited number of 
different variable clustered Pcdh isoforms in a monoallelic manner, while the C-type 
isoforms are expressed from both the maternal and the paternal allele (i.e. biallelic 
expression) (Esumi et al., 2005, Esumi et al., 2006, Hirano et al., 2012). A compensation 
phenomenon ensures that the dual expression (both monoallelic and biallelic expression) is 
always maintained in the expression of clustered Pcdha isoforms (Noguchi et al., 2009). This 
mechanism operates regardless of whether the number of variable region Pcdha exons at the 
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locus is duplicated or deleted, which might suggest that the variable isoforms (monoallelic 
expression of Pcdha1-Pcdha12) and C-type isoforms (biallelic expression of PcdhaC1 and 
PcdhaC2) are regulated independently. Further studies suggest that there are about 15 
possible Pcdh isoforms which can be expressed by an individual neuron (i.e. 4 Pcdha, 4 
Pcdhb and 7 Pcdhg, including both the random monoallelically expressed variable isoforms 
and the biallelically expressed C-type containing isoforms of Pcdha and Pcdhg) (Esumi et al., 
2005, Esumi et al., 2006, Hirano et al., 2012). Since protocadherin proteins form tetramers on 
the cell surface, theoretically there are a total of approximately 3x1010 unique combinations 
of clustered Pcdh tetramers that can be generated (Yagi, 2012) (Figure 2). This is sufficient to 
serve as the molecular basis for determining individual identity for each neuron and shows 
that enormous phenotypic diversity can be created using limited genetic diversity.  
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Figure 2. Calculating the total possible number of unique clustered Pcdh tetramer 
combinations that can be formed.  
For each neuron, 4 Pcdha isoforms, 4 Pcdhb isoforms and 7 Pcdhg isoforms are expressed, 
for a total of 15 Pcdh isoforms. Protocadherins can form into hetero cis-tetramer protein 
complexes displayed on the surface of the mature neuron. Therefore, there are a total of 
approximately 3x1010 unique combinations of clustered Pcdh tetramers that can be generated. 
Figure modified from (Yagi, 2012) (See appendix 14. Frontiers Copyright Statement).  
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An increasing number of studies are revealing the importance of clustered Pcdh gene 
expression in neuronal function. There is no obvious defect in Pcdha knockout mice as they 
are viable and fertile (Hasegawa et al., 2008, Katori et al., 2009, Suo et al., 2012), however, 
loss of the constant region of Pcdha results in abnormal projections of serotonergic neurons 
and olfactory sensory neurons (Hasegawa et al., 2008, Katori et al., 2009). Additionally, it is 
proposed that Pcdha proteins are involved in regulating spine morphogenesis and dendritic 
branching in CA1 pyramidal neurons (Suo et al., 2012). In contrast to Pcdha-deficient mice, 
the loss of Pcdhg expression results in neuronal apoptosis (Wang et al., 2002b, Weiner et al., 
2005, Lefebvre et al., 2008, Prasad et al., 2008) and/or the loss of dendritic self-avoidance 
(Lefebvre et al., 2012, Toyoda et al., 2014). Furthermore, several studies have proposed that 
the combinatorial homophilic interaction of Pcdh isoforms is involved in mediating self-
recognition and non-self-discrimination in vertebrate central nervous systems (Schreiner and 
Weiner, 2010, Zipursky and Sanes, 2010, Thu et al., 2014, Rubinstein et al., 2015). A recent 
study has reported that clustered Pcdhb gene expression co-operates with the Olfr genes in 
subjects with extreme obesity (Mariman et al., 2015). Therefore, it has been proposed that 
clustered Pcdha and Pcdhg genes can play a role relative to neuron organization and 
function, such as neuron projection, while the expression of Pcdhb is involved in controlling 
tissue development (Mariman et al., 2015).  
 
1.4.2 Epigenetic regulation of clustered Pcdh gene expression 
 
Given the complexity of both the structure of the clustered Pcdh locus and the pattern of 
expression of the clustered Pcdh isoforms, it is not surprising that many details in relation to 
the epigenetic mechanisms underlying the control of expression from this locus remain 
unknown. As yet there is no cohesive picture of how the epigenetic mechanism might 
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operate, rather the many disparate pieces of evidence in the literature are only beginning to 
form a coherent model. Some of these epigenetic features identified are discussed in the 
following paragraphs. 
 
As mentioned previously, alternative promoter choice is one of the proposed methods of 
generating diversity in clustered Pcdh isoforms expression, and therefore, the specific 
structure of the promoter area should be important for the alternative choice. It is known that 
each variable exon of the clustered Pcdh genes is associated with its own promoter, most of 
which contain a highly conserved sequence element (CSE), with a core CGCT sequence 
located upstream of the transcription start site (TSS) (Wu et al., 2001). Both the CSEs and 
their adjacent upstream region are required for clustered Pcdh promoter activity. 
 
Long-range cis-regulatory enhancer elements are also critical for promoter activity in the 
Pcdh gene cluster (Ribich et al., 2006, Yokota et al., 2011). There are two different enhancer 
elements identified in the Pcdha gene cluster. These coincide with DNaseI hypersensitive 
sites (HS) and are called HS5-1 and HS7, both of which are located near the common exons 
of Pcdha. HS5-1 is located after the last exon of the common region and is responsible for 
expression in the central nervous system (e.g. nerves within the cortex), while HS7 lies 
between common exons three and four, which is active in the sensory organs (Ribich et al., 
2006). Deletion of the HS5-1 region in mice results in strong down-regulation of the variable 
Pcdha exons. The effect of HS5-1 deletion is strongest for the variable exons that lie closest 
to HS5-1 and weakest for those that lie at a greater distance from HS5-1 (Kehayova et al., 
2011). Interestingly, the expression of PcdhaC2, which lies closest to the HS5-1 enhancer, is 
not affected by HS5-1 deletion. In contrast, the expression of all clustered Pcdha isoforms is 
reduced in mice carrying a HS7 deletion (Kehayova et al., 2011). Thus, multiple enhancer 
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elements regulate the expression of the Pcdha gene cluster. Furthermore, six DNaseI HS 
(HS16, HS17, HS17’ and HS18 to HS20), called the cluster control region (CCR), have been 
identified downstream of the Pcdhg gene cluster (Yokota et al., 2011). In mice carrying a 
deletion of the CCR, there is a down-regulated expression of all of the Pcdhb cluster genes 
and variable expression of the Pcdhg isoforms, but no effect on the expression of Pcdha 
isoforms. Other elements that are specific for regulating the Pcdhg isoforms are predicted to 
be located downstream of the Pcdhg genes and are called HS7L (located between clustered 
Pcdhg common exon 3 and 4), HS5-1aL and HS5-2bL (located after the last common exon of 
Pcdhg) (Guo et al., 2012). 
 
In addition, cis- and trans-chromosomal interactions contribute to the promoter choice in 
clustered Pcdh gene expression. Ctcf protein is a core element that acts as a mediator of 
chromosomal interactions (Phillips and Corces, 2009). The clustered Pcdh locus, including 
the CCR and HS5-1 enhancer region, contain multiple Ctcf-binding sites. Ctcf also binds to 
the CSE located in each individual promoter region of the clustered Pcdh genes to activate 
expression (Kehayova et al., 2011, Handoko et al., 2011, Monahan et al., 2012). Another key 
mediator for chromosomal interactions is the cohesion complex which acts in association 
with Ctcf. Mice with a heterozygous mutation in Nipped-B-Like, which promotes cohesion 
loading onto DNA, show a significant decrease in clustered Pcdhb gene expression 
(Kawauchi et al., 2009). Normally, the cohesion complex subunit SA1 (cohesion-SA1) binds 
to TSSs of the clustered Pcdh genes, but in its absence, down-regulation of the clustered 
Pcdh genes is observed in the brain (Remeseiro et al., 2012). Furthermore, the cohesion 
complex subunit Rad21 has been found to directly bind, with Ctcf, to the active Pcdha 
promoters over both the CSE and HS5-1, in order to activate transcription of the expressed 
exons. Knockdown of Rad21 reduces the expression of PcdhaC1 and PcdhaC2 (Monahan et 
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al., 2012). This might be the reason that PcdhaC1 and PcdhaC2 are expressed differently 
from the variable isoforms (Pcdha1 to Pcdha12). In combination, these data indicate that 
Ctcf/cohesion mediated DNA looping is required for choosing which promoter is used to 
drive random expression of the clustered Pcdha isoforms (Guo et al., 2012). A recent study 
shows that the expression of clustered Pcdh is relative to the direction of DNA looping and 
the orientation of the Ctcf binding sites (Guo et al., 2015).  
 
There is a great deal of evidence indicating that the CpG methylation state of the promoter 
region of genes influences their expression. This is also true for the clustered Pcdh genes. 
Non-expressed clustered Pcdh isoforms are hyper-methylated, whereas expressed clustered 
Pcdh isoforms are hypo-methylated. In the brain, in contrast to the constitutively expressed 
isoforms (i.e. the C-type), randomly expressed clustered Pcdh isoforms exhibit mosaic or 
mixed methylation states (Kawaguchi et al., 2008). This is because of the inter-cell variation 
of the clustered Pcdh isoforms which are being expressed. Single cell analysis of Purkinje 
cells showed that Dnmt-3b deficiency results in increased expression of Pcdh isoforms and 
that those cells exhibited abnormal dendritic arborisation (dendritic self-crossing or loss of 
self-avoidance) (Toyoda et al., 2014). Furthermore, ChIP studies using an antibody specific 
for MeCP2 showed that MeCP2 binds to the promoter of PCDHB1 and that disruption of 
MeCP2 expression can lead to the up-regulation of PCDHB1 transcription in SH-SY5Y cells 
(Chahrour et al., 2008).  
 
Other than playing critical roles in promoter choice, emerging evidence also shows that Ctcf 
and MeCP2, together with DNA methylation, modulate the elongation rate of RNA 
polymerase II to regulate alternative splicing (Shukla et al., 2011, Maunakea et al., 2013). 
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This mechanism is likely to operate in the generation of individual clustered Pcdha and 
Pcdhg isoform expression. 
 
In summary, the distinctive expression pattern of the clustered Pcdh isoforms confers each 
individual neuron with a unique individual identity, displayed on its cell surface. The 
molecular mechanism underlying this unique form of combinatorial monoallelic gene 
expression remains poorly characterized, but is known to involve many epigenetic factors, 
such as DNA methylation, Ctcf/cohesion, Rad21, MeCP2 and, most recently, Smchd1.  
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1.5 Hypothesis 
 
Smchd1 participates in an epigenetic mechanism that drives random combinatorial 
monoallelic expression of the clustered Pcdh genes. The mechanism, involving chromatin 
looping and allelic gene silencing, defines the combination of unique protocadherin 
molecules displayed on the surface of each neuron. This provides each neuron with the 
individual identity that is necessary for the formation of complex neural circuits. 
 
1.6 Aims 
 
1. Characterise clustered Pcdh isoform expression in Smchd1+/+ and 
Smchd1MommeD1/MommeD1 NSCs. 
2. Determine the in vivo consequences of Smchd1-loss on individual Purkinje 
neurons.  
3. Use clonal tumour cell lines to investigate the role of Smchd1 in the epigenetic 
mechanism controlling clustered Pcdh expression.  
 
To address these aims, qRT-PCR, Transcriptome-seq , MBD-seq and single cell qRT-
PCR were used to analyse the expression of clustered Pcdh genes in Smchd1+/+ and 
Smchd1MommeD1/MommeD1 NSCs. Additionally, single Purkinje cells from P21 Smchd1+/+ 
and Smchd1MommeD1/MommeD1 male mice were used to perform single cell qRT-PCR and the 
confocal images of single Purkinje cells were used to analyse the cell morphology. 
Finally, SMCHD1 knockdown and knockout human neuroblastoma cell lines (SK-N-SH 
and SH-SY5Y) were used to investigate whether the loss of SMCHD1 function results in 
altered clustered PCDHA expression or chromatin conformation changes at the locus. 
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Chapter 2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals and reagents 
 
The following is an alphabetical list of all the major chemicals and reagents used while 
conducting this project, along with the suppliers from which they were purchased. 
All chemicals are molecular biology grade, unless otherwise stated. 
 
Accutase Cell Dissociation Reagent, Gibco 
Agarose, SeaKem LE (electrophoresis grade), Lonza 
Bovine serum albumin (BSA), Sigma-Aldrich 
Chloroform, Ajax Fine Chemicals 
Deoxyribonucleoside triphosphates (dATP, dCTP, dGTP, dTTP), Bioline 
DL-cysteine HCL, Sigma-Aldrich 
Dimethyl sulphoxide, Sigma-Aldrich 
Dulbecco’s modified Eagle’s medium, Sigma-Aldrich 
Ethylenediaminetetra acetic acid disodium dihydrate (EDTA), Sigma-Aldrich 
EmbryoMax ES cell Qualified Fetal bovine serum (FBS), Merck Millipore 
Formaldehyde, Sigma-Aldrich 
Glucose, Ajax Fine Chemicals 
Glycogen, Bioline 
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Heparin, StemCell Technologies 
Isopropanol, Ajax Fine Chemicals 
Laminin, Invitrogen 
NeuroCult NSC Basal Medium(Mouse), StemCell Technologies 
NeuroCult Proliferation Supplement(Mouse), StemCell Technologies 
NP40, Thermo Scientific 
Pen Strep, Gibco 
Phenylmethanesulfonyl fluoride (PMSF), Sigma-Aldrich 
Prolong Gold, Life Technologies 
Propidum iodide, Sigma-Aldrich 
Puromycin, Gibco 
rhEGF, Peprotech 
rhFGF, Peprotech 
SsoFast EvaGreen Supermix with Low Rox, Bio-Rad 
SYBR safe DNA gel stain, Invitrogen 
TRIZOL Reagent, Invitrogen 
T4 Gene 32 Protein, New England Biolabs 
Water for molecular biology, diethylpyrocarbonate-treated and sterile filtered, Sigma-Aldrich 
0.2% IGEPAL, Sigma-Aldrich 
5’-Azacytidine, Sigma-Aldrich 
2x Assay Loading Reagent, Fluidigm 
20x GE Sample Loading Reagent, Fluidigm 
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2.1.2 Buffers and solutions 
 
All solutions and buffers, along with their formulas and concentrations, are listed below. All 
solutions and buffers were prepared using Milli-Q water, unless otherwise stated. 
 
Blocking solution 100mL 
Skim Milk powder 5g; BSA 1g; add PBST up to 100 mL 
Buffer for dissolving Proteinase K 
50mM Tris pH 8.0; 10mM CaCl2 
Cell lysis buffer (5C) 
10 mM Tris pH 7.4; 10mM NaCl; 0.2% IGPAL; 1x protease inhibitors  
Citrate buffer 
10mM Sodium Citrate; 0.05% Tween 20, pH6.0 
Low EDTA Tris buffer  
10mM Tris-HCL; 0.01mM EDTA in nuclease-free water 
PBST 1 Litre 
10x PBS 100mL; Tween 1mL ; water to 1 litre 
Saturated sodium chloride 1 Litre 
357g sodium chloride in water 
Tail tip buffer  
50mM Tris pH8.0; 20mM EDTA pH8.0; 0.2% SDS  
Xgal staining buffer  
0.1M Phosphate buffer pH 7.3 supplemented with 2mM MgCl2; 5mM potassium 
ferrocyanide and 5mM potassium ferricyanide 
Xgal stock solution  
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20 µg X-gal/mL in DMSO  
4x SDS loading buffer 50 mL 
4x Tris acid pH6.8 12.5 mL; Glycerol 10 mL; SDS 2 g; DTT 1.55 g 
8M Urea Buffer 50 mL  
Urea 24g; SDS (20% solution) 2.5 mL; Glycerol 5 mL; 1M DTT 25 µl; 1M TRIS pH6.8 500 
µl; add PMSF for cells or protease inhibitor cocktail for tissue lysate just before use (20 µl 
per 1.5 mL 8M Urea Buffer) 
10x Running buffer 1 Litre 
Glycine 114g; Tris base 30.24g; SDS 10g 
10x Transfer buffer 1 Liter 
Glycine 75.07g; Tris base 12.114g 
50x TAE 
2 M Tris base, 1 M glacial acetic acid, 0.5 M EDTA (pH 8.0) 
 
2.1.3 Enzymes 
 
All enzymes (listed below) were used as per the conditions specified by the manufacturer. 
 
Deoxyribonuclease I from bovine pancreas, Sigma-Aldrich 
Recombinant RNasin Ribonuclease Inhibitor, Promega 
T7 Endonuclease I, New England Biolabs 
Papain from papaya latex, Sigma-Aldrich 
Proteinase K, Promega  
SUPERase-in RNase Inhibitor, Ambion 
USB ExoSAP-IT PCR product cleanup, Affymetrix 
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2.1.4 Commercial kits 
 
All of the commercial kits used during the course of this project are listed below, along with 
their suppliers. 
 
AllPrep DNA/RNA Mini Kit, Qiagen 
AllPrep RNA Mini Kit, Qiagen 
BigDye Terminator Kit, Applied Biosystems 
Clarity Western ECL Blotting Substrate, Bio-Rad 
DNaseI, Invitrogen 
Exonuclease I kit, New England Biolabs 
Ion PGM Sequencing 200 v2 Kits, Life Technologies 
Ion PGM Template OT2 Solutions 200 Kit, Life Technologies 
MethylMiner methylated DNA enrichment Kit, Life Technologies 
NucleoSpin Gel and PCR Clean-up, Macherey-Nagel 
Pierce BCA Protein Assay Kit, Thermo Scientific 
SuperScript III First-Strand Synthesis Super Mix, Invitrogen 
SuperScript VILO Reaction Mix, Invitrogen 
TaqMan PreAmp Master Mix, Applied Biosystems 
TaqMan Universal PCR Master Mix, No AmpErase UNG, Applied Biosystems 
Ampli Taq Gold Kit, Applied Biosystems 
 
2.1.5 Antibodies 
 
Anti-EGFP antibody - ChIP Grade (ab290, Abcam) 
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Alexa488-labelled goat anti-rabbit Ig (A-11034, Molecular Probes, Inc) 
Anti-GAPDH (407972, SIGMA)  
Polyclonal goat antirabbit IgG-HRP, (P0448, Dako) 
Rabbit polyclonal anti-SMCHD1 (HPA039441, SIGMA) 
 
2.1.6  Commercial cell lines and plamid vectors 
 
SHSY-5Y (CRL-2266, ATCC) 
 
SK-N-SH (HTB-11, ATCC) 
 
293T (12022001, ECACC) 
 
lentiCRISPR v2 (52961, Addgene) 
 
psPAX2 (12260, Addgene) 
 
pCMV-VSV-G (8454, Addgene) 
 
pCMV-gag-pol (RV-111, Cell Biolabs Inc) 
 
2.1.7 Mouse strains and housing conditions 
 
Pcp2-Cre mice (JAX Stock number 006207 Tg(Pcp2-Cre)1Amc) and Z/EG mice (JAX Stock 
number 00392 Tg(CAG-Bgeo/EGFP)21Lbe/J) were obtained from The Jackson Laboratory. 
Pcp2-Cre mice express Cre recombinase under the control of the Pcp2 promoter. Z/EG is a 
double reporter mouse line that contains a loxP flanked β-geo-stop sequence followed by the 
EGFP sequence. The Z/EG mice express β-geo ubiquitously, except in the cells expressing 
Cre recombinase, which express EGFP due to deletion of the loxP flanked β-geo-stop 
sequence. Mice carrying the MommeD1 mutation were obtained from Prof Emma Whitelaw 
(QIMR Berghofer) and maintained on the FVB/N inbred background. Additionally, C57BL/6 
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MommeD1 congenic mice were obtained from Dr Marnie Blewitt (WEHI) who backcrossed 
the MommeD1 mice with C57BL/6 mice for more than 15 generations. All procedures using 
animals were performed in accordance with the Australian Code for the Care and Use of 
Animals for Scientific Purposes (8th edition) (2013) and approved by the QIMR Berghofer 
Animal Ethics Committee (Protocol P786-Breeding A0703-601B and Protocol P1226-
Experimental A0812-610M) and the QUT Animal Ethics Committee (Approval number 
1300000126). 
 
2.1.8 Primer sequences (see appendix 13) 
 
The primers used in this thesis are shown in Appendix 13 (Table 2 to Table 7). All primers 
were purchased from Integrated DNA Technologies, Inc. Taqman probes for genotyping 
MommeD1 mice were purchased from Applied Biosystems. 
 
2.2 General methods 
 
2.2.1 Design and test clustered Pcdh primers 
 
While the previously used full set of clustered Pcdh primers worked perfectly with SYBR 
green (Mould et al., 2013), some of them did not work well with EvaGreen as the fluorescent 
DNA intercalating agent. Since EvaGreen must be used when using the Fluidigm system, the 
full set of mouse clustered Pcdh gene primers were re-designed and confirmed functional 
with the EvaGreen containing PCR reagent. Firstly, the cDNA sequences of each clustered 
Pcdh genes were found using the UCSC genome browser (http://genome.ucsc.edu/) (Kent et 
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al., 2002). The sequences were then used for primer design using the online Primer3 software 
(http://bioinfo.ut.ee/primer3-0.4.0/) (Koressaar and Remm, 2007, Untergasser et al., 2012). 
Most parameters were set to the default value, except Primer Tm (Min 63.0; Opt 65.0 Max 
68.0), CG clamp (2) and product size ranges (100-400). Several primer candidates were 
generated for each clustered Pcdh gene isoform. The in silico PCR program in the UCSC 
genome browser (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start) was used to analyse 
whether the primers were likely to amplify a unique sequence in the mouse (or human) 
genome. The chosen primer pairs were purchased and tested in qRT-PCR using the Viia 7 
and sequencing of the PCR products. This process was repeated until each clustered Pcdh 
PCR amplified product had only one peak present in its melt analysis and based on its 
sequence, was confirmed to be the correct product. After testing the primers in single cell 
qRT-PCR, it was found that some primer pairs formed dimers. To minimize the noise signal, 
a Taqman-like probe was designed for the clustered Pcdha and Pcdhg isoforms and this was 
a far superior approach. In Aim 3, where human neuroblastoma cells were used, it was 
necessary to design some human clustered PCDH primers. Therefore, the full set of mouse 
clustered Pcdh isoforms and a subset of the primers for analysis of human PCDHA (i.e. 
PCDHA1-13 and PCDHAC1-2) were designed. qRT-PCR primers which amplified the 
appropriate control genes (Pcp2, Rala, Actb, RALA) were also designed and tested.  
 
2.2.2 Genomic DNA extractions for genotyping mice 
 
When the mice were 10 days old (PN10) they were ear tagged to positively identify each 
mouse and provide a source of DNA for genotyping. Each ear clip was placed into an 
appropriately labelled 1.5 mL microfuge tube which contained a mixture of 200 µL tail tip 
buffer and 20 µL Proteinase K solutions (10 mg/mL). The tubes were incubated at 55°C 
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overnight, and then 70 µL of saturated NaCl was added to precipitate excess SDS. After 
centrifugation, the DNA in the supernatant was precipitated by addition of 200 µL 
isopropanol and washed with 70% ethanol. The DNA was air-dried and then fully dissolved 
in 30 µL low EDTA-Tris buffer before storage overnight at 4°C. 
 
2.2.3 Z/EG transgene genotyping 
 
To genotype the mice carrying the Z/EG transgene, ear clips were placed into a labelled 96-
well plate. A staining solution, prepared by mixing 10 µL Xgal stock solution and 100 µL 
Xgal staining buffer, was added to each ear clip and observed for 2-4 hours for the 
development of deep blue staining, which indicated the mouse was positive for the Z/EG 
transgene. After the Z/EG transgene status was recorded the ear tag was removed from the 
staining solution so the DNA could be prepared for use in other genotyping assays.  
 
2.2.4 Pcp2-Cre genotyping 
 
Touchdown PCR was performed to detect whether the mice carried the Pcp2-Cre transgene. 
The target DNA purified from the ear tag was amplified by PCR to detect the Cre 
recombinase gene. Each 25 µL PCR reaction contained: 25 ng DNA template, 0.125 µL Taq 
DNA polymerase, 200 nM of forward Cre3 and reverse Cre4 primers, 200 μM of each dATP, 
dTTP, dCTP and dGTP, 1.5 µL MgCl2, and 2.5 µL of 10x PCR buffer. The touchdown PCR 
protocol was: 94°C for 10 minutes as an initial denaturation step, followed by 11 touchdown 
cycles of denaturation at 94°C for 30 seconds, annealing from 64°C at the first cycle and then 
each cycle dropped by 0.5°C (each cycle lasted for 30 seconds and was followed by 
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elongation at 72°C for 1.5 minutes). The next stage was 24 cycles of denaturation at 94°C for 
30 seconds, annealing at 55°C for 30 seconds and elongation at 72°C for 1 minute. Finally, an 
elongation stage at 72°C for 5 minutes completed the reaction. PCR amplified DNA was then 
visualised by gel electrophoresis on a 2% agarose gel. 
 
2.2.5 Smchd1 genotyping 
 
A Taqman PCR primer and probe set was designed to detect the MommeD1 mutation (SNP at 
position mouse chr17:71,400,085). Each 10 µL PCR reaction contained 5 ng DNA, 5 µL of 
2x Taqman mix and 0.25 µL primer mix (forward SMCHD1-MOMF and reverse primers 
SMCHD1-MOMR and two TaqMan MGB probes SMCHD1-MOMV2 and SMCHD1-
MOMM2). The PCR reaction was conducted using the following protocol: 92°C for 10 
minutes as an initial denaturation step, followed by 40 cycles of denaturation at 92°C for 15 
seconds, annealing and elongation at 60°C for 1 minute. After running the PCR, an endpoint 
analysis (allelic discrimination) was performed on an Applied Biosystems 7900HT Fast Real-
Time PCR system (Applied Biosystems) or Viia 7 Real-Time PCR System (Applied 
Biosystems) to determine whether the mouse was Smchd1+/+, Smchd1MommeD1/+ or 
Smchd1MommeD1/MommeD1. 
 
2.2.6 Sequencing to verify PCR amplification products 
 
Firstly a touchdown PCR was performed. The touchdown PCR was conducted using the 
following protocol: 94°C for 10 minutes as an initial denaturation step, followed by 11 
touchdown cycles of denaturation at 94°C for 30 seconds, annealing from 64°C at the first 
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cycle and then each cycle dropped by 0.5°C (each cycle lasted for 30 seconds and was 
followed by elongation at 72°C for 1.5 minutes). The next stage was 24 cycles of 
denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and elongation at 72°C 
for 1.5 minutes. Finally, an elongation stage at 72°C for 5 minutes completed the reaction.  
 
The product of touchdown PCR product was treated with USB ExoSAP-IT PCR Product 
Cleanup according to the manufacturers’ supplied protocol. The treated PCR product was 
used as a template for sequencing, where 1 ng of treated PCR product was required for every 
100 bp of expected PCR product size. The BigDye Terminator kit was used for preparing 
sequencing reactions. Each 12 µL sequencing reaction contained purified PCR products, 2.1 
µL of 5x reaction buffer; 0.3 µL 10 pmol/µL reverse primer and 0.6 µL Dye Terminator mix. 
The sequencing reaction was carried out according to the following protocol: 96°C for 2 
minutes as an initial denaturation step, followed by 30 cycles of denaturation at 96°C for 10 
seconds, annealing at 50°C for 5 seconds and elongation at 60°C for 2 minutes. After the 
sequencing reaction, the products were precipitated with isopropanol, air dried and then 
transferred to the sequencing service department at QIMR Berghofer for analysis (Applied 
Biosystems 3130 Genetic Analyzer).  
 
2.2.7 Immunohistochemistry 
 
The brains were removed from mice and fixed in 3% paraformaldehyde (PFA) in Phosphate 
buffered saline (PBS) for at least 24 hours, then transferred to 75% ethanol before sending to 
the histology laboratory for processing. For EGFP immunostaining, the sections were 
dewaxed in Leica ST5010 autostainer XL (Leica Biosystems) and then de-cloaked by 
autoclaving in with citrate buffer at 125°C for 5 minutes. The sections were then incubated in 
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blocking buffer (2% Fetal Bovine Serum (FBS) in PBS) for 20 minutes and then in a primary 
EGFP antibody (1/200 Anti-EGFP antibody, 2% FBS in PBS) for 2 hours at room 
temperature or overnight at 4°C. The sections were washed 3 times in PBS with 0.05% 
Tween 20 for 5 minutes each wash, and then incubated for 2 hours at room temperature with 
a secondary antibody (1/200 Alexa488-labelled goat anti-rabbit Ig). The sections were again 
washed 3 times in PBS with 0.05% Tween 20 for 5 minutes per wash, then fixed for 5 
minutes with 3% PFA in PBS. After mounting with setting Prolong Gold, the cover-slipped 
Immunofluorescence sections were stored in a dark place until viewing on Aperion FL Slide 
scanner (Leica Biosystems). 
 
2.2.8 qRT-PCR 
 
The cDNA was generated from total RNA isolated from NSCs using Superscript III 
according to the manufacturers’ instructions. Total RNA (1 μg), 1 μL dNTP mix (10 mM 
each), 1 μL gene-specific primer mix (2 pmol/μL each) and Nuclease-free water to a total 
volume of 13 μL was denatured at 65°C for 5 minutes and then placed on ice for at least 1 
minute. cDNA was synthesised following the addition of 1 µl 200 U/µl SuperScript III 
Enzyme, 4 µl 5x First Strand Buffer, 1 µL 0.1 mM DTT and 1 µL 40 U/µL RNasin 
ribonuclease inhibitor, and incubation at 55°C for 60 minutes. The reaction was stopped by 
heating to 70°C for 15 minutes. The synthesised cDNA samples were diluted up to 400 µL 
with Nuclease-free water and stored at -80°C until they were analysed.  
 
PrimeTime (Integrated DNA Technologies) qRT-PCR Assays for Pcdha and Pcdhg were 
conducted as follows: each 5 µL PCR reaction contained 2.5 µL Taqman Universal master 
mix, 0.45 µL 10 pmol/µL forward primer, 0.45 µL 10 pmol/µL reverse primer, 0.125 µL 10 
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pmol/µL PrimeTime probe (Integrated DNA Technologies), 0.475 µL Nuclease-free water 
and 1 µL diluted cDNA sample. The relative standard curve qRT-PCR method for analysing 
the relative abundance of Pcdha and Pcdhg transcripts was carried out according to the 
following protocol: 95°C for 10 minutes as an initial denaturation step, followed by 40 cycles 
of denaturation at 95°C for 15 seconds and annealing/elongation at 60°C for 1 minute. 
 
EvaGreen DNA-binding dye assays for Pcdhb were conducted as follows: each 5 µL PCR 
reaction contained 2.5 µL Eva green master mix, 0.2 µL 10 pmol/µL forward primer, 0.2 µL 
10 pmol/µL reverse primer, 1.1 µL Nuclease-free water and 1 µL diluted cDNA sample. The 
relative standard curve qRT-PCR method for analysing the relative abundance of Pcdhb 
transcripts was carried out according to the following protocol: 95°C for 2 minutes as an 
initial denaturation step, followed by 40 cycles of denaturation at 95°C for 15 seconds, 
annealing at 60°C for 20 seconds and elongation at 72°C for 1 minute, with a final melting 
stage at 95°C for 15 seconds, 60°C for 15 seconds, ramping to 95°C at 0.05°C per second and 
then 95°C for 15 seconds. 
 
Standard curves were generated from a serial dilution series of cDNA pooled from all 
samples used in the assay. The generated data were plotted using the Graphpad Prism 6.0 
program. 
 
2.2.9 RNA extraction 
 
RNA was extract from undifferentiated NSCs using an AllPrep RNA Mini Kit according to 
the manufacturers’ instructions. The extracted RNA was used for synthesizing cDNA for 
qRT-PCR analysis.  
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2.2.10 Transcriptome-seq  
 
Total RNA was extracted from Smchd1+/+ and Smchd1MommeD1/MommeD1 male NSCs using an 
AllPrep DNA/RNA Mini Kit according to the manufacturer’s instructions and quantified 
using the NanoDrop 1000 Spectrophotometer (Thermo Scientific). RNA yields and integrity 
were assessed using a 2100 Bioanalyser (Agilent Technologies, Australia) according to the 
manufacturer’s instructions. The RNA samples were stored at -80°C in a 1.5 mL tube and 
sent to be processed for Transcriptome-seq by the Australian Genome Research Facility. 
Sequencing reads were processed and analysed as described in the Bioinformatics Analysis 
section (below). These data are available under GEO series accession number GSE65749. 
 
2.2.11 MBD-seq 
 
Genomic DNA was extracted from Smchd1+/+ and Smchd1MommeD1/MommeD1 male NSCs using 
an AllPrep DNA/RNA Mini Kit and quantified using the NanoDrop 1000 Spectrophotometer 
(Thermo Scientific). DNA was fragmented using a Covaris S220 Focused-ultrasonicator 
(Covaris Inc.), which was set to a peak power of 175, duty factor of 10 and 200 cycles/bursts 
for a duration of 600 seconds (according to the manufacturers’ instructions), in order to yield 
fragments ranging from 50 bp to 400 bp with an average size of 200 bp, as confirmed by an 
Agilent Bioanalyser 2100 (Agilent Technologies). Methylated DNA was isolated by binding 
to the methyl-CpG binding domain of human MBD2 protein coupled beads using the 
MethylMiner methylated DNA enrichment kit according to the manufacturer’s instructions. 
The DNA was eluted from MBD coupled beads in two salt concentration cuts, the first of 
which was a 600 mM NaCl cut to remove poorly methylated DNA, followed by a 2 M NaCl 
cut to elute highly methylated DNA. The highly methylated cut was then used for the 
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preparation of libraries for next-generation sequencing. Next-generation library preparation 
(Illumina TruSeq DNA sample preparation kit) and sequencing (Illumina HiSeq 2000 
platform for 49 bp single-end reads) was performed by BGI Tech Solutions, Hong Kong. 
Sequencing reads were processed and analysed in the same manner as described below in the 
Bioinformatics section. These data are available under GEO series accession number 
GSE65749. 
 
2.2.12 Bioinformatics Analysis 
 
The analysis pipeline performs a sequence quality control using FastQC, and maps reads to 
the mouse reference genome (GRCm38/mm10) using TopHat (Trapnell et al., 2009, 
Langmead et al., 2009, Kim and Salzberg, 2011, Kim et al., 2013). The number of reads per 
transcript were counted using HTSeq (Anders et al., 2014). The counts obtained were 
analysed for differential expression using three programs: (DESeq (Love et al., 2014), EdgeR 
(Robinson et al., 2010) and Cufflinks (Trapnell et al., 2012).  
 
For the MBD-Seq analysis, tags were mapped to GRCm38/mm10 using BWA (Li and 
Durbin, 2009). Peaks for each of the samples were identified using MACS (Zhang et al., 
2008) with a P-value threshold of P <10-5. Methylated regions (identified using MACS) that 
were present in all three wild type samples were selected and used as "defined regions" to 
count tags mapped to those regions in all Smchd1+/+ and Smchd1MommeD1/MommeD1 samples. The 
obtained counts were further normalised and analysed for differentially methylated regions 
between Smchd1+/+ and Smchd1MommeD1/MommeD1 using DESeq (Love et al., 2014). The regions 
were annotated using the program PeakAnalyser 
(http://www.bioinformatics.org/peakanalyzer/wiki/) (Salmon-Divon et al., 2010) based on the 
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nearest transcription start site and the CGI. Selected regions were visualised in IGV 
(Integrative Genomics Viewer, Broad Institute) (Robinson et al., 2011, Thorvaldsdóttir et al., 
2013) and were then compared with other publically available data in the UCSC Genome 
Browser (Kent et al., 2002). 
 
2.3 Method for single cell qRT-PCR 
 
2.3.1 Isolated single NSCs 
 
NSCs were initially derived from Smchd1+/+ and Smchd1MommeD1/MommeD1 male E14.5 mouse 
brains in the laboratory of Dr Marnie Blewitt (WEHI). The cells were transferred to QIMR 
Berghofer as cryopreserved culture cells and stored in liquid nitrogen until required. To 
reanimate the NSCs, an ampule was removed from liquid nitrogen and immediately placed 
into the 37°C incubator until it was thawed. The cells were then cultured in NeuroCult NSC 
Basal Medium (Mouse) containing NeuroCult Proliferation Supplement (Mouse), with 20 
ng/mL rhEGF, 20 ng/mL rh bFGF and 2 μL/mL Heparin on laminin coated flasks at 37°C in 
a 5% CO2 atmosphere.  
 
For isolating individual cells for analysis, the NSCs were detached from the culture flasks 
using StemPro Accutase Cell Dissociation Reagent and resuspended in sterile PBS containing 
propidium iodide (final concentration 3 µg/mL) to discriminate between dead and live cells. 
Single NSCs were sorted by the QIMR Berghofer Flow Cytometry Facility using a Moflo 
XDP High Speed Cell Sorter (Beckman Coulter) into 96-well plates containing 0.25 μL 10% 
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NP40, 0.35 μL 10x DNaseI buffer, 0.3 μL 20 U/μL SUPERase-In and 2.1 μL nuclease-free 
water per well.  
 
2.3.2 Isolation of single Purkinje cell 
 
Once the mice carrying the desired genotype were generated, the cerebella were dissected 
from the mice at an appropriate age and digested with 90 units of papain at 37°C for 30 
minutes in 10 mL of dissociation solution (0.002% DL-cysteine HCl, 0.05% DNaseI, 0.1% 
bovine serum albumin (BSA), and 0.05% glucose). The digested tissue was centrifuged for 8 
minutes at 300×g and the pellet was resuspended in Dulbecco’s modified Eagle’s medium. 
The cells were filtered through a 100 μm cell strainer (Falcon) to remove debris and put into a 
tube with 2 mL PBS with 1% BSA (Kaneko et al., 2006). Single Purkinje cells dissociated 
from cerebella tissue were sorted by the QIMR Berghofer Flow Cytometry Facility using a 
Moflo XDP High Speed Cell Sorter (Beckman Coulter) or manually picked using 
micropipettes under an inverted microscope.  
 
2.3.3 cDNA Synthesis and pre-amplification 
 
The sorted/isolated cells were incubated at 65°C for 90 seconds to aid cell lysis and RNA 
denaturation. To degrade genomic DNA, 0.1 μL 1 U/μL DNaseI, 0.3 μL 20 U/μL SUPERase-
In and 0.1 μL Nuclease-free water were added to each well and the plate was incubated at 
25°C for 10 minutes. DNaseI was inactivated by the addition of 0.04 μL 0.5 M EDTA and 
0.46 μL Nuclease-free water per well and incubated at 70°C for 2 minutes. cDNA was 
synthesised after adding 1.2 μL SuperScript VILO Reaction mix, 0.3 μL gene specific reverse 
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primer mix (2 pmol/μL of each reverse primer), 0.15 μL 10x SuperScript Enzyme Mix, 0.12 
μL 10 mg/mL T4 Gene 32 Protein and 0.23 μL Nuclease-free water per well and incubating 
at the following temperatures (25°C for 5 minutes, 50°C for 30 minutes, 55°C for 25 minutes, 
60°C for 5 minutes and 70°C for 10 minutes). This was followed by adding an STA (specific 
target amplification) Reaction Mix, which contained 7.5 μL TaqMan PreAmp Master Mix, 
1.5 μL gene specific primers mix (500 nM each) and 0.075 μL 0.5 M EDTA The plate was 
then placed the plate into the ViiA 7 Real-Time PCR System (Applied Biosystems) to run an 
STA program as follows: denaturation at 95°C for 10 minutes, 20 cycles of denaturation at 
96°C for 5 seconds, annealing and elongation at 60°C for 4 minutes. Then, 0.6 μL 
Exonuclease I Reaction Buffer, 1.2 μL 20,000 U/mL Exonuclease I and 4.2 μL Nuclease-free 
water were added, before the sample was returned to the ViiA 7 PCR machine to perform a 
cleanup step at 37°C for 30 minutes and enzyme denaturation at 80°C for 15 minutes. The 
prepared cDNA was then diluted (added up to 75 µL with low Tris-EDTA buffer) and stored 
at -20°C until it was needed for the next step.  
 
2.3.4 Fluidigm PCR 
 
Synthesised cDNA and assay mixes were loaded onto 48.48 Dynamic Array Integrated 
Fluidic Chips (Fluidigm) and the qRT-PCR for the clustered Pcdh genes and control genes 
(Rala and Actb) was performed on the Biomark HD System (Fluidigm). The cycling program 
for Pcdha and Pcdhg PrimeTime qRT-PCR Assays was: 95°C for 10 minutes, 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute. The cycling program for Pcdhb EvaGreen DNA-
binding dye assays was: 95°C for 2 minutes, followed by 40 cycles of 95°C for 15 seconds, 
60°C for 20 seconds and 72°C for 1 minute, and a final melting stage of 95°C for 15 seconds, 
60°C for 15 seconds, ramping to 95°C at 0.33°C per seconds and then 95°C for 15 seconds. 
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2.4 Method for SMCHD1 knockdown and SMCHD1 knockout 
 
2.4.1 Knockdown of SMCHD1 in neuroblastoma cells 
 
Validated shRNA expressing retrovirus backbone vectors targeting human SMCHD1, as well 
as control scrambled shRNA, were obtained from Dr Marnie Blewitt (WEHI). The shRNA 
expressing retrovirus particles were generated according to the following protocol. 293T cells 
were seeded in a DMEM medium containing 10% FBS. The next day, cell density was 
checked for maximum efficiency (cell confluence should have been  80 %) and the cells 
were shifted to a medium containing 25 M chloroquine and returned to the incubator for 30 
minutes. During this time the transfection cocktail was prepared by mixing the Transfer 
vector (LTR mir30 puromycin-blue fluorescent protein (LMP-BFP) vector, a modified 
version of LMP-EGFP (Dickins et al., 2005) containing the appropriate shRNA sequence), 
Packaging vector (pCMV-gag-pol) and Envelope vector (pCMV-VSV-G) at a ratio of 5:3:2 
and adding water, CaCl2 and 2xHBS while vortexing. The transfection cocktail was then 
added to the cells one drop at a time around the plate and mixed by gentle rocking. This was 
followed by incubating for 8 to 10 hours, then changing to medium without chloroquine and 
incubated overnight. The following day, the transfected cells were re-fed with fresh medium 
and incubated for a further 24 hours. The medium containing infective retrovirus was then 
harvested and centrifuged at 1500 rpm for 10 minutes to remove cellular debris. The clarified 
supernatant was then aliquoted in 1 mL volumes and snap frozen on dry ice before storage at 
-80°C or directly used for infection.  
 
SHSY5Y (or/and SK-N-SH) cells were plated at a density of 1.0 x 106 (or 1.0 x 105 SK-N-SH) 
cells in each well of a 6-well plate with 2 mL of medium. Once the cells reached 50-80% 
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confluency (normally 4 to 5 hours after plated), the medium was replaced with 2 mL of fresh 
medium containing 4 µg/mL polybrene and 1 mL of virus stock was added to each well. The 
transduced cells were then incubated at 37°C overnight or for 24 hours. The medium was 
then replaced with fresh medium containing 2 µg/mL puromycin. From then on, all media for 
culturing the cells contained 2 µg/mL puromycin. After 2 to 3 passages, these cells could be 
used for making RNA or treated with 5 µM 5-Azacytidine (5’-AZC). 
 
2.4.2 Knockout SMCHD1 in neuroblastoma cells. 
 
CRISPR/Cas9 (CRISPR, The Clustered Regularly Interspaced Short Palindromic Repeats, 
Cas9, Clustered Regularly Interspersed Palindromic Repeats associated protein 9) constructs 
were made for editing the SMCHD1 gene in human cells and tested for the genome editing 
efficiency. The constructs were based on lentiCRISPR v2 ((Sanjana et al., 2014)), which is a 
lentivirus structural vector designed by the Zhang lab and available from Addgene. The 
lentiCRISPR v2 plasmid was designed to co-express the bacterial Cas9 nuclease, along with 
the guide RNA for targeting the gene of interest (in this case SMCHD1). Guide RNA 
sequences were identified using an online tool (CRISPR Design Tool (http://www.genome-
engineering.org/crispr/) (Hsu et al., 2013)) and oligos of the appropriate sequence were 
cloned into the lentiCRISPR v2 plasmid. Off-target sequences and positions in the human 
genome GRCh38/hg38 were identified by another online tool Cas OFFinder 
(http://www.rgenome.net/cas-offinder/) (Bae et al., 2014). After cloning, plasmids containing 
the correctly inserted oligo were identified by sequencing and then used to generate 
lentivirus. The lentivirus production method was similar to that for the production of 
retrovirus but the vectors used were: Transfer vector (lentiCRISPR v2), Packaging vector 
(psPAX2) and Envelope vector (pCMV-VSV-G). The packaged lentivirus was then used to 
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transduce the desired cell lines (in this case the human neuroblastoma cell lines SHSY-5Y 
and SK-N-SH).  
 
Transduction of the cells with the appropriate lentivirus was carried out as follows: each well 
of a 6-well plate contained 1.0 x 106 (or 1.0 x 105 SK-N-SH) cells and 2 mL of medium. Once 
the cells attached and were 50-80% confluent (normally 4 to 5 hours after plating), the 
medium was replaced with 2 mL of medium containing 4 µg/mL polybrene, and 1 mL of 
virus stock was added to the first well of the 6-well plate. The medium was mixed and 1 mL 
was removed and placed into the next well of the plate. This dilution series was repeated for 5 
of the 6 wells and the final well on the plate had no added virus. Once the serial dilution was 
completed, the cells were incubated at 37°C overnight or for 24 hours. The medium was then 
replaced with fresh medium containing 2 µg/mL puromycin. From then on, all media for 
culturing the cells contained 2 µg/mL puromycin. After 2 to 3 passages, the cells could be 
cloned, used for making RNA or treated with 5 µM 5’-AZC. 
 
Cloning of the CRISPR-based genome edited cells was achieved by plating the cells at a 
limiting dilution in 96-well plates (i.e. a plating density of approximately 30 cells per 96-well 
plate). Plated cells were observed over the subsequent culture period to identify wells 
containing a single cell. These were marked and once the well contained a cell colony of 
sufficient size the cells were expanded through increasing size culture vessels until a cloned 
cell line was established. The cloned cell lines were screened by the Surveyor assay and 
sequenced to determine the specific SMCHD1 mutation, followed by qRT-PCR and western 
blot to determine the extent of SMCHD1 or SMCHD1 knockout.   
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2.4.3 Western Blotting 
 
Cells were grown to 80% confluency on the 60 mm petri dishes for making protein lysates. 
The dishes were then placed on ice, the media was aspirated and the wells were washed with 
cold PBS. After removal of the PBS wash buffer, 200 µL of urea lysis buffer was scrubbed 
over dishes to lyse the cells. Cell lysates were collected in 1.5 mL tubes and stored at -80°C. 
To degrade viscous genomic DNA in the samples, the lysates were sonicated at 4°C (Branson 
Sonifier 250) for 3-4 seconds. The tubes were centrifuged for 10 minutes at high speed and 
the supernatant collected in fresh tubes. The concentration of protein in the lysates was 
determined using the BCA assay (Thermo-Fisher) with reagents mixed at a 50:1 ratio (A:B) 
as per the manufacturer’s instructions. Briefly, 200 µL of the BCA assay solution was placed 
in each well of a 96-well plate and 5 µL of lysate added to each well. Each sample was 
analysed in triplicate. The plate was incubated at 37°C for 20 minutes and then the 
absorbance was read on a BioTek plate-reader at 562 nm. The protein concentration in each 
sample was calculated by extrapolation from a standard curve. 
 
Samples were prepared for western blotting by combining the protein lysate with 4x SDS 
loading buffer and a urea lysis buffer. Protein was denatured at 98°C for 10 minutes. A mini-
protean-TGX-precast gel 4-15 % (Bio-Rad) was placed in a gel running tank containing 1x 
running buffer. Wells were loaded with 20 µg of protein, or with 10 µL of the Kaleidoscope 
Precision plus Protein Standard (Bio-Rad). Samples were run out at 100 V until there was 
clear resolution of the appropriate marker band.  
 
Proteins were transferred from the gel to an Immobilon PVDF transfer membrane (Merck 
Millipore) in complete transfer buffer for 1 hour at 100 V. After transfer, the membrane was 
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placed in a blocking solution on a rocker for 1 hour and then briefly washed twice in PBST. 
Membranes were incubated in primary antibodies diluted in blocking solution, overnight at 
4°C. The primary antibodies and dilutions applied were as follows: rabbit polyclonal anti-
SMCHD1 1:250; anti-GAPDH 1:1000. 
 
Membranes were then subjected to 3 washes (5 minutes per wash) in PBST and then 
incubated in 20 mL of secondary antibody solution for 1 hour. Membranes were washed 5 
more times in PBST (5 minutes per wash). Bands were visualised using the Clarity Western 
ECL Substrate (Bio-Rad). Reagents were mixed at a 1:1 ratio, as per the manufacturer’s 
instructions, and 1 mL was applied to each membrane for 5 minutes. Pictures were obtained 
using the GE ImageQuant LAS or the DNR ChemiBis bio-imaging system. 
 
2.4.4 Surveyor assay 
 
Cell clones were grown on 6-well plates and once 80% confluent, were collected for DNA 
and RNA purification using the Qiagen AllPrep DNA/RNA Mini Kit, according to the 
manufacturer’s instructions. A 50 µL PCR reaction was then set up including 100 ng of 
genomic DNA, 0.25 µL Taq DNA polymerase, 200 nM of forward and reverse primers for 
(a) SMCHD1 Ex3 No.1, (b) SMCHD1 Ex3 No.2 and (c) SMCHD1 Ex2 No.1, 200 µM each 
of dATP, dTTP, dCTP and dGTP, 3 µL MgCl2 (25 mM) and 5 µL of 10x PCR buffer. The 
touchdown PCR protocol used was: 95°C for 10 minutes as an initial denaturation step, 
followed by 15 touchdown cycles of denaturation at 95°C for 15 seconds, annealing from 
64°C at the first cycle and then each cycle decreased by 0.5°C, each cycle for 15 seconds, 
followed by elongation at 72°C for 1.5 minutes. The next stage was 35 cycles of denaturation 
at 95°C for 15 seconds, annealing at 55°C for 15 seconds and elongation at 72°C for 1.5 
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minutes, followed by a final elongation stage at 72°C for 5 minutes. The PCR amplified DNA 
was then visualised by gel electrophoresis on a 2% agarose gel. 
 
PCR products were cleaned up by using NucleoSpin Gel and PCR Clean-up Kit (Macherey-
Nagel) as per the manufacturer’s instructions. The concentration of purified PCR product was 
determined on a Nanodrop spectrophotometer. For each sample, 100 ng of PCR product from 
the parental cell line was mixed with 100 ng PCR product from the CRISPR-based genome 
edited clone for denaturation/renaturation with 2µL 10x NEB buffer 2 and made up to a final 
volume of 19 µL with nuclease free water. The denaturation/renaturation conditions were: 
95°C for 5 minutes as denaturation step, followed by consecutive decreases in temperature by 
5°C, holding at each step for 20 seconds, until the temperature reached 25°C, at which point 
the temperature was held indefinitely. The denatured/renatured PCR products were then 
digested with T7 Endonuclease I by adding 1 µL T7 Endonuclease I to the annealed PCR 
products (19 µL) and incubated for 30 minutes at 37°C. The digested products were then 
visualised by gel electrophoresis on a 2% agarose gel. 
 
2.4.5 Chromosome Conformation Capture Carbon Copy (5C) assay 
 
The 5C procedure involved formaldehyde cross-linking of chromatin and digesting DNA in 
the cross-linked chromatin with a restriction enzyme (in this case EcoRI), followed by re-
ligation of DNA in dilute solution. After de-crosslinking and purification of the religated 
DNA, the resulting chromosome conformation capture (3C) library DNA was then hybridised 
with a pool of primers designed to be adjacent to the EcoRI sites within the region of interest 
using reverse primers within anchor EcoRI fragments (i.e. the fragments known to contain 
enhancers) and forward primers in all other EcoRI fragments. The primers were ligated with 
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Taq ligase and then PCR amplified to generate the 5C library. The 5C library was then next 
generation sequenced on the Ion Torrent PGM to identify junction molecules that indicated 
close proximity and chromatin interaction. The primers were designed and the data output 
analysed using the my5C tool (http://my5c.umassmed.edu/welcome/welcome.php) (Lajoie et 
al., 2009). Since 3C libraries are difficult to prepare reproducibly, they were made by the 
QIMR Berghofer service run by Drs. Stacey Edwards and Juliet French, who take 
formaldehyde crosslinked chromatin pellets and return the 3C libraries ready for 5C library 
generation.  
 
SH-SY5Y-Scr, SH-SY5Y-SMCHD1.1 and SH-SY5Y-SMCHD1.2 cell lines were cultured in 
Dulbecco's Modified Eagle Medium DMEM/F-12 (a 1:1 mix of DMEM and Ham's F-12) 
supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 2 µg/mL puromycin and 5 
µM 5’-AZC. All cell lines were grown at 37°C in 5% CO2 for 7 days. The collected cells 
were cross-linked with 1% formaldehyde for 10 minutes at room temperature. The reaction 
was quenched by the addition of 0.125 M glycine, followed by incubation on ice for 30 
minutes in a cell lysis buffer. Cell lysis was completed with 10 strokes of a Dounce 
homogeniser. The nuclei were stored at -80°C until the experiment was continued.  
 
For 3C library generation the nuclei were then resuspended in 1 mL of restriction enzyme 
buffer. After adding 21 µL 10% SDS, it was incubated for 30 minutes at 37°C whilst being 
shaken. Then 200 µL 10% Triton was added to each tube and incubated for 30 minutes at 
37°C whilst being shaken. Subsequently, 1500U EcoRI was added and incubated at 37°C 
overnight. 
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The next day, two 20 µL aliquots from each sample were de-crosslinked by adding 25 µL 10 
mM Tris pH 7.5 and 5 µL Proteinase K (10 mg/mL), and incubating for 1 hour at 65°C. A 25 
µL aliquot of each sample was then run on a 1% agarose gel to analyse the initial digestion. 
The other aliquot was used for analysis of digestion efficiency by qPCR. 
 
Next, 150 µL of 10% SDS was added to all the samples and incubated  at 65-80°C for 20 
minutes to inactivate the restriction enzyme. During this incubation the tubes were shaken 
every 5 minutes. The samples were then transferred to a 50 mL Falcon tube to which 5.1 mL 
water, 800 µL 10% Triton, 920 µL 10x Ligase buffer, 80 µL 10 mg/mL BSA and 80 µL 100 
mM ATP were added and incubated for 1 hour at 37°C. After the 1 hour of incubation, 
4000U Ligase was added to each tube and incubated for 4 hours at 16°C, followed by 30 
minutes at room temperature. After this incubation, 300 µg Proteinase K was added to each 
sample and incubated at 65°C overnight to de-crosslink the samples. The de-crosslinked 
ligated DNA can then be stored at -20°C as a pause point. 
 
The next day, 300 µg of RNase A was added to each sample and incubated at 37°C for 45 
minutes, followed by extraction with 8 mL Phenol-Chloroform. Each sample was then 
centrifuged at 4000 g for 15 minutes at 4°C. The supernatant was transferred to a new 50 ml 
Falcon tube, extracted with 8 mL chloroform and centrifuged again at 4000g for 15 minutes 
at 4°C. The supernatant was transferred to high speed autoclaved centrifuge tubes containing 
4mL H2O, 10 µL Glycoblue, 1.1 mL 3M sodium acetate and 27 mL 100% Ethanol, and 
incubated for another 45 minutes at -80°C. Then after 45 minutes of centrifuging at 20,000 g 
at 4°C, the supernatant was removed and 20 mL 70% ethanol was added to each tube. The 
spinning step was repeated at the same speed, time and temperature. The 70% ethanol wash 
was repeated at least 2 more times to remove all of the white fluffy contaminant. Then, the 
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final supernatant was removed and the DNA pellet briefly dried at room temperature. The 
DNA pellet was dissolved in 100 to 200 µL 10 mM Tris (pH 7.5) and incubated overnight at 
4°C on a roller to fully resuspend the DNA. The resulting 3C libraries were quantitated and if 
necessary aliquots were stored at -20°C. 
 
For the generation of the 5C libraries, 3.4 nM of each 5C primers were annealed with the 3C 
library at 95°C for 5 minutes, ramped at -0.1°C/s to 48°C and then incubated at 48°C 
overnight. The next day 10 µl of the ligation master mix (i.e. containing Taq ligase) or 
control master mix (i.e. not containing Taq ligase) were added to each annealing reaction 
while they were still in the thermocycler and incubated at 48°C for 1 hour, after which they 
were kept on ice. Then PCR amplification reactions were immediately set up for each library 
and control sample. The following thermocycling protocol was followed: 98°C for 30 
seconds, then 25, 26 or 27 cycles of 98°C for 5 seconds, followed by 72°C for 30 seconds and 
finally 72°C for 2 minutes. The PCR products were then electrophoresed on a 3% agarose gel 
and visualised using GelRed (Biotium) to choose the 5C library titration and PCR cycle 
number that yielded a PCR amplicon of the correct size (i.e. it was just visible on the gel). 
The PCR product was then prepared in bulk by repeating the PCR cycling using the optimal 
cycle number. Pooled PCR reactions of the same 5C library were concentrated with 
NucleoSpin Gel and PCR Clean-up kit, then run again on a 3% agarose gel. The amplicons 
were excised from the gel and purified using NucleoSpin Gel and PCR Clean-up kit, and 
melted with 200 µl NTI buffer per 100 mg gel before elution in 25 µL. A 5 µL aliquot of the 
purified amplicons was then quantified using the Qubit dsDNA HS quantification assay (Life 
Technologies) and the remainder was stored at -80°C until ready for sequencing.  
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Each 5C library was then subject to next generation sequencing using Ion 314 sequencing 
chips on the Ion Torrent Personal Genome Machine (Life Technologies), according to the 
manufacturers’ instructions. The sequence data obtained were then analysed using the Dosti 
lab custom Galaxy server (http://galaxy.bci.mcgill.ca) and the my5C website 
(http://my5c.umassmed.edu/about/about.php) (Dostie et al., 2006). The sequencing reads 
mapped to an in silico generated “genome” that contained the total possible combinations of 
each forward primer ligated to each reverse primer. The mapped reads were then counted and 
converted to an interaction frequency file, which was then converted to a heat map. The 
resulting BED files generated from the data were visualised on the UCSC Genome Browser 
(http://genome.ucsc.edu/). 
 57 | P a g e  
 
Chapter 3  Expression of Clustered Pcdh genes in NSCs 
 
3.1 Introduction  
 
Since it has been reported that most of the clustered Pcdh genes are expressed in a random 
combinatorial monoallelic manner in individual Purkinje cells (Kaneko et al., 2006, Hirano et 
al., 2012), the best way to characterise the transcript profile is by using single cell qRT-PCR 
with the Fluidigm system. It was decided to use NSCs to work up the single cell qRT-PCR 
methodology since they can be cultured and are easily manipulated to isolate viable single 
cells for analysis. Once it was confirmed that the method was generating reliable results, it 
could then be applied to the Purkinje cells isolated from the cerebella of mice (see Chapter 4). 
This was done because we anticipated that obtaining Prukinje cells in sufficient numbers and 
of sufficient viability would prove problematic.  
 
In this chapter, Smchd1+/+ and Smchd1MommeD1/MommeD1 NSCs were used to investigate 
whether the Smcdh1 mutation would change the expression level or the expression pattern of 
the clustered Pcdh genes. Initially, RNA isolated from bulk NSC cultures was analysed for 
clustered Pcdh expression by qRT-PCR and genome-wide by Transcriptome-seq. The DNA 
isolated from bulk NSC cultures was also analysed at the genome-wide level by MBD-seq. 
This was followed by the single NSC qRT-PCR analysis. 
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3.2 Results 
 
3.2.1 qRT-PCR in bulk NSCs  
 
Previously published results from the laboratory have shown that, using RNA extracted from 
whole brains, clustered Pcdh gene expression is disrupted in Smchd1MommeD1/MommeD1 mice 
relative to Smchd1+/+ mice (Mould et al., 2013). Whether the clustered Pcdh genes would be 
expressed and display similar disruption in NSCs was unknown. The cortical NSC cell lines 
(NSC1.1, NSC1.2 and NSC1.3 isolated from Smchd1MommeD1/MommeD1 mice and NSC1.4, 
NSC1.13 and NSC1.14 isolated from Smchd1+/+ mice) used in these studies were obtained 
from Dr Marnie Blewitt (WEHI). The cell lines were isolated from individual E14.5 
Smchd1MommeD1/MommeD1 and Smchd1+/+ embryos by previously published methods (Lee et al., 
2009). Undifferentiated NSCs were cultured in NSC medium, RNA was extracted from the 
cell lines of both genotypes and qRT-PCR was performed for all of the clustered Pcdh 
isoforms. Transcript levels of many of the Pcdha and Pcdhb isoforms increased significantly 
in Smchd1MommeD1/MommeD1 compared to Smchd1+/+ NSCs, while Pcdhg was less disrupted 
(Figure 3).  
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Figure 3. Comparsion of clustered Pcdh in NSCs isolated from 
Smchd1MommeD1/MommeD1 and Smchd1+/+ mice. 
Pcdh expression level comparison between Smchd1MommeD1/MommeD1 (n=3) and Smchd1+/+ 
(n=3) NSCs. The X axis shows the genes analysed (including all Pcdha, Pcdhb and Pcdhg 
isoforms, and a control gene Actb). The Y axis shows the expression level relative to the 
housekeeping gene Rala and is normalised to the level in Smchd1+/+ NSCs. A T-test was 
performed on the data with a Benjamin Hochberg adjustment on P-values. (*P<0.05; ** 
P<0.01; *** P<0.01) 
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3.2.2 MBD-seq and Transcriptome-seq of NSCs  
 
Transcriptome-seq and MBD-seq using RNA and DNA extracted from both 
Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs were performed to further investigate the 
genome-wide consequences of Smchd1 loss and, in particular, whether clustered Pcdh 
isoform expression was disrupted in these cells.  
 
Analysis of the Transcriptome-seq data comparing genome-wide expression differences 
between Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs (n=3 for each genotype) was 
undertaken with the aid of a QIMR Berghofer Bioinformatician (Dr Pamela Mukhopadhyay). 
The analysis pipeline used three different programs, DESeq (Love et al., 2014), EdgeR 
(Robinson et al., 2010) and Cufflinks (Trapnell et al., 2012), to identify differentially 
expressed genes. Principal component analysis identified sample NSC1.4 (a cell line 
genotyped as Smchd1+/+) as not grouping with the other Smchd1+/+ NSC cell lines, nor did it 
group with the 3 Smchd1MommeD1/MommeD1 NSC cell lines (Figure 4). Therefore, it was decided 
to conduct the differential expression analysis both with and without inclusion of the NPC1.4 
sample. The full listing of differentially expressed genes detected by the analysis and ranked 
by statistical significance is contained in the Supplementary Excel File #1 (Sheet No.2 to 
No.7). Graphs generated from the Transcriptom-seq analyses are shown in Figures 4-9.  
 
It can be seen in the Venn diagram for differential expression analysis (with the NSC1.4 
sample included) that the total gene count for all three programs was 15,180, with only 209 
genes showing differential expression in the overlap between all three programs (Figure 5). In 
contrast, when the differential expression analysis was conducted without the NSC1.4 sample, 
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the total gene count was 15,091, with 2,093 found in the overlap between the three programs 
(Figure 6).   
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Figure 4. Principal component analysis plot of Transcriptome-seq data from 
Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs. 
NSC1.4 did not cluster with either the Smchd1+/+ (wild-type) mice (NSC1.13 and NSC1.14) 
or the Smchd1MommeD1/MommeD1 (mutant) mice (NSC1.1, NSC1.2 and NSC1.3).  
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Figure 5. Venn diagram of the differential expression analysis (with NSC1.4). 
The Venn diagram was generated from the Transcriptome-seq data (with sample NSC1.4 
included) and shows the overlap of differential gene expression detected by the three 
different programs (edgeR, DESeq and Cufflinks). 
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Figure 6. Venn diagram of the differential expression analysis (without NSC1.4). 
The Venn diagram was generated from the Transcriptome-seq data (without sample NSC1.4 
included) and shows the overlap of differential gene expression detected by the three 
different programs (edgeR, DESeq and Cufflinks).  
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The heatmap (Figure 7) shows that the samples clustered into 2 groups (Smchd1+/+ and 
Smchd1MommeD1/MommeD1). The top 30 genes which were significantly differentially expressed 
between the two groups have been listed, with many clustered Pcdh genes included in the list 
(i.e. Pcdha1, Pcdha5, Pcdha6, Pcdha7, Pcdha8, Pcdha9, Pcdhb2, Pcdhb3, Pcdhb4, Pcdhb5, 
Pcdhb6, Pcdhb10, Pcdhb11 and Pcdhb22). The MA plots (Figure 8) and Volcano plots 
(Figure 9) also show that many of the clustered Pcdha and Pcdhb genes were expressed at 
increased levels in Smchd1MommeD1/MommeD1 NSCs. 
 
As anticipated, all 3 programs (both with and without the NSC1.4 sample included) identified 
Smchd1 as the gene with the most significantly decreased expression in 
Smchd1MommeD1/MommeD1 NSCs compared to Smchd1+/+ NSCs. All 3 programs also identified 
the imprinted genes Ndn, Mkrn3, and Peg12 as having significantly increased expression in 
Smchd1MommeD1/MommeD1 samples, as seen previously in the RNA-seq analysis for embryos and 
whole brain samples (Gendrel et al., 2013, Mould et al., 2013). The analysis of NSC cell lines 
including NSC1.4 identified additional imprinted genes with significantly altered expression 
in Smchd1MommeD1/MommeD1 samples (e.g. Peg10, Rian, Grb10, Po2, Sfmbt2 and Ampd3). 
These imprinted genes have not been previously identified as deregulated in the absence of 
Smchd1 function and may indicate a universal role for Smchd1 in genomic imprinting. Other 
genes near the top of the list were Pisd-ps3, Gm18756, Klhl4, Gabrb3, Csmd3, Dbc1, 
9830147E19Rik, A330076H08Rik, 1700030C10Rik, Dcafl2l1, 5730507C01Rik, Dpp10 and 
Eef1a2. Of these genes, Gabrb3 may be of particular interest since there is conflicting 
evidence in the literature as to whether it is part of the Snrpn cluster of imprinted genes and 
thus, subject to genomic imprinting (Buettner et al., 2004, Nicholls et al., 1993, Yamasaki et 
al., 2003, Meguro et al., 1997, Bittel et al., 2003, Bittel et al., 2005, Kubota et al., 1994, 
Gabriel et al., 1998). 
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In agreement with the qRT-PCR analysis, the transcript levels of most of the clustered Pcdha 
and Pcdhb genes (28 isoforms in total) were significantly up-regulated in 
Smchd1MommeD1/MommeD1 samples, regardless of whether or not the data for the NPC1.4 sample 
was included in the analysis. Interestingly, Pcdhga12 and Pcdhgb6 were shown to be down-
regulated in Smchd1MommeD1/MommeD1 samples. In the bulk NSCs qRT-PCR analysis the 
transcript of Pcdhga12 also showed decreased expression in Smchd1MommeD1/MommeD1 NSC 
cell lines, but there was no significant difference of Pcdhgb6 expression between Smchd1+/+ 
and Smchd1MommeD1/MommeD1 samples.  
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Figure 7. Heatmap showing differential expression analysis using DESeq (with 
NSC1.4). 
The samples clustered into two groups according to their significantly different expression 
level. NSC1.1, NSC1.2 and NSC1.3 were Smchd1MommeD1/MommeD1 NSCs, while NSC1.4, 
NSC1.13 and NSC1.14 were Smchd1+/+ NSCs. The top 30 differentially expressed genes, 
ranked by significance level, are shown. Smchd1 was the highest ranking differentially 
expressed gene and many clustered Pcdh genes were near the top of the list.  
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Figure 8. MA plot showing differential expression analysis of Transcriptome-seq 
data using DESeq (with NSC1.4). 
Data was plotted as log2 fold change between Smchd1
MommeD1/MommeD1 and Smchd1+/+ NSCs 
(n=3 per genotype) versus the average expression in log counts per million (LogCPM). Each 
dot represents the differential expression for an individual gene. The red dots are either up-
regulated or down-regulated genes with an adjusted P< 0.05.  
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Figure 9.  Volcano Plot showing differential expression analysis of Transcriptome-
seq data using DESeq (with NSC1.4). 
Data was plotted as -Log10 P-value versus log2 fold change between Smchd1
MommeD1/MommeD1 
and Smchd1+/+ NSCs (n=3 per genotype). Each dot represents the differential expression for 
an individual gene. The red dots are either up-regulated or down-regulated genes with an 
adjusted P<0.05. Among the up-regulated genes, there are many clustered Pcdh genes as 
indicated in this Figure. Smchd1 was not included in this plot as its -Log10 P-value was off 
scale (P=2.23E-156). 
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MBD-seq analysis was also conducted with the assistance of our in-house Bioinformatician 
(Dr Pamela Mukhopadhyay). Differentially methylated regions were identified using DESeq 
and the full listing is contained in the Supplementary Excel File #1 (Sheet No.8).  
 
The level of CpG methylation at the promoters of individual clustered Pcdha isoforms 
(predominantly for Pcdha1 to a12) was reduced in Smchd1MommeD1/MommeD1 NSCs (without 
Pcdha1, a7 and a9) (Figure 10). This was consistent with the qRT-PCR result. However, only 
two Pcdhb isoforms were decreased in Smchd1MommeD1/MommeD1 NSCs (Pcdhb17 and Pcdhb21) 
(Figure 10). The qRT-PCR detected many more Pcdhb genes with increased expression in 
Smchd1MommeD1/MommeD1 NSCs. This was likely because the resolution of the MBD-seq 
analysis was not sufficient to detect differences at the Pcdhb loci at the depth of sequencing 
that was used.  
 
In addition to the Pcdh genes, differential CpG methylation between Smchd1+/+ and 
Smchd1MommeD1/MommeD1 NSCs was identified at regions associated with three imprinted genes 
(Mkrn3, Peg12, Ndn in the Snrpn cluster of imprinted genes). Again, this was consistent with 
the Transcriptom-seq data and previous studies (Mould et al., 2013). Additionally, 
differential CpG methylation was identified at two regions distal of Snrpn (at positions Chr7: 
60492356-60492843 and Chr7: 60391208-60391661). This differential CpG methylation 
(with decreased methylation in Smchd1MommeD1/MommeD1 NSCs) did not correspond with the 
DMR or imprint control region that is associated with imprinting of Snrpn cluster 
(Chamberlain and Brannan, 2001, Bielinska et al., 2000, Yang et al., 1998) which has 
previously been shown to maintain its differential methylation in Smchd1MommeD1/MommeD1 
mice (Gendrel et al., 2013, Mould et al., 2013). The differential CpG methylation distal to 
Snrpn identified in the MBD-seq analysis of NSC does, however, coincide with Smchd1 
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binding sites that were later identified by our collaborators (Kelan Chen and Marnie Blewitt) 
in their Smchd1 ChIP-seq (Chen et al., 2015).  
 
The other major differential CpG methylation detected in the MBD-seq analysis was 
associated with Rn4.5s (decreased methylation in Smchd1MommeD1/MommeD1 NSCs). Rn4.5s 
encodes a poorly characterised nuclear RNA transcript of unknown function (Gogolevskaya 
et al., 2010). The Rn4.5s locus has recently been shown to become hypermethylated in the 
brains of female mice exposed to lead (Sánchez-Martín et al., 2015).  
 
The Transcriptome-seq data and MBD-seq data subsequently were re-analysed by 
Bioinformaticians at WEHI as part of our collaboration with Kelan Chan and Dr. Marnie 
Blewitt. The analysis pipeline used different programs for sequence mapping (Rsubread 
program version 1.10.5), sample normalisation and detection of differentially expressed 
genes (edgeR and limma Bioconductor software) than those used by our Bioinformatician at 
QIMR Berghofer. The re-analysis produced an essentially similar set of genes showing the 
most significant expression changes between the genotypes. This analysis was used in our 
recent publication on which I am second author (Chen et al., 2015). 
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Figure 10. Volcano Plot showing differential methylation analysis of MBD-seq data 
using DESeq (with NSC1.4). 
The data was plotted as -log10 P-value versus log2 fold change of methylation peak heights 
between Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs (n=3 per genotype). Each dot 
represents a methylation peak as identified by MACS. The red dots are differential 
methylation peak heights with an adjusted P<0.05. Most of red dots are methylation peaks 
associated with clustered Pcdh genes. 
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3.2.3 Single cell qRT-PCR analysis of NSCs 
 
The Fluidigm system was used to perform single cell qRT-PCR analysis of the clustered 
Pcdhs isoforms. This was done to determine whether the disrupted expression observed in 
bulk Smchd1MommeD1/MommeD1 NSC cultures resulted from altered expression levels generally, 
or from disruption of the random combinatorial selection process that operates to choose a 
limited number of clustered Pcdh isoforms to be expressed by individual cells.  
 
The single cell qRT-PCR analysis required considerable methodological refinement in order 
to achieve reliable results. Parameters that were varied included different types of cDNA 
synthesis kit and cDNA synthesis primer type (i.e. gene specific, oligo dT or a combination 
of gene specific and random primers), pre-amplification reagents and conditions, cell lysis 
reagents and FACS conditions for sorting individual cells. Only the results obtained from the 
optimal method chosen are included in the following discussion. Unfortunately, it was not 
possible to determine whether the monoallelic nature of expression of the clustered Pcdh 
isoforms was also disrupted, because the NSC were not generated from embryos carrying the 
multiple SNPs necessary to ascertain the allelic origin of the transcripts.  
 
The clustered Pcdh isoforms produce very similar transcripts, which are likely to behave 
similarly in terms of their half-life and when expressed, are likely to be expressed at similar 
levels. As a result, the analysis of qRT-PCR data obtained from single cells on the Fluidigm 
platform was treated as gene expression detection rather than quantitative expression 
analysis. A gene was considered to be expressed by a cell if the Ct was <33. This avoided 
many of the complications encountered in current single cell expression studies involving 
RNA-seq data for genome-wide expression analysis. 
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The heat maps (Figures 11, 12 and 13) show that in general, more Pcdha and b isoforms were 
detectable in Smchd1MommeD1/MommeD1 than in Smchd1+/+ NSCs, while there appeared to be no 
difference for Pcdhg isoforms. To quantify this, the numbers of detected isoforms were 
counted in each individual cell and plotted as the number of isoforms expressed per cell (X 
axis) versus the number of cells (Y axis) for each cluster (i.e. Pcdha, b and g) (Figure 14, 15 
and 16). The graphs demonstrated that Smchd1MommeD1/MommeD1 NSCs expressed more Pcdha 
and Pcdhb isoforms per cell than Smchd1+/+ cells. The incidence rates between 
Smchd1MommeD1/MommeD1 NSC and Smchd1+/+ NSC for expression of clustered Pcdha and 
Pcdhb isoforms were 2.62 and 2.59 times, respectively (P<0.001 in each case). However, the 
number of Pcdhg isoforms expressed in single NSCs was not significantly different between 
Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs. Quantification of the number of cells 
expressing each of the clustered Pcdha, b, and g isoforms (n=66 for each genotype) was also 
in general agreement with the previous bulk NSCs qRT-PCR assay. 
 
Overall, the clustered Pcdha and b genes were disrupted by loss of Smchd1 function more 
than the clustered Pcdhg genes. Expression of the Pcdha variable isoforms (i.e. Pcdha1 to 
12) was detected in 33% of the Smchd1+/+ NSCs (22 cells out of 66 cells analysed). Further, 
in those cells that did express the Pcdha variable isoforms, 1, 2 or sometimes 3 different 
isoforms were detectable. More Smchd1+/+ NSCs showed expression of the constant isoforms 
(58 cells out of 66 cells analysed, with 20 cells expressing PcdhaC1 and 38 cells expressing 
PcdhaC2). In contrast, many more of the Smchd1MommeD1/MommeD1 NSCs showed expression 
of the variable Pcdha isoforms (55 cells out of 66 cells analysed). More than 60% of those 
cells (36 cells of 55 cells with expression) expressed 3 or more of the variable isoforms. 
Some cells had as many as 10 different variable Pcdha isoforms that were able to be detected. 
Given this result, it was surprising that expression of the constant Pcdha isoforms was 
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somewhat decreased in Smchd1MommeD1/MommeD1 NSCs (28 cells out of 66 cells analysed, with 
19 cells expressiong PcdhaC1 and 16 cells expression PcdhaC2). 
 
The increase in variable Pcdha isoform expression seen in Smchd1MommeD1/MommeD1 NSCs was 
somewhat mirrored by the numbers of cells expressing Pcdhb isoforms (58 of the 66 
Smcdh1+/+ cells analysed, compared with 65 of the 66 Smchd1MommeD1/MommeD1 cells 
analysed). More striking was the number of different Pcdhb isoforms expressed by individual 
cells. Only 14% of the Smchd1+/+ cells expressing Pcdhb isoforms had more than 5 different 
isoforms detectable (8 of the 58 cells with detectable Pcdhb isoforms), while 60% of 
Smchd1MommeD1/MommeD1 NSCs expressed more than 5 different Pcdhb isoforms (39 of the 65 
cells with detectable Pcdhb isoforms).  
 
For Pcdhg isoforms, there was no real difference between the genotypes for the number of 
cells expressing either the variable or constant isoforms. All cells expressed PcdhgC3, with 
fewer cells expressing PcdhgC4 and PcdhgC5. On average, individual cells expressed 
approximately 5 variable isoforms with no difference between the genotypes (average 4.8 for 
Smchd1+/+ NSCs and 4.6 for Smchd1MommeD1/MommeD1 NSCs). 
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Figure 11.  Heat map for clustered Pcdha isoform expression comparing Smchd1+/+ 
and Smchd1MommeD1/MommeD1 NSCs at the single cell level. 
Each column shows an individual clustered Pcdha isoform or control gene (Rala) that was 
detected and each row is the result for a single cell. The right panel is the heat map for 
Smchd1+/+ NSCs and the left panel is the heat map for Smchd1MommeD1/MommeD1 NSCs. In the 
heat map, from top to bottom, the color changes from yellow through purple and blue to 
black to represent Ct from low to high (i.e. expression level from high to low). The minus 
reverse transcriptase control (-RT) is indicated in each case.  
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Figure 12.  Heat map for clustered Pcdhb isoform expression comparing Smchd1+/+ 
and Smchd1MommeD1/MommeD1 NSCs at the single cell level. 
Each column shows an individual clustered Pcdhb isoform or control gene (Rala) that was 
detected and each row is the result for a single cell. The right panel is the heat map for 
Smchd1+/+ NSCs and the left panel is the heat map for Smchd1MommeD1/MommeD1 NSCs. In the 
heat map, from top to bottom, the color changes from yellow through purple and blue to 
black to represent Ct from low to high (i.e. expression level from high to low). The minus 
reverse transcriptase control (-RT) is indicated in each case.  
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Figure 13.  Heat map for clustered Pcdhg isoform expression comparing Smchd1+/+ 
and Smchd1MommeD1/MommeD1 NSCs at the single cell level. 
Each column shows an individual clustered Pcdhg isoform or control gene (Rala) that was 
detected and each row is the result for a single cell. The right panel is the heat map for 
Smchd1+/+ NSCs and the left panel is the heat map for Smchd1MommeD1/MommeD1 NSCs. In the 
heat map from top to bottom, the color changes from yellow through purple and blue to black 
to represent Ct from low to high (i.e. expression level from high to low). The minus reverse 
transcriptase control (-RT) is indicated in each case. 
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Figure 14.  Quantification of the number of clustered Pcdh isoforms expressed per 
individual cell for all Pcdha, Pcdhb and Pcdhg isoforms (including variable isoforms). 
(A) The incident rate for Pcdha isoforms in Smchd1MommeD1/MommeD1 NSCs was 2.62 greater 
times the incident rate of Smchd1+/+ NSCs (P<0.001). (B) The incident rate for Pcdhb 
isoforms in Smchd1MommeD1/MommeD1 cells was 2.59 greater times the incident rate in 
Smchd1+/+ NSCs (P<0.001). (C) The incident rate for Pcdhg isoforms in 
Smchd1MommeD1/MommeD1 NSCs was 0.94 greater times the incident rate of Smchd1+/+ NSCs 
(P=0.379). 
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Figure 15.  Quantification of the number of clustered Pcdh isoforms expressed per 
individual cell for Pcdha and Pcdhg variable isoforms only. 
(A) The incident rate for variable Pcdha isoforms in the Smchd1MommeD1/MommeD1 NSCs was 
6.06 times greater than that of Smchd1+/+ NSCs (p<0.001). (B) The incident rate for variable 
Pcdhg isoforms in the Smchd1MommeD1/MommeD1 NSCs was 0.9742766 times the incident rate 
of the Smchd1+/+ cells (p=0.747). 
 
  
Chapter 3 Expression of clustered Pcdh genes in NSCs 
86 | P a g e  
 
 
  
Chapter 3 Expression of clustered Pcdh genes in NSCs 
87 | P a g e  
 
Figure 16.  Quantification of the frequency of all clustered Pcdh isoforms expressed 
in individual cells. 
The X axis shows the isoforms of Pcdha (A) Pcdhb (B) and Pcdhg (C). The Y axis shows the 
number of cells expressing each clustered Pcdh isoform. 
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3.3 Discussion 
 
When clustered Pcdh expression was analysed using RNA isolated from bulk cultures of 
undifferentiated NSC, there was considerable disruption detected in Smchd1MommeD1/MommeD1 
compared with Smchd1+/+ cells. The majority of the clustered Pcdha and Pcdhb isoforms 
showed increased expression in Smchd1MommeD1/MommeD1 NSC, with the clustered Pcdhg 
isoforms being less perturbed. The overall change was quite similar to the qRT-PCR result 
obtained when using RNA isolated from whole adult male mouse brains, except that in the 
brains there was more perturbation of Pcdhg isoforms (Mould et al., 2013).  
 
The result was confirmed using genome-wide Transcriptome-seq, where many of the Pcdha 
and Pcdhb isoforms were among the genes showing the most significant changes in 
Smchd1MommeD1/MommeD1 compared with Smchd1+/+ NSCs. MBD-seq analysis revealed that the 
most significantly hypo-methylated regions in Smchd1MommeD1/MommeD1 compared with 
Smchd1+/+ were the promoter regions of clustered Pcdhs, most notably in promoter regions 
associated with the alternative Pcdha first exons. The genome-wide analysis of other 
epigenetic marks (undertaken by our collaborators Kelan Chen and Marnie Blewitt and 
reported in our recent publication) (Chen et al., 2015) has also shown significant differences 
associated with the clustered Pcdh loci. They detected increased H3K4me3 at the promoters 
associated with the alternative Pcdha first exons in Smchd1MommeD1/MommeD1 compared with 
Smchd1+/+ NSC. Their Smchd1 ChIP-seq data also showed that Smchd1 binds at specific sites 
within the alternative Pcdha promoters and to HS5-1a and HS5-1b, which are proposed to act 
as enhancers for expression of clustered Pcdha. From these analyses we proposed that, in 
Smchd1+/+ NSC, the Smchd1 protein binds to the alternative promoters and enhancers (HS5-
1a and HS5-1b) of the clustered Pcdha gene to initiate or maintain the methylated status of 
the promoters, and to help maintain the epigenetic repression of selected individual Pcdha 
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isoforms. This would act in opposition to factors that serve to enhance or maintain specific 
Pcdha isoform expression. It has previously been proposed that the Ctcf/Cohesin complex 
recruits selected Pcdha promoters to the HS5-1 site to form an active transcriptional hub that 
drives a specific chosen set of Pcdha isoform expression (Guo et al., 2012). We also found 
that many of the Smchd1 binding sites overlapped with Ctcf binding sites and thus, proposed 
that Smchd1 and Ctcf binding act in opposition to each other at these loci (Chen et al., 2015).  
  
Since it has been proposed that individual Purkinje cells express unique subsets of the 
clustered Pcdh variable isoforms (Kaneko et al., 2006, Hirano et al., 2012), it was important 
to undertake single cell expression analysis in the NSCs. This analysis was required to 
distinguish between the possible alternative scenarios that could explain the results from the 
analysis of bulk cultures: (a) that loss of Smchd1 function may result in a general increase in 
clustered Pcdh isoform expression; or (b) that the loss of Smchd1 disrupts the mechanism that 
chooses which and how many isoforms will be expressed. The single cell qRT-PCR analysis 
was consistent with bulk NSCs qRT-PCR, Transcriptome-seq and MBD-seq results showing 
that the clustered Pcdha and b isoform expression is disrupted in Smchd1MommeD1/MommeD1 
NSCs and Pcdhg expression less disrupted.  
 
Published data indicate that individual Purkinje cells express 2 or 3 different Pcdha viable 
isoforms, 4 or 5 Pcdhb isoforms and 4 or 5 Pcdhg variable isoforms, with the 5 C-type 
clustered Pcdhs (i.e. PcdhaC1, C2, PcdhgC3, C4, and C5) being expressed by all cells 
(Kaneko et al., 2006, Hirano et al., 2012, Chen and Maniatis, 2013). It has been proposed that 
all mature neurons are likely to follow this pattern of clustered Pcdh isoform expression. It 
was hoped that NSCs might provide an ideal in vitro system in which to study Smcdh1 
function in terms of the mechanism that operates to choose which variable clustered Pcdh 
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isoforms are expressed by each individual cell. This would have been analogous to mouse ES 
cells, which can initiate XCI upon differentiation, making them ideal models for studying 
XCI. Since NSC can also differentiate into many types of new neurons, it was postulated that, 
while undifferentiated NSC might not have yet chosen their expression pattern, this might be 
decided by the cells upon initiation of, or during differentiation to establish their individual 
identity. Based on the data presented here, this does not seem to be the case, especially for the 
variable Pcdhg isoforms which appear to have already been chosen in undifferentiated NSC 
and were largely unperturbed by the loss of Smchd1 function. It remains possible that Pcdha 
isoform selection is not yet finalised in undifferentiated NSC, because only very few 
individual cells had detectable variable or constant Pcdha isoform expression and the number 
of isoforms expressed was perturbed by loss of Smchd1 function. The situation for Pcdhb 
isoform expression appears to be midway between what was seen for the variable Pcdha and 
Pcdhg isoforms. Most individual Smchd1+/+ NSCs expressed a limited number of isoforms 
and many individual Smchd1MommeD1/MommeD1 NSCs expressed considerably more, with some 
individual cells expressing as many as 21 to 28 Pcdh isoforms (including Pcdha, b and g). 
 
An alternative possibility to explain the increased clustered Pcdh expression, in the absence 
of Smchd1 function, could be that the Smchd1MommeD1/MommeD1 NSCs were more differentiated 
than the Smchd1+/+ NSCs. Since Smchd1MommeD1/MommeD1 NSCs showed a greater level of 
clustered Pcdh expression, this may indicate that the cell lines were partially differentiated. 
However this seemed unlikely, because visually the Smchd1MommeD1/MommeD1 and Smchd1+/+ 
cell lines showed identical stem cell morphology (Figure 17). Additionally, the qRT-PCR 
result of several lineage specific markers for neural stem cells (e.g. Nes) and neural 
progenitor cells (e.g. Map2 and Tubb3) or a terminal neuron specific marker (e.g. Gfap) 
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showed no significant difference in expression levels between Smchd1MommeD1/MommeD1 and 
Smchd1+/+ NSCs (Figure 18).  
 
  
Smchd1+/+ NSCs  Smchd1MommeD1/MommeD1 NSCs 
 
Figure 17.  Smchd1MommeD1/MommeD1 and Smchd1+/+ NSC cell morphology. 
The images show the morphology of Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs. There 
was no visual difference between the two cell types. 
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Figure 18. Lineage specific marker expression in Smchd1MommeD1/MommdeD1 and 
Smchd1+/+ NSCs. 
Nes, Map2, Tubb3 and Gfap expression level comparison between Smchd1MommeD1/MommeD1 
and Smchd1+/+ NSCs. The X axis shows the gene name. The Y axis shows the expression 
level relative to the housekeeping gene Rala. Neither the neural stem cell marker (Nes), the 
neural progenitor cell markers (Map2 and Tubb3) nor a terminal neuron specific marker 
(Gfap) showed significant differences in expression between Smchd1MommeD1/MommeD1 and 
Smchd1+/+ NSCs. 
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Chapter 4 Analysis of single Purkinje cells 
 
4.1 Introduction  
 
Previous work has shown that clustered Pcdh gene expression levels were disrupted in 
Smchd1MommeD1/MommeD1 mice (Mould et al., 2013). In this previous study, RNA was extracted 
from a whole mouse brain (both Smchd1+/+ and Smchd1MommeD1/MommeD1) and analysed for 
steady state mRNA transcript levels. However, the clustered Pcdh genes are subject to 
random combinatorial monoallelic and biallelic expression, and each individual Purkinje 
neuron expresses a unique combination of clustered Pcdha, b, and g isoforms (Kaneko et al., 
2006, Yokota et al., 2011). It was not known whether the loss of Smchd1 resulted in generally 
altered levels of clustered Pcdh gene expression or whether individual cells were each 
expressing more clustered Pcdh isoforms than wild type cells. To clarify this, it was 
necessary to investigate clustered Pcdh isoform expression in individual cells comparing 
Purkinje cells isolated from Smchd1MommeD1/MommeD1 and Smchd1+/+ mice.  
 
Additionally, studies using mice that were lacking all 22 clustered Pcdhg genes have revealed 
abnormal dendritic arborisation and loss of the self-avoidance in Purkinje cells (Lefebvre et 
al., 2012). Furthermore, Dnmt3b-KO mice, which show abnormal expression of clustered 
Pcdha, b and g isoforms also display loss self-avoidance in Purkinje cell dendrites (Massah et 
al., 2014). Therefore, it was important to analyse Smchd1MommeD1/MommeD1 mice to determine 
whether the deregulated clustered Pcdh expression was also associated with the loss of self-
avoidance ability in Purkinje cells. 
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This chapter reports on studies aimed at identifying whether clustered Pcdh isoform 
expression was disrupted in single Purkinje cells in the absence of Smchd1 and whether those 
Purkinje cells displayed abnormal dendritic arborisation indicating loss of self-avoidance. 
 
4.2 Results 
 
To aid identification, Purkinje cells were initially isolated from genetically engineered mice, 
where the Purkinje neurons were labelled with EGFP. To obtain the desired mice, the 
Smchd1MommeD1/MommeD1 mice were crossed with Z/EG transgenic mice (Novak et al., 2000) 
and with Pcp2-Cre transgenic mice (Zhang et al., 2004). Double transgenic progeny from this 
cross expressed Cre recombinase in Purkinje neurons, which resulted in deletion of the floxed 
β-geo (i.e. lacZ-neo fusion) part of the ubiquitously expressed Z/EG transgene and bright 
green EGFP fluorescence only in Purkinje cells (Figure 19). These transgenes were crossed 
into mice carrying the Smchd1MommeD1/+ allele in order to generate Smcdh1+/+ and 
Smchd1MommeD1/MommeD1 male progeny with EGFP labelled Purkinje neurons. From these 
crosses only male progeny could be studied, as Smchd1MommeD1/MommeD1 female embryos are  
mid-gestation lethal (Blewitt et al., 2005). 
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Figure 19. Double transgene reporter system. 
 
Z/EG transgene is a double reporter transgene which includes β-geo and EGFP reporter 
genes. It has a strong pCAGGS promoter that directs ubiquitous expression of a loxP-flanked 
β-geo fusion gene. The cells expressing β-geo can be stained blue using Xgal solution. In 
cells that express Cre recombinase, the loxP-flanked β-geo fusion gene is deleted and EGFP 
is expressed. The Pcp2-Cre transgene expresses Cre recombinase only in the Purkinje cells.  
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4.2.1 Verifying the double transgene is working as expected  
 
When breeding mice according to the genotypes shown in Table 1, the probability of 
generating animals of the correct genotype is 1/32 of all conceptuses, as only male progeny 
can be used for analysis and female Smchd1MommeD1/MommeD1 progeny die at E9.5-11.5. This 
means that it would require considerable time to generate progeny with the appropriate 
genotype. Ear tags from young mice (i.e. around PN10) were used for identification of the 
Z/EG transgene positive mice by X-gal staining, followed by DNA extraction for Cre PCR 
for identification of Pcp2-Cre transgene positive mice and Smchd1 allelic discrimination to 
verify the Smchd1 genotype of the mice. Once a mouse carrying both the Z/EG and Pcp2-Cre 
transgenes, as well as being Smchd1MommeD1/+ was identified, the mouse was dissected to 
remove its brain (genotyping result shown in Figure 20). The whole brain was imaged under 
both bright field and EGFP epifluorescence (Figure 21). This showed bright green 
fluorescence only in the cerebellum under the EGFP epifluorescence. The brains were then 
fixed in 4% PFA/PBS for 24 hours and sent to the QIMR Berghofer Histology Department 
for blocking and sectioning. The sections from the brains were immunostained by EGFP 
immunofluorescence to verify that only Purkinje cells were labelled by anti-EGFP antibody 
(Figure 22). This finding confirmed that the double transgene approach was working as 
expected.   
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Table 1. Breeding table 
  
Genotypes crossed Relevant genotype of progeny 
obtained 
Frequency 
1st cross 
♂ Smchd1MommeD1/+ 
x ♀ Z/EG+/- 
and 
♂ Smchd1MommeD1/+ 
x  ♀ Pcp2-Cre+/- 
 
♂ or ♀ Smchd1MommeD1/+;Z/EG+/- 
 
 
♂ or ♀ Smchd1MommeD1/+;Pcp2-Cre+/- 
 
 
1 in 4 
2nd cross 
♂ Smchd1MommeD1/+;Z/EG+/- 
x 
♀ Smchd1MommeD1/+;Pcp2-Cre+/- 
(or reciprocal) 
 
♂ Smchd1+/+;Z/EG+/-;Pcp2-Cre+/- 
and 
♂ Smchd1MommeD1/MommeD1;Z/EG+/-
;Pcp2-Cre+/- 
 
1 in 32 
but Smchd1MommeD1/MommeD1 
females die 
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Figure 20. Genotyping example. 
(A) Smchd1 allelic discrimination plot. The blue, green and redspots are 
Smchd1MommeD1/MommeD1, Smchd1MommeD1/+ and Smchd1+/+ samples, respectively and the black 
crosses are no template controls. (B) Cre transgene genotyping. The PCR amplifies a 518 bp 
DNA fragment from the transgene. Lanes I, III, V and VIII are Cre positive, while II, IV, VI 
and VII are Cre negative. (C) Z/EG transgene genotyping. The ear clip does not change color 
in I (Z/EG transgene negative), but it turns to blue in II (Z/EG transgene positive). 
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Figure 21. Image of mouse brain with EGFP positive Purkinje cells due to transgene 
expression.  
The brains were dissected from a three month old mouse carrying both Z/EG and Pcp2-Cre 
transgenes. A (above) and B (below) are under the bright field illumination, and C (above) 
and D (below) are under the EGFP epifluorescence illumination. The EGFP is only detected 
in the cerebellum area.  
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Figure 22. Immunofluorescence for both Smchd1+/+ and Smchd1MommeD1/MommeD1 
mouse brains with Purkinje specific EGFP. 
Images of sagittal sections of mouse brains stained by immunofluorescence for EGFP and 
with DAPI. A, C and E are 4x images of a Smchd1+/+ EGFP brain, Smchd1MommeD1/MommeD1 
EGFP brain and Smchd1+/+ no EGFP brain, respectively. B, D and F are 20x images of 
Purkinje cell layer in cerebellum area for a Smchd1+/+ EGFP brain section, 
Smchd1MommeD1/MommeD1 EGFP brain section and Smchd1+/+ no EGFP brain section, 
respectively.  
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4.2.2 Single Purkinje cell qRT-PCR 
 
Due to the difficulty in obtaining mice of the desired genotype (i.e. Z/EG+/-;Pcp2-Cre+/-
;Smchd1+/+ and Z/EG+/-;Pcp2-Cre+/-;Smchd1MommeD1/MommeD1), mice carrying just the Z/EG 
and Pcp2-Cre transgenes were also used to work up the Purkinje cell isolation protocol 
(Esumi et al., 2006). Three different dissociation enzymes (i.e. Papain, Trypsin and Accutase) 
and varying times for enzymatic digestion were tested for isolation of Purkinje cells. Papain 
gave the best result in terms of appropriate enzyme activity, a reasonable number of single, 
and apparently intact, cells after enzyme dissociation and minimal debris.  
 
Once enzymatic digestion conditions were optimised the cells were subject to FACS sorting 
using the MoFloTM XDP Cell Sorter, together with EGFP to help identify Purkinje cells and 
propidium iodide (PI) to help to identify intact cells (i.e. dead versus live cells based on 
whether the cells stained with PI). It was anticipated that many cells would be damaged due 
to the dendrites being broken off during enzymatic dissociation, with only the cell body 
remaining. At the age where Purkinje cells can easily be isolated by FACS, according to 
published methods (Tomomura et al., 2001), very few expressed EGFP using the double 
transgene system or the EGFP signal was not strong enough to be detected. Several 
populations of cells from different regions of the FACS profile were sorted and only the cells 
sorted from the boxed area in Figure 23 had the characteristic Purkinje cells morphology 
when viewed under light microscopy. However, almost all of the cells isolated from this 
region had intermediate red fluorescence after adding PI rather than being classified as PI 
bright or PI negative (Figure 23). This indicated that the cells had disrupted cell membranes 
and were not likely to be useful for qRT-PCR analysis. A set of single cells isolated in this 
manner from Smchd1MommeD1/MommeD1 and Smchd1+/+ mice were taken through the qRT-PCR 
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analysis and a large proportion were shown not to retain detectable levels of the clustered 
Pcdh transcripts, even though the control gene, Actb, could be detected in some cells (Figure 
24).   
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Figure 23. Sorted single Purkinje cells. 
Single Purkinje cells were sorted by FACS according to EGFP and PI signal. (A) The 
conditions used to sort the single Purkinje cells (i.e. lower PI and higher EGFP signal). (B) 
Sorted cells observed under the microscope showing that according to their shape and size, 
they were likely to have a high proportion of Purkinje cells.  
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Figure 24. Sorted single Purkinje cell qRT-PCR.  
Result of single Purkinje cell qRT-PCR using Fluidigm system, almost none of clustered 
Pcdh isoforms were detectable and only occasional cells had detectable Actb. Each column 
shows an individual clustered Pcdha or Pcdhg isoform or control gene (Actb) that was 
detected and each row is the result for a single cell. The top panel are single cells from 
Smchd1MommeD1/MommeD1 mice and the bottom panel are single cells from Smchd1+/+ mice. In 
the heat map, from top to bottom, the color changes from yellow through purple and blue to 
black to represent Ct from low to high (i.e. expression level from high to low).  
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Since the FACS sorting did not prove successful, manual picking of the individual cells using 
a micropipette based on the unique morphology of Purkinje cells was attempted (Figure 25). 
The benefit of this method was that mice with EGFP labelled Purkinje cells were not 
necessary. This increased the rate at which mice of the required genotype could be obtained 
(i.e. Smchd1+/+ and Smchd1MommeD1/MommeD1). The method used the same protocol to 
dissociate cerebellum tissue as previously used for the FACS sorting but the individual 
Purkinje cells were observed under microscope and manually picked up in micropipettes 
(Figure 25). After further optimisation of multiple conditions (e.g. picking time period, 
cDNA synthesis kit and pre-amplification conditions) the individual cells were subject to 
qRT-PCR. The samples were initially amplified for only Actb, Pcp2 and PcdhaC1. 
Unfortunately, a small percentage of the Purkinje cells that were analysed had detectable 
levels of all three genes. When the Pcp2 positive cells were analysed for the full set of Pcdha 
and g isoforms using the Fluidigm system, the detection of gene expression was improved 
compared to the FACS sorted individual cells, but it was still not sufficient for the analysis of 
large numbers of individual cells (Figure 26). Clearly, further optimisation was required for 
this assay to be successful. Limited by time and money, it was decided not to continue with 
this part of the project and to focus on other aspects that were less expensive and likely to be 
more productive. 
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Figure 25. Manual picking of single Purkinje cell. 
(A) Isolated Purkinje neurons are indicated by arrows. (B) Single Purkinje cell being picked 
up for analysis. 
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Figure 26. qRT-PCR of manually picked single Purkinje cells. 
The qRT-PCR analysis showed that many cells had detectable control gene (i.e. Pcp2) and 
confirmed that Purkinje cells were being correctly identified by morphology. More cells also 
had detectable PcdhaC1 and PcdhaC2 expression than was detected in the FACS sorted 
single Purkinje cells. Unfortunately the result was still suboptimal and precluded for further 
analysis. Each column shows an individual clustered Pcdha isoform or control gene (Pcp2) 
that was detected and each row is the result for a single cell. The top panel are single cells 
from Smchd1MommeD1/MommeD1 mice and the bottom panel are single cells from Smchd1+/+ mice. 
In the heat map, from top to bottom, the color changes from yellow through purple and blue 
to black to represent Ct from low to high (i.e. expression level from high to low). 
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4.2.3 Cell morphology of single Purkinje cells  
 
Both Z/EG+/-;Pcp2-Cre+/-;Smchd1+/+ and Z/EG+/-;Pcp2-Cre+/-;Smchd1MommeD1/MommeD1 mice 
were used to analyse the cell morphology of Purkinje neurons. The brains from mice of the 
correct genotype were dissected at PN15 to PN17 days. Since the EGFP labelling of the 
Purkinje neurons increases with increasing age it was found that if the mouse was too young 
there were insufficient numbers of Purkinje cells labelled with EGFP. Conversely, if the mice 
were too old then too many Purkinje cells were EGFP labelled and it was not possible to 
identify single isolated EGFP labelled Purkinje neurons. Once confocal Z stack images of 
EGFP labeled Purkinje cells from both Smchd1MommeD1/MommeD1 and Smchd1+/+ were obtained, 
they were processed to generate 3D reconstructions and the dendrites were traced using 
Imaris software (Fogarty et al., 2013) (Figure 27).  
 
To quantify the self-crossing of Purkinje cells dendrites, counts were made of the number of 
dendritic branches from a single Purkinje cell that crossed over another branch and were 
clearly making contact. Care was taken to ensure that apparent crossovers that could be 
resolved as dendrites avoiding each other in 3D were not counted. The total number of 
dendritic crossovers per cell was plotted for cells of each genotype (Figure 28). The number 
of self-crossings were significantly higher in Purkinje cells from Z/EG+/-;Pcp2-Cre+/-
;Smchd1MommeD1/MommeD1 mice compared to those from Z/EG+/-;Pcp2-Cre+/-;Smchd1+/+ mice 
(P<0.05).  
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Figure 27. Images of single Purkinje neurons.  
(A) Confocal image of individual EGFP positive Purkinje neuron from Smchd1+/+mouse. (B) 
Confocal image of individual EGFP positive Purkinje neuron from Smchd1MommeD1/MommeD1 
mouse. (C) Traced Smchd1+/+ Purkinje neuron showing apparent crossover of dendrites. (D) 
Traced Smchd1MommeD1/MommeD1 Purkinje neuron showing apparent crossover of dendrites. (E 
and F) Amplified areas from (D), where (E) is from the red box I and (F) is from the red box 
II. Self-crossings are indicated by red arrows.  
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Figure 28. Single Purkinje cell dendritic self-crossing count.  
Self-crossing counts compared between single Smchd1+/+ and Smchd1MommeD1/MommeD1 
Purkinje cells. T-test was performed on the data (P<0.05).  
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4.3 Discussion 
 
Based on our finding that a loss of Smchd1 function resulted in disrupted clustered Pcdh 
expression in both the whole mouse brain and in mouse NSCs, when analysed in bulk or at 
the individual cell level, it was proposed that the expression of clustered Pcdhs would be 
disrupted when single Smchd1MommeD1/MommeD1 Purkinje cells were analysed. Unfortunately, 
the qRT-PCR analysis of single Purkinje cell was not successful at the time of writing this 
thesis and the methods require further refinement in order to test this proposal fully. 
  
Prof. Yagi’s group has published a series of papers where the expression pattern of the 
clustered Pcdh genes was determined in individual Purkinje cells (Esumi et al., 2005, Kaneko 
et al., 2006, Hirano et al., 2012, Toyoda et al., 2014). In all of these studies, the Purkinje cells 
were manually picked up using micromanipulators. Since manually picking up cells is 
extremely laborious it was decided to initially try a system where the cells could be isolated 
using FACS to sort individual cells into 96-well plates. Mice suitable for this were bred 
carrying both Z/EG and Pcp2-Cre transgenes which resulted in EGFP labelled Purkinje cells. 
It was planned that the EGFP would enable isolation of single Purkinje cells by FACS. The 
critical requirement was to isolate viable single Purkinje cells from the cerebellum, so that the 
cells retained their mRNA. Most published studies where FACS is used to isolate single 
Purkinje cells in this manner (Tomomura et al., 2001, Lee et al., 2009, Bouslama-Oueghlani 
et al., 2012) have utilised quite young mice (i.e. newborn to PN10) for isolating/purifying 
viable cells that can be successfully cultured. At the stage of newborn to PN10, the Purkinje 
cells have not developed extensive networks of dendrites, making it much easier isolate intact 
Purkinje cells. Prof. Yagi’s group used mice between 3 and 4 weeks of age (Esumi et al., 
2005, Kaneko et al., 2006, Katori et al., 2009, Hirano et al., 2012, Kaneko et al., 2014, 
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Toyoda et al., 2014) where the Purkinje cells would be more mature and likely to express 
higher levels of the clustered Pcdhs. Since Prof. Yagi’s group had successfully analysed 
clustered Pcdh expression in Purkinje cells from older mice, PN21 mice were chosen as a 
compromise. In the mice carrying the transgene combination used here, younger mice (i.e. 
younger than PN13 to PN15) did not express detectable EGFP in a sufficient number of 
Purkinje cells and therefore, few obviously viable Purkinje cells were obtained from the older 
mice. Despite numerous attempts it was not possible to identify viable cells even at PN21, as 
determined by PI staining or cells containing EGFP using the MoFlo cell sorter. Ultimately, 
manual picking of the cells was used, identifying the cells by morphology and choosing the 
most phase bright cells as those most likely to be intact/viable. 
 
Using manual picking had the advantage that it was no longer necessary to use mice carrying 
the transgene EGFP positive Purkinje cells and greater numbers of mice could be obtained for 
isolation of the desired cells. One disadvantage was that the slow speed of picking up cells 
meant that the cells had to be picked within a 2 hour period, in order to give the greatest 
chance of obtaining viable cells (Esumi et al., 2006). Only about 30-50 individual cells could 
be collected from each preparation within this period and not every single Purkinje cell 
picked up generated usable data as determined by detection of the control genes (i.e. Pcp-2 
and Actb). The clustered Pcdha isoforms were never reliably detected in any of the cells 
analysed, but occasional cells had detectable expression of PcdhaC1 and PcdhaC2 isoforms. 
Prof. Yagi’s group was contacted for assistance and at their suggestion of using a different 
cDNA synthesis enzyme was tested, but that this modification did not improve the assay.  
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As yet, all attempts at analysing individual Purkinje cells by qRT-PCR have not provided the 
quality of results required to unambiguously determine whether the loss of Smchd1 function 
interferes with the pattern of clustered Pcdh expression.  
 
The confocal microscopic analysis of Purkinje cell dendritic morphology was more 
successful, although the absolute number of cells analysed to date is relatively low. The 
analysis indicated that the Smchd1MommeD1/MommeD1 Purkinje cells had more dendritic self-
crossings than Smchd1+/+ Purkinje cells and thus, loss of self-avoidance. 
 
It is known that abnormal expression of Pcdhg results in loss of self-avoidance in neurons 
(Lefebvre et al., 2012, Toyoda et al., 2014) and clustered Pcdh expression has been disrupted 
in Smchd1MommeD1/MommeD1 mice (Mould et al., 2013). Therefore, clustered Pcdh would be the 
most likely candidate that is responsible for loss of dendritic self-avoidance. Even assuming 
that the clustered Pcdh are the deregulated genes responsible for loss of self-avoidance in 
Smchd1MommeD1/MommeD1 mice, it is still not clear which isoform (or indeed combination of 
isoforms) is exactly responsible for this abnormal dendritic morphology. Clustered Pcdha, 
Pcdhb and, to a lesser extent, Pcdhg are deregulated in Smchd1MommeD1/MommeD1 mice (Mould 
et al., 2013)), which is similar to Dnmt3b-deficient mice, where clustered Pcdha, Pcdhb and 
Pcdhg are disrupted (Toyoda et al., 2014). 
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Chapter 5 PCDHA expression and chromatin structure in human neuroblastoma 
cells 
 
5.1 Introduction  
 
Analysis of the chromatin structure at the clustered Pcdh locus is difficult using non-clonal or 
primary cell cultures (or tissues), because individual cells express a varying and unique 
subset of the clustered Pcdh isoforms. As a result, an analysis of chromatin structure would 
yield an average signal for the whole cell population and be difficult to interpret. Previous 
studies (Guo et al., 2012, Massah et al., 2014) have used clonal tumour cell lines (e.g. the SK-
N-SH neuroblastoma cell line) because they stably express the specific combination of 
clustered PCDH isoforms that were expressed by the individual cell from which the tumour 
originated. Therefore, such cell lines provide an ideal model for conducting genome-wide and 
locus specific analysis of chromatin structure of the clustered PCDH genes. In order to study 
the role of SMCHD1 in organising the chromatin structure, it would be necessary to engineer 
knockdown or knockout of the SMCHD1 gene in these cells. It would also be necessary to 
determine whether cell lines carrying such engineered mutations displayed disrupted patterns 
of clustered PCDH expression, as would be anticipated given the results from 
Smchd1MommeD1/MommeD1 NSCs and mice. 
 
First of all, the SK-N-SH and SH-SY5Y (a subline of SK-N-SK) cell lines were obtained and 
the pattern of clustered PCDHA isoform expression confirmed. Next, retroviral mediated 
shRNA expression was used to knockdown SMCHD1 levels in the cell lines, the resulting 
cells were analysed for SMCHD1 and clustered PCDHA isoform expression, followed by 5C 
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analysis. Since it was possible that shRNA knockdown was insufficient to totally abrogate 
SMCHD1 protein function, CRISPR/Cas9-based SMCHD1 knockout clonal lines of the SH-
SY5Y cell line were generated and analysed for SMCHD1 and PCDHA isoform expression. 
As the SK-N-SH cell line grows very slowly, only cloned SH-SY5Y cell lines were generated 
and analysed. 
 
5.2 Results 
 
5.2.1 Confirmation of PCDHA isoform expression in neuroblastoma cell lines.  
 
The SK-N-SH cell line was obtained from ATCC and the SH-SY5Y cell line from another 
laboratory at QIMR Berghofer. SH-SY5Y (a subline of SK-N-SH) grows more rapidly than 
the SK-N-SH cell line. Both cell lines were sent to the QIMR Berghofer Scientific Services 
Department for STR analysis for mycoplasma testing and to confirm their authenticity. Both 
cell lines were mycoplasma negative and carried the expected STR profile (see Appendix 7 
and 8 for STR profiles, Amelogenin, X; CSF1PO, 11; D13S317, 11; D16S539, 8, 13; 
D5S818, 12; D7S820, 7, 10; THO1, 7, 10; TPOX, 8, 11; vWA, 14, 1). The SH-SY5Y cell 
line showed a reduction in the height of the D16S539, 8 signal compared to the profile for 
SK-N-SH, possibly indicating the high passage number for this cell line.  
 
The cell lines were grown to provide RNA for qRT-PCR analysis, in order to verify that the 
expected pattern of clustered PCDHA expression was maintained. Both cell lines expressed 
appreciable levels of an identical subset of the clustered PCDHA isoforms, PCDHA4, A8, 
A12, AC1 and AC2 (as previously published, (Guo et al., 2012)), however both cell lines also 
Chapter 5 PCDHA expression and chromatin structure in human neuroblastoma cells 
120 | P a g e  
 
showed a significant qRT-PCR signal for PCDHA11 (Figure 29). Only small signals were 
evident for PCDHA1, A3, A6, A7 and A10, but this was not consistent between the two cell 
lines. All of the RT-PCR products were then re-verified by sequencing the RT-PCR product 
amplified from whole human brain RNA. The sequencing confirmed that all primer pairs 
were amplifying the correct PCR products, including PCDHA11 (Appendix 10). This 
prompted a re-examination of the published ENCODE data, which includes RNA-seq, 
DNaseI hypersensitivity and ChIP-seq profiles for the SK-N-SH cell line. Within ENCODE 
there appeared to be conflicting data, with RNA-seq profiles showing considerable levels of 
PCDHA11 (as well as appreciable levels of PCDHA2 and A3) expression, in addition to 
PCDHA4, A8, A12, AC1 and AC2. In contrast, H3K4me3 ChIP-seq of the SK-N-SH cell line 
displayed significant peaks only at PCDHA4, A8, A12, AC1 and AC2, which would indicate 
that only those isoforms were expressed. Note that only H3K4me3 ChIP-seq data for SK-N-
SH treated with retinoic acid is currently available in ENCODE. Given that: (a) the PCR 
primers used were confirmed as amplifying the correct product, (b) the apparently conflicting 
data for the SH-N-SH cell line existed in the ENCODE dataset, and (c) the promoter choice 
made in these two clonal lines appear to be epigenetically stable, it was decided to continue 
using the cell lines for the proposed studies.  
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Figure 29. Human PCDHA expression levels in SK-N-SH and SH-SY5Y cells. 
The X axis shows the 15 isoforms PCDHA, the Y axis shows the expression level relative to 
the control gene RALA. Both cell lines predominantly express PCDHA4, A8, A11, A12, AC1 
and AC2. 
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5.2.2 Generation of SMCHD1 knockdowns in neuroblastoma cell lines  
 
5.2.2.1 Knockdown of SMCHD1 expression 
 
Retroviral expression vectors containing previously validated shRNAs targeting knockdown 
of SMCHD1 (i.e. shRNA-SMCDH1.1 and shRNA-SMCHD1.2) and a control scrambled 
sequence (i.e. shRNA-Scr) were obtained from Dr. Marnie Blewitt (WEHI). 293T cells 
(supplied by the European Collection of Cell Cultures (ECACC), Salisbury, United Kingdom, 
and purchased from CellBank Australia, Westmead, NSW, Australia, see Appendix 9 for 
STR analysis) were co-transfected with each of the shRNA expression vectors and the 
appropriate 2nd generation retroviral packaging vectors to generate infective retrovirus.  
 
The neuroblastoma cell lines were transduced with the retroviral shRNA-SMCHD1.1 and 
shRNA-SMCHD1.2, as well as shRNA-Scr expression vectors, selected with puromycin and 
maintained thereafter with puromycin in the medium. qRT-PCR was performed to test the 
expression level of SMCHD1 in the transduced cells. This indicated that both shRNAs 
targeting SMCHD1 worked well. The expression level of SMCHD1 in shRNA-SMCHD1 
knockdown cell lines was at least 70% less than the control shRNA-Scr transduced cells 
(Figure 30). Western blot analysis showed that there was no detectable SMCHD1 protein in 
these two retrovirus transduced cell lines, compared to control shRNA-Scr transduced cells 
(Figure 31).  
 
Then qRT-PCR for the clustered PCDHA isoforms using shRNA-Scr, shRNA-SMCHD1.1 
and shRNA-SMCHD1.2 RNA samples was conducted (Figure 32). The PCDHA isoform 
expression pattern in both SK-N-SH and SH-SY5Y cell lines after SMCHD1 knockdown did 
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not change dramatically, with the cells retaining the robust expression of PCDHA4, A8, A11, 
A12, AC1 and AC2. However, there were decreased levels of these predominant isoforms 
detected in the shRNA-SMCHD1.2 transduced SK-N-SH cells compared with the shRNA-
Scr transduced cells. There were some small increases for PCDHA1 and A3 in shRNA-
SMCHD1.2 transduced SH-SY5Y cells and for PCDHA2 in shRNA-SMCHD1.1 transduced 
SH-SY5Y cells. In shRNA-SMCHD1.1 transduced SK-N-SH cells, PCDHA1 and A9 were 
slightly increased, while PCDHA2 was slightly increased in shRNA-SMCHD1.2 transduced 
SH-SY5Y cells. PCDHA10 also showed small increases in both shRNA-SMCHD1.1 and 
shRNA-SMCHD1.2 cells. These isoforms were either undetectable or almost undetectable in 
the control shRNA-Scr transduced cell lines (both SK-N-SH and SH-SY5Y). 
 
The shRNA-Scr, shRNA-SMCHD1.1 and shRNA-SMCHD1.2 cell lines were then treated 
with 5µM 5’-AZC for 20 days and RNA was again isolated for qRT-PCR analysis (Figure 
33). The main pattern of clustered PCDHA isoform expression did not change strongly, 
however some of the previously silent isoforms became detectable after 5’-AZC treatment, 
regardless of whether the cells were those treated with shRNA-Scr, shRNA-SMCHD1.1 or 
shRNA-SMCHD1.2 (e.g. PCDHA1, A2, A3, A 9, A10 and A13). 
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Figure 30. SMCHD1 expression level in shRNA-Scr, shRNA-SMCHD1.1 and 
shRNA-SMCHD1.2 knockdown SK-N-SH and SH-SY5Y cell lines. 
The X axis shows each cell line transduced by different shRNA retrovirus. The Y axis shows 
the expression level relative to the control gene RALA. shRNA-Scr is the scrambled control 
retrovirus not targeting SMCHD1, while shRNA-SMCHD1.1 and shRNA-SMCHD1.2 are 
two different retroviruses targeting SMCHD1.  
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Figure 31.  Western blot result for shRNA-Scr, shRNA-SMCHD1.1 and shRNA-
SMCHD1.2 knockdown SH-SY5Y cell lines. 
The image shows the western blot for SMCHD1 protein in SH-SY5Y shRNA-Scr and 
shRNA-SMCHD1.1 and shRNA-SMCDH1.2 knockdown cells. There is no detectable 
SMCHD1 protein in both SMCHD1 knockdown cell lines (i.e. shRNA-SMCHD1.1 and 
shRNA-SMCHD1.2). The original image of the western blot is shown in Appendix 4.  
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Figure 32. PCDHA expression levels in shRNA retrovirus-transduced human SK-N-
SH and SH-SY5Y cells. 
The X axis shows the 15 PCDHA isoforms, the Y axis shows the expression level relative to 
control gene RALA. The main expression pattern of PCDHA is not greatly changed after 
SMCHD1 knockdown in either cell line. 
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Figure 33. PCDHA expression level in 5μM 5’-AZC treated SK-N-SH and SH-SY5Y 
cell lines. 
The X axis shows the 15 isoforms of PCDHA, the Y axis shows the expression level relative 
to control gene RALA. There are more isoforms of PCDHA beginning to become expressed 
after 5’-AZC treatment but no real differences between the shRNA-Scr (i.e. control) and 
shRNA-Smchd1.1 or shRNA-SMCHD1.2 (i.e. SMCHD1 knockdown) cell lines. 
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In summary, the chosen pattern of clustered PCDHA isoform expression was not strongly 
altered in either SH-SY5Y or SK-N-SH after SMCHD1 knockdown. However, PCDHA1 was 
up-regulated by a small amount in both cell lines. After 5’-AZC treatment, the predominant 
expression pattern was still not changed significantly, although in the SK-N-SH cell line, 
PCDHA8 and AC1 became up-regulated. PCDHA1, A2, A3, A10 and A13 were also 
detectable, but no strong differences were found between shRNA-Scr (control) and shRNA-
SMCHD1 knockdown samples.  
 
5.2.2.2 5C analysis 
 
The aim of using 5C analysis was to attempt to map the chromatin interactions that underlie 
SMCDH1 regulation at the clustered PCDH locus. Comparing the 5C interaction map of the 
shRNA-Scr control cell line with that obtained from the shRNA-SMCHD1.1 and shRNA-
SMCHD1.2 cell lines should reveal whether interactions between the known (or putative) 
enhancers and the alternative first exons were changed in the SMCHD1 knockdown cell lines. 
The shRNA retrovirus transduced SH-SY5Y knockdown cell lines grew most robustly and 
after 5’-AZC treatment were used for the 5C analysis. 
 
5C primers were designed using the Web-based my5C tool 
(http://my5c.umassmed.edu/my5Cprimers/5C.php) (Lajoie et al., 2009). The 5C design was 
based on using 3C libraries generated using EcoRI with 5C bait primers (i.e. 5’-
phosphorylated reverse primers) assigned to EcoRI fragments containing known or putative 
enhancer regions for the clustered PCDH genes (i.e. indicated by the red coloured EcoRI 
fragments in Figures 34 and 35). All the 5C test primers (i.e. forward primers) were assigned 
to the remaining EcoRI fragments within an approximately 1Mb region containing the three 
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clustered PCDH loci (i.e. indicated by blue EcoRI fragments in Figures 34 and 35). A 
limiting factor of 5C design was that not all EcoRI fragments were suitable for the design of 
appropriate primers. As a result, some of the promoters of the PCDHA alternative first exons 
could not be analysed (i.e. PCDHA5, A6, A7, AC1 and AC2 were not covered by an EcoRI 
fragment where usable 5C primers could be designed). 
 
Preliminary 5C data from an analysis comparing shRNA-SMCDH1 knockdown and control 
shRNA-Scr SH-SY5Y cells is presented in Figures 34 and 35. In this analysis, only bait 
primers for the HS7 and HS5-1 enhancers were used for generating the 5C library, however 
all test primers covering the whole locus were included. In all samples, the strongest 
interactions with HS5-1 and HS7 enhancer associated baits were with EcoRI fragments from 
within (or near) the region containing the clustered PCDHA isoforms (as indicated by the 
dark green and black coloured EcoRI fragments). These same baits made only weak 
interactions with primers in EcoRI fragments from the regions containing the clustered 
PCDHB and PCDHG genes (indicated by predominantly white through to light green 
coloured EcoRI fragments associated with these genes) (Figure 34). This is consistent with 
the previous 3C studies, which indicated that these enhancers were involved in the control of 
clustered PCDHA isoform expression but not with necessarily with PCDHB or PCDHG 
expression (Guo et al., 2012).  
 
The strongest interactions with HS7 enhancer associated baits were located either upstream of 
the PCDHA region or at the common PCDHA exons (Figure 35). The HS5-1 enhancer bait 
showed the strongest interaction with promoter regions of the PCHDA4 (in 4 of 6 samples 
tested, but with no consistent difference between control or SMCHD1 knockdown samples) 
and PCDHA8 alternative first exons (in 2 of 4 control samples, but not in SMCHD1 
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knockdown samples) (Figure 35). This is in reasonable agreement with previous 3C analysis 
for wild type SK-N-SH cells, which should show the same interaction pattern as the SH-
SY5Y cells used here. It was surprising that a strong interaction was not shown with the 
promoters of the PCDHA11 and PCDHA12 alternative first exons given that the qRT-PCR 
results showed that they were strongly expressed. However, it is likely that the EcoRI 
fragment representing the PCDHA12 alternative exon did not include the promoter region. 
 
Overall, the preliminary 5C analysis showed relatively poor concordance between the results 
from technical and biological replicate samples. Clearly further work will be required in order 
to obtain reliable results from this demanding technique. The single experiment undertaken 
did show strong interactions between some of the expressed alternative PCDHA isoforms and 
the HS5-1 enhancer region. There did not appear to be any obviously strong and consistent 
differences between the shRNA-Scr and shRNA-SMCHD1 knockdown cell lines, although 
this was expected, since no expression differences were found between these cell lines.  
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Figure 34. Preliminary 5C data UCSC track (full PCDH region). 
The UCSC track shown includes preliminary 5C data for the shRNA-Scr, shRNA-
SMCHD1.1 and shRNA-SMCHD1.2 SH-SY5Y cell lines after 5’-AZC treatment. The first 
three rows show technical replicates of 5C interactions between bait primers on EcoRI 
fragments associated with the PCDHA enhancers (i.e. HS7 No.1, HS7 No.2 and HS5-1, 
coloured red in EcoRI fragment track) and test EcoRI fragments covering the full region of 
PCDH (coloured blue in EcoRI fragment track) for each cell line. Also included are UCSC 
tracks showing the RefSeq genes and some ENCODE data for the SK-N-SH cell line (i.e. 
CTCF ChIP-seq, H3K4me3 ChIP-seq, DNase1 Hypersensitivity clusters and RNA-seq). For 
the 5C data, the heatmap colour of the EcoRI fragments range from white though green to 
black and represents the interaction strength from weak to strong for the interaction with the 
specific bait fragment (shown in orange). Black EcoRI fragments are only apparent in the 
PCDHA region rather than PCDHB and PCDHG regions. The area of the HS7 enhancer did 
not show a very strong interaction with the alternative PCDHA promoter areas, but HS5-1 is 
showing relatively strong interaction with PCDHA4 and A8.  
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Figure 35.  Preliminary 5C data UCSC track (PCDHA region). 
The chromatin interaction between HS5-1 and the alternative exons of PCDHA for the 
shRNA-Scr, shRNA-SMCHD1.1 and shRNA-SMCHD1.2 SH-SY5Y cell lines after 5’-AZC 
treatment. The HS5-1 region is located downstream of the last PCDHA exon (orange color). 
For the 5C data the heatmap colour of the EcoRI fragments range from white though green to 
black to represent the interaction strength (from weak to strong). Also included are tracks 
indicating the RefSeq genes and several tracks of ENCODE data from the SK-N-SH cell line 
(i.e. CTCF ChIP-seq, H3K4me3 ChIP-seq, DNase1 Hypersensitivity clusters and RNA-seq). 
There were some strong interactions between HS5-1 and EcoRI fragments covering the 
promoters of the PCHDA4 and A8 alternative exons (black color), but not with PCDHA11 or 
A12. No data was available for PCDHAC1 and C2 because suitable primers could not be 
designed. No consistent differences between shRNA-Scr and the two shRNA-SMCHD1 
knockdown cell lines were evident. 
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5.2.2.3 Knockout of SMCHD1 in neuroblastoma cell lines. 
 
Although the western blot results showed that SMCHD1 was not detectable in the SMCHD1 
knockdown cell lines, it is possible that there was sufficient SMCHD1 produced after shRNA 
knockdown for stable epigenetic maintenance of the clustered PCDH isoform expression 
pattern. Therefore, it was decided to knockout SMCHD1 using CRISPR/Cas9 genome editing 
to see whether more robust effects could be achieved using gene knockout rather than 
knockdown.  
 
CRISPR/Cas9 constructs were made for genome editing of the SMCHD1 gene in human cells 
to generate SMCHD1 knockout cell lines. The constructs were made in lentiCRISPR v2 
(Addgene Plasmid #52961), which is a lentivirus structural vector designed by the Zhang lab 
at MIT. The lentiCRISPR v2 vector was designed to co-express a humanised version of the S. 
pyogenes Cas9 nuclease along with the sgRNA for targeting the gene of interest (i.e. in this 
case SMCHD1). The sgRNA sequences that were used were identified using the Zhang lab 
online tool (http://www.genome-engineering.org/crispr/) within Exon 3 of the human 
SMCHD1 gene and oligos of the appropriate sequences were cloned into the lentiCRISPR v2 
plasmid (see Table 4 for oligo sequences of sgRNA targets and Appendix 12 and 13 for 
CRISPR design tool output). Off-target sequences and the positions in the human genome 
GRCh38/hg38 were identified using the Zhang lab online tool (http://www.genome-
engineering.org/crispr/) and confirmed using another online tool 
(http://www.rgenome.net/cas-offinder/). After cloning, plasmids containing the correctly 
inserted oligo were identified by sequencing and then used to generate lentivirus for 
transduction of the SH-SY5Y and SK-N-SH cell lines.  
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5.2.2.3.1 Transduction with the lentiCRISPR v2 constructs.  
 
The SK-N-SH and SH-SY5Y cell lines were transduced with the lentiCRISPR v2 constructs 
and selected with puromycin. After puromycin selection, bulk cultures of surviving cells were 
tested using the Surveyor assay, which indicated that the SMCHD1 gene had been edited as 
designed, with a high level of efficiency (Figure 36).  
 
Individual cloned cell lines were isolated by limit dilution and each cloned cell line tested for 
genome editing efficiency. As this was a time consuming process and the SK-N-SH cell line 
grows extremely slowly, only CRISPR/Cas9 genome edited SH-SY5Y cell clones were 
screened. The clones were grown and pellets collected to make RNA, DNA and protein for 
analysis by the qRT-PCR, Surveyor assay, sequencing and western blot. Clones showing 
homozygous mutation of the SMCHD1 gene and lacking detectable SMCHD1 protein were 
then selected for analysis of PCDHA isoform transcript levels. The cloned cell lines were also 
treated with 5’-AZC for qRT-PCR analysis of clustered PCDHA isoform expression.  
 
5.2.2.3.2 Verification of clones and analysis of PCDHA isoform expression  
 
The Surveyor assay verified that some of the isolated clones carried SMCHD1 mutations 
(Figure 37). Next, sequencing was conducted for these clones, and 8 clones were identified 
which had edited both SMCHD1 alleles (Figure 38). They were numbered 411, 413, 415, 
416, 4110, 4112, 4113 and 511. There were 5 clones carrying different SMCHD1 knockout 
mutations (i.e. 413, 416, 4110, 4112, and 511) and 3 clones carrying the same mutation (i.e. 
411, 415 and 4113). Clones 416 and 511 were tested using a Surveyor assay for off-target 
genome editing at the three highest scoring off-target sites for each on-target guide, 
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respectively. At the sensitivity achievable with the Surveyor assay, there did not appear to be 
any off-target editing in either of these clones (Figure 39). 
 
The cloned cell lines were then subject to qRT-PCR analysis of SMCHD1 expression. Each 
clone showed decreased SMCHD1 transcript, however the decrease was not dramatic in all 
clones (Figure 40A). This was different from our expectation, which was that SMCHD1 
would be barely detectable. Although in each clone both alleles had been edited, there was 
still the possibility that the mutant SMCHD1 mRNA could be transcribed and that the mutant 
transcript was not translated into protein. Therefore, SMCHD1 western blot was used to 
verify the SMCHD1 knockout cell lines (Figure 40B). While several clones showed residual 
immune reactive SMCHD1 protein, some (e.g. 416, 4112, 4113 and 511) had complete loss 
of SMCHD1.  
 
Next, we examined PCDHA expression in all of these 8 single clones. Again, the major 
expression pattern was not greatly changed, with each clone predominantly expressing the 
fixed isoforms (i.e. PCDHA4, A8, A11, A12, AC1 and AC2). In some clones, there were small 
amounts of other PCDHA isoforms detectable. Moreover, the expression level of the fixed 
isoforms changed, being either up-regulated or down-regulated in different clones relative to 
the parental cell line (Figure 40). After 5’-AZC treatment (Figure 41), the control gene RALA 
was barely detectable in almost all of cloned cell lines, making it difficult to analyse the 
relative PCDHA expression levels. As a result, it was decided not to progress with 5C 
analysis of the SMCHD1 knockout clones.  
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Figure 36. Surveyor assay results. 
Lane No.1 is SMCHD1 exon 3 of no virus infected SK-N-SH cell (negative control); lane 
No.2 is SMCHD1 exon3 of virus 4 infected SK-N-SH; lane No.3 is exon 3 no virus infected 
SH-SY5Y cell (negative control); lane No.4 is exon 3 of virus 4 infected SH-SY5Y cells. The 
original gel image is in Appendix 1. 
 
 
 
Figure 37. Single clones Surveyor assay results.  
Surveyor assay result for 8 different single clones isolated from lentivirus transduced SH-
SY5Y cells. The original gel image is in Appendix 2.  
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Figure 38.  Sequence analysis of CRISPR/Cas9 mediated knockout of SMCHD1 in 
SH-SY5Y cells showing mutations found in two separate clones. 
The letters in red are the PAM sequences for the sgRNA sequences. The letters in green are 
inserted DNA bases, and the gap between single clone allele and the wild type allele is the 
deleted DNA sequence. In clones #411, #415 and #4113 only a single mutant allele was 
detected (addition of an A). This could be due to either both alleles carrying the same 
modification, or one allele carrying a mutation that prevented it from being amplied by the 
PCR primers used. 
  
Exon 3 No.1 
 
         CCTGCTA____CAGTCGGTCAATCAGT    Guide 
CACCTTATACCTGCTA____CAGTCGGTCAATCAGTTAC Wt allele 
 
CACCTTATACCTGCTAA___CAGTCGGTCAATCAGTTAC Clone #411, #415, #4113 
 
CACCTTATACCTGCTG____CAGTCGGTCAATCAGTTAC Clone #416 
CAC-TTATACCTGATTTATACAGTCGGTCAATCAGTTAC 
 
 
CACCT___________________CGGTCAATCAGTTAC Clone #4110 
CACCTTATACCTGC___________________AGTTAC 
 
CACCTTATAC___________AGTCGGTCAATCAGTTAC Clone #4112 
CACCTTATACCTGCTA____C_______________________________ 
 
(#413 has a big deletion, which is not shown above) 
 
Exon3 No.2 
 
  CCTTATA_CCTGCTACAGTCGGTC           Guide 
CACCTTATA_CCTGCTACAGTCGGTCAATCAGTTAC Wt allele 
 
CACCTTATACCCTGTACAGTCGGTCAATCAGTTAC Clone #511 
CACCTGCTAAAGTC_________GTCAATCAGTTAC 
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Figure 39. Single clones off-target Surveyor assay result.  
The top three off-target sequences and the positions in the human genome GRCh38/hg38 for 
both SMCHD1 Exon3 No.1 and No.2 were identified using the Zhang lab online tool, which 
were named 311, 312 and 313 (the three off-target sequences for Exon3 No.1) , and 321, 322 
and 323 (three off-target sequences for Exon3 No.2). The single clones 416 and 511 were 
used to perform the off-target Surveyor assay for Exon3 No.1 and Exon3 No.2, respectively. 
From the image there is only one band in each lane, which indicated that there did not appear 
to be any significant off-target editing in either of these clones. (The original image for off-
target analysis is shown in Appendix 3). 
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Figure 40. SMCHD1 expression level and western blot result in single SMCHD1 
knockout clones. 
(A) The upper image is the SMCHD1 expression level in the 8 different SMCHD1 knockout 
clones as measured by qRT-PCR. (B) The western blot for SMCHD1 protein in the same 8 
SMCHD1 knockout clones. The original image of the western blot is in Appendix 4.  
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Figure 41. PCDHA expression level in single clone 511. 
X axis shows the 15 isoforms of PCDHA, the Y axis shows the expression level relative to 
the control gene RALA. The qRT-PCR result of PCDHA for the other 7 clones is shown in 
Appendix 5. 
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Figure 42. PCDHA expression level in 5µM 5’-AZC treated single clone 511. 
X axis shows the 15 isoforms of PCDHA, the Y axis shows the expression level relative to 
control gene RALA. The qRT-PCR result of PCDHA for the other 3 clones is shown in 
Appendix 6. 
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5.3 Discussion  
 
The analysis of NSC cell lines presented in Chapter 3 demonstrated that each individual cell 
expressed a unique subset of the clustered Pcdh isoforms. Because there are no methods with 
the level of sensitivity necessary for analysing chromatin structure at the single cell level, 
another cell system would be needed to study the role of Smchd1 at this level. Previous 
studies have shown that human neuroblastoma cell lines (e.g. SK-N-SH and its subclone SH-
SY5Y) stably express a restricted subset of clustered PCDHA isoforms (Guo et al., 2012). 
Presumably, this restricted pattern was that which was originally chosen by the single cell 
from which the tumour originated and has been epigenetically maintained since. Thus, it was 
decided to engineer SMCHD1 knockdown or knockout in these cell lines and to assess 
whether they were be suitable for the proposed chromatin structure analyses. 
 
The SK-N-SH and SH-SY5Y cell lines were obtained and reanalysed for their clustered 
PCDH isoform expression profiles, before being used for engineering the SMCHD1 
mutations. The results showed that both cell lines expressed PCDHA4, A8, A11, A12, AC1 
and AC2, but previous studies had not detected PCDHA11 in SK-N-SH (Guo et al., 2012). 
Sanger sequencing confirmed that the PCR primers used were amplifying the correct 
sequences and short tandem repeat (STR) profiling confirmed that the cell lines obtained 
were authentic. Examination of ENCODE data for the SK-N-SH cell line revealed conflicting 
evidence for and against expression of the PCDHA11 isoform. Thus, it was decided to use the 
available cell lines, as it was possible that PCDHA11 expression was detected, because the 
qRT-PCR using Taqman-like probes was more sensitive than the end point PCR, followed by 
gel electrophoresis used in previous publications (Kaneko et al., 2006).  
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It was hypothesised that if SMCHD1 function was knocked down or knocked out in these cell 
lines, then the PCDHA isoform expression pattern would be disrupted. SMCHD1 knockdown 
cell lines were successfully obtained using retrovirus mediated shRNA expression in both 
SK-N-SH and SH-SY5Y cell lines. Effective knockdown was confirmed by SMCHD1 qRT-
PCR and SMCHD1 western blotting. In these knockdown cell lines, the PCDHA expression 
pattern was changed slightly, with PCDHA1 and PCDHA10 becoming detectable in addition 
to those isoforms normally expressed, albeit not at high levels. The SMCHD1 knock down 
cells were then treated with 5’-AZC to remove some DNA methylation, because previous 
XCI studies in the lab had shown that 5’-AZC treatment was necessary to reveal Smchd1 
involvement in Xi maintenance, where Smchd1 function had been knocked down by shRNA 
(unpublished data). The 5’-AZC treatment resulted in minimal change in the predominant 
PCDHA isoform expression pattern, but very low levels of additional PCDHA isoforms 
became detectable. The 5C analysis showed a strong interaction between enhancer (HS5-1) 
and the promoter associated with the alternative PCDHA4 and PCDHA8 first exons, two of 
the expressed isoforms in these cell lines. No consistent differences were evident between the 
control (i.e. shRNA-Scr) and SMCHD1 (i.e. shRNA-SMCHD1.1 and shRNA-SMCHD1.2) 
knockdown cell lines. Unfortunately, due to design limitations, there were no fragments 
reporting the interaction for several of the alternative promoters (PCDHA5, A6, A7, AC1 and 
AC2). 
  
Since it was considered that residual SMCHD1 expression in the shRNA transduced cells 
may be sufficient to maintain the epigenetic status at the clustered PCDH locus, it was 
decided to try CRISPR/Cas9 based genome editing, in order to obtain complete SMCHD1 
knockout in the cell lines.  
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CRISPR/Cas9 based genome edited SMCHD1 knock-out cloned cell lines were successfully 
generated and confirmed by Sanger sequencing to be carrying homozygous mutations of 
SMCHD1. Western blotting showed loss of SMCHD1 protein. In total 8 cloned cell lines 
were generated and of these, complete loss of SMCHD1 protein was shown in 4 cell lines 
(i.e. clones 416, 4112, 4113 and 511). When these clones were analysed for PCDHA isoform 
expression each clone showed extremely variable levels of expression of the isoforms 
normally expressed by the parental cell line and few showed expression of additional 
PCDHA isoforms. After 5’-AZC treatment to remove DNA methylation, the expression of all 
of the analysed genes was quite low, including that of the control gene (RALA), making it 
very difficult to quantify PCDHA expression compared to the parental cell lines. It is likely 
that high degree clonal variation resulted from the extended treatments required for the 
genome editing (i.e. virus transduction, puromycin selection, single cell cloning, and 5’-AZC 
treatment). As a result, these clones were not subject to further investigation. 
 
The SMCHD1 knockdown and SMCHD1 knockout results indicated that the loss of 
SMCHD1 and some DNA methylation was not sufficient to totally change the pattern of 
PCDHA isoform expression, which had been chosen in the human neuroblastoma cell lines 
SK-N-SH and SH-SY5Y. 
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Chapter 6 General discussion and possible future directions 
 
Since its identification as an epigenetic modifier in the ENU screen, some headway has been 
made in characterising the role of Smchd1. In XCI, Smchd1 is involved late in the cascade of 
epigenetic events that result in stable CGI methylation and silencing of genes on the Xi 
(Blewitt et al., 2008). In XCI, there appears to be a subset of X-linked genes where the 
associated CGI becomes methylated in a Smchd1-independent manner, while the remainder 
(i.e. the majority of the CGIs associated with X-linked genes) are methylated in a Smchd1-
dependent manner (Guo et al., 2012). Smchd1 is involved in Lrif1-meditated interactions 
with Xist lncRNA at H3K27me3 decorated chromatin, to establish the highly compact 
heterochromatin that is characteristic of the Xi (Nozawa et al., 2013). Loss of Smchd1 
function also leads to aberrant autosomal gene expression of some imprinted genes (e.g. 
certain genes within the Igf2r and Snrpn clusters of imprinted genes) and the clustered Pcdh 
genes (Gendrel et al., 2013, Mould et al., 2013). However, it is unknown how Smchd1 
functions in the control of expression at clustered Pcdh genes, where a complicated 
mechanism of random combinatorial monoallelic expression is proposed to result in a unique 
cell surface identity on individual neurons. In addition, SMCHD1 mutations are associated 
with the less common form Facioscapulohumeral muscular dystrophy, Type 2 (FSHD2) (De 
Greef et al., 2010). At this locus, SMCHD1 function is necessary for CpG methylation and 
maintenance of heterochromatin in both FSHD1 and FSHD2 (Sacconi et al., 2013, Larsen et 
al., 2014). 
 
The overall objective of this project was to study the function of Smchd1 in the control of 
gene expression, specifically at the clustered Pcdh locus. The three different aims of the 
project were conceived in order to approach this study in three different systems.  
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Aim 1 utilised NSCs as an in vitro model in which to study the role of Smchd1 in the 
epigenetic mechanism that chooses clustered Pcdh isoforms for expression in individual cells. 
The analysis of clustered Pcdh expression using RNA isolated from bulk cultures of 
undifferentiated NSCs showed considerable disruption in Smchd1MommeD1/MommeD1 compared 
with Smchd1+/+ cells, with most Pcdha and Pcdhb isoforms showing significantly increased 
expression in Smchd1MommeD1/MommeD1 cells. The Transcriptome-seq analysis confirmed this 
finding, but also identified additional imprinted genes that were expressed in a deregulated 
manner in the absence of Smchd1. The MBD-seq result revealed significant hypomethylation 
of CGIs associated with the promoters of the alternative Pcdha exons in 
Smchd1MommeD1/MommeD1 NSC. However, the methylation levels of CGIs associated with the 
clustered Pcdhb and Pcdhg promoters were not significantly different between 
Smchd1MommeD1/MommeD1 and Smchd1+/+ cells, which was not consistent with the result of bulk 
cell qRT-PCR and Transcriptome-seq analysis. It is possible that with greater sequencing 
depth differences in DNA methylation at the promoters of the Pcdhb genes may be identified 
by this type of MBD-seq analysis.  
 
The single cell qRT-PCR result again confirmed the bulk culture analysis and indicated that 
more individual Smchd1MommeD1/MommeD1 NSCs expressed more clustered Pcdh isoforms than 
Smchd1+/+ NSCs. This was evident for the clustered Pcdha and Pcdhb genes, but not for the 
Pcdhg genes, where the pattern of isoform expression was indistinguishable between the 
genotypes. Neither genotype expressed the precise pattern previously demonstrated for 
terminally differentiated neurons (Kaneko et al., 2006, Hirano et al., 2012). Relatively few 
individual Smchd1+/+ NSCs expressed detectable clustered Pcdha constant isoforms and very 
few individual cells expressed the variable isoforms, although those that did expressed either 
1, 2 or 3 variable isoforms (i.e. about the expected number identified in terminally 
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differentiated Purkinje neurons). A much greater percentage of the Smchd1MommeD1/MommeD1 
NSCs had detectable variable isoforms and many of these individual cells expressed more 
than the expected number of these variable isoforms. The situation was similar for Pcdhb 
isoform expression, with individual Smchd1+/+ NSC conforming more closely to the expected 
number of isoforms than individual Smchd1MommeD1/MommeD1 NSCs.  
 
A possible explanation for the observed results was that the Smchd1MommeD1/MommeD1 NSCs 
were more differentiated than the Smchd1+/+ NSCs. Analysis of the morphology and lineage 
specific markers for both Smchd1MommeD1/MommeD1 and Smchd1+/+ NSCs excluded this 
possibility. 
 
While it is clear that in the absence of Smchd1 more individual cells express more individual 
isoforms, it is not clear how Smchd1 interacts with other epigenetic modifications and 
modifiers that have been reported to influence clustered Pcdh expression (e.g. Ctcf, Rad21, 
DNA methylation). Some clarity around this question has been provided from the result of 
additional analysis that was undertaken by our collaborators Kelan Chen and Marnie Blewitt 
and reported in our recent publication (Chen et al., 2015). Their genome-wide ChIP-seq 
analysis showed significant differences associated with the clustered Pcdh loci using the 
same NSCs. There was increased H3K4me3 at the promoters associated with the alternative 
Pcdha first exons in Smchd1MommeD1/MommeD1 compared with Smchd1+/+ NSC. Their Smchd1 
ChIP-seq data also showed that Smchd1 binds at specific sites within the alternative Pcdha 
promoters and to HS5-1a and HS5-1b, which are proposed to act as enhancers for expression 
of clustered Pcdha. From these analyses we proposed that, in Smchd1+/+ NSC, the Smchd1 
protein binds to the alternative promoters and enhancer (HS5-1a and b) of the clustered 
Pcdha gene to initiate CGI methylation or to maintain the CGI methylated status, and to help 
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maintain the epigenetic repression of individual Pcdha isoforms that were not selected for 
expression by the cell. This would act in opposition to factors that act to enhance or maintain 
specific Pcdha isoform expression. It has previously been proposed that the Ctcf/Cohesin 
complex recruits selected Pcdha promoters to the HS5-1 site to form an active transcriptional 
hub that drives a specific chosen set of Pcdha isoforms for expression (Guo et al., 2012). We 
also found that many of the Smchd1 binding sites overlap with Ctcf binding sites, and 
therefore, we proposed that Smchd1 and Ctcf binding act in opposition to each other at these 
loci (Chen et al., 2015). Taken together (i.e. findings presented in this thesis and Chen’s data) 
it is likely that Smchd1 binds to the clustered Pcdha promoter and is associated with 
initiation or maintenance of the DNA methylation of the CGI and the stable repression of the 
associated isoform (Figure 43). From the analysis of NSCs presented in this thesis, it is likely 
that a similar mechanism operates at the Pcdhb locus, but not necessarily at the Pcdhg locus, 
because no difference in expression or methylation could be demonstrated in the 
Smchd1MommeD1/MommeD1 NSCs. It remains possible that Smchd1 plays a role at the Pcdhg 
locus at later stages of differentiation, which were not investigated in this project. 
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Figure 43. Model of how Smchd1 might function to maintain DNA methylation in 
Pcdha cluster. 
This model is based on a hypothetical individual Smchd1+/+ cell that has established 
monoallelic expression of clustered Pcdha2, a7 and a10, and constant biallelic expression of 
PcdhaC1 and aC2. This cell would be unmethylated at the CGIs associated with expressed 
exons and the CSE within the unmethylated CGIs would be associated with Ctcf. The CSE 
within the CGIs associated with non-expressed exons would be associated with Smchd1, 
which is necessary to establish and/or maintain the CpG methylation. In the 
Smchd1MommeD1/MommeD1 cell, the CSE does not become methylated or methylation is not 
maintained, allowing Ctcf to bind and the exon becomes expressed. A possible scenario is 
presented for this cell showing different combinations of mono- or bi-allelic expression of the 
alleles. In the hypothetical Smchd1MommeD1/MommeD1 cell, Pcdha1 to a12 can display either 
monoallelic or biallelic expression and the cell also expresses an increased, but still random 
number of variable isoforms compared to Smchd1+/+ cells. 
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While the NSCs have proven very useful as an in vitro model system, the question of whether 
undifferentiated NSCs have chosen their pattern of clustered Pcdh expression was not 
resolved in this project. It remains possible that an individual NSC has a fluid or evolving 
pattern of expression which becomes epigenetically stable when the cells initiate 
differentiation. This question could only be addressed by cloning the NSCs and then 
reanalysing the expression patterns of individual cells in the cloned lines both before and 
after the initiation of differentiation. These experiments could prove difficult, as initial 
attempts at cloning the NSCs were unsuccessful (data not shown as cells failed to survive 
cloning). If NSCs prove to have already chosen (or partly chosen) the pattern of expression, 
an alternative in vitro system that could be utilised are mouse ES cells, which can be 
differentiated into NSCs and ultimately other neuronal cell types. Ideally, F1 ES cells 
(Laboratory strain x Castaneous) would be used. This would allow the monoallelic nature of 
clustered Pcdh expression to be addressed, as there are many SNPs within gene coding 
regions throughout the whole genome in these mice. Additionally, CRISPR-mediated 
mutation of Smchd1 in F1 ES cells or Castaneous mice would be necessary to generate the ES 
cells that would be needed for this approach. It has previously been reported that the Pcdha 
cluster is methylated during early embryogenesis (Borgel et al., 2010). This may indicate that 
the choice event happens early, however this analysis was done on DNA isolated from whole 
embryos and does not have the single cell resolution necessary for interpreting studies of the 
clustered Pcdh locus. The cloned ES cells or/and NSCs isolated from F1 mice could be used 
to analyse the methylation status at the clustered Pcdh promoter regions to address this 
question unambiguously. 
 
The objective of Aim 2 was to characterise the mice carrying the Smchd1MommeD1 mutant 
allele in an in vivo model, where the phenotypic effects of Smchd1 loss could be studied. This 
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animal model could then be used to conduct behavior analysis, as it has been reported that the 
clustered Pcdh genes are involved in regulating learning and memory functions in the mouse 
brain (Fukuda et al., 2008). The major problem that was encountered in this aim was the 
isolation of intact/live single Purkinje cells from the cerebellae of the mice. Expression of the 
variable clustered Pcdh isoforms were never reliably detected in any analysed Purkinje cells, 
either FACS sorted or manually picked single cells. The Purkinje cells at PN21 were 
relatively mature, with substantial development of the axon and dendrite network. Only the 
cell body was left after the enzymatic dissociation of the cerebellum, which was likely to 
result in loss of RNA and cell viability. Possible improvements to the cell isolation method 
that could be tested in the future are using alternative GFP transgenic mice that exhibit 
Purkinje specific expression at an earlier age (e.g. L7-GFP transgenic mice that show GFP 
fluorescence from E17), and different dissociation enzymes or combinations of enzymes 
(Tomomura et al., 2001, Bouslama-Oueghlani et al., 2012). It would then be possible to 
isolate viable Purkinje neurons from the cerebellae of younger mice, where the dendritic 
network was not as developed and, if necessary, to culture the Purkinje neurons (Lee et al., 
2009) until they had established detectable clustered Pcdh isoform expression. Alternatively, 
it is possible to differentiate NSC in culture to form specific neuronal types (Wang et al., 
2015) and then undertake the single cell qRT-PCR.  
 
The confocal microscopic analysis experiments produced more successful results and 
indicated that Smchd1MommeD1/MommeD1 Purkinje cells show more dendritic self-crossings than 
Smchd1+/+ Purkinje cells and thus, loss of self-avoidance. Unfortunately, the number of single 
Purkinje cells analysed for self-avoidance was relatively small. This was partly because the 
birth rate of the required mice was quite low. This was especially the case for 
Smchd1MommeD1/MommeD1 mice, because theoretically only 1/32 conceptuses were of this 
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genotype and some male Smchd1MommeD1/MommeD1 mice died before the age of analysis (which 
was made it even lower than 1/32). Another problem was the difficulty finding single isolated 
EGFP positive Purkinje cells. Before PN15, very few Purkinje cells were EGFP positive and 
after PN16, there were many EGFP positive Purkinje cells and most had their dendrites 
overlapping with dendrites of neighboring EGFP positive Purkinje cells. A third problem was 
that the cell tracing was very time consuming. Some of these problems could be overcome in 
future studies by using Brainbow 3.2 transgenic mice (Cai et al., 2013) to label single 
Purkinje cells with many different colors rather than the Z/EG mice used in this study.  
 
While the single Purkinje cell qRT-PCR for clustered Pcdh did not provide reliable results, it 
was clear that clustered Pcdh expression was disrupted in Smchd1MommeD1/MommeD1 mice 
(Mould et al., 2013) and in NSC (results presented here and (Chen et al., 2015)). Since loss of 
self-avoidance has been demonstrated in other knockout mice with abnormal clustered Pcdh 
expression (Lefebvre et al., 2012, Toyoda et al., 2014), they remain the most likely candidate 
genes whose aberrant expression is responsible for loss of dendritic self-avoidance. However, 
neither the findings presented in this thesis, nor those in the Dnmt3b-deficient mouse study 
(Toyoda et al., 2014) can totally and unambiguously attribute the loss of self-avoidance to 
aberrations in clustered Pcdh expression. This is because both Smchd1 and Dnmt3b 
deficiencies result in the aberrant expression of many more genes expressed by neurons than 
just the clustered Pcdh genes. For example, Smchd1MommeD1/MommeD1 mice display loss of 
imprinting at the Snrpn imprinted gene cluster, with several imprinted genes from the cluster 
being expressed biallelically and at double the level seen in wild type animals (Mould et al., 
2013, Gendrel et al., 2013). These genes are known to be expressed in the brain and also 
likely to be deregulated in Dnmt3b-deficient neurons. Assuming that the clustered Pcdh 
genes are the responsible deregulated genes, comparing the different animal models might 
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give further insight into which of the clustered Pcdh are most important for self-avoidance. 
This is because the Dnmt3b-deficient cells show loss of regulation of both Pcdha and Pcdhg 
variable isoforms (Toyoda et al., 2014). Data for the expression of Pcdhb isoforms were not 
reported in the paper, although there is data showing loss of DNA methylation of Pcdhb CGIs 
in the Dnmt3b-deficient mice. In contrast, the NSC bulk culture and single cell qRT-PCR 
analysis indicate that loss of Smchd1 function mainly affects Pcdha and Pcdhb isoform 
expression. In these analyses there does not seem to be a significant affect on Pcdhg isoform 
expression, which is also supported by the qRT-PCR analysis from Smchd1MommeD1/MommeD1 
brains (Mould et al., 2013). 
 
In Aim 3 it was hoped that engineering Smchd1 mutations (i.e. knockdown or knockout) in 
cell lines, where the pattern of clustered Pchd isoform expression was chosen and 
epigenetically stable, would provide a system where the role of Smchd1 in chromatin 
organisation might be studied. The neuroblastoma cell line SK-N-SH and its subclone SH-
SY5Y provide such a model, as it has been reported that these cell lines stably express a 
restricted subset of clustered PCDHA isoforms (Guo et al., 2012). Both cell lines were 
subject to engineered knockdown or knockout of SMCHD1 function and analysed to see 
whether the expression pattern of clustered PCDH isoforms was altered and whether the 
chromatin topography was altered at the clustered PCDH locus.  
 
The PCDHA isoform expression pattern was not changed to any noticeable degree after 
shRNA mediated SMCHD1 knockdown (in combination with loss of some CpG methylation 
by 5′-azacytidine treatment) in both the SK-N-SH and SH-SY5Y cell lines. Minimal changes 
were also evident in the 5C analysis comparing the control (i.e. shRNA-Scr expressing) and 
SMCHD1 knockdown (i.e. shRNA-SMCHD1expressing) cell lines. SMCHD1 knockout was 
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also tested to exclude the possibility that residual SMCHD1 expression in the shRNA 
transduced cells may have been sufficient to maintain the epigenetic restraint that imposes a 
stable pattern of PCDH isoform expression. SMCHD1 knockout was achieved using 
CRISPR/Cas9 mediated genome editing. The resulting homozygous SMCHD1 knockout 
clones showed considerable variation in the absolute levels of PCDHA isoform expression 
compared to the parental cell lines, but generally retained the familiar pattern of predominant 
expression of the PCDHA4, A8, A11, A12, AC1 and AC2 isoforms. These results indicated 
that the loss of SMCHD1 (with or without some loss of CpG methylation) was not sufficient 
to disrupt the stability of the epigenetic mechanism that governs the clustered PCDHA 
isoform expression pattern once it has been established and maintained.  
 
The remarkable stability of epigenetically imposed gene silencing has previously been seen in 
XCI studies, where Xi-linked EGFP transgene reactivation has been assayed (Chan et al., 
2011). Different strategies for enhancing the reactivation have utilised 5′-AZC (to remove 
CpG methylation and inhibit DNMT1 function) alone or in combination with trichostatin A 
(an inhibitor of class I and II mammalian histone deacetylases) (Lorincz et al., 2000, Yang et 
al., 2010) or etoposide (a topoisomerase inhibitor) (Minajigi et al., 2015). Many different 
treatment concentrations and time regimens of these afore-mentioned reagents have been 
utilised by numerous studies. In a single experiment the 5′-AZC and etoposide combination 
was tested using the published regimen (Minajigi et al., 2015), however this was also 
ineffective at altering clustered PCDHA isoform expression in the SMCHD1 knockdown cell 
lines used here (data not shown). It is possible that further studies using different 
combinations of inhibitors targeting various aspects epigenetic maintenance or different 
treatment regimens could reveal enhanced reactivation of clustered Pcdh isoform expression 
in the absence of Smchd1 function. These were outside the scope of this project. 
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Another aspect that could be considerably improved in future studies is the 5C assay. For 
example, the 3C library was generated using EcoR1 and as a result, not all of the alternative 
exon 1 sequences were amenable to the design of usable 5C primers. Complementary 3C 
libraries and 5C primers based on other restriction enzymes (e.g. BamH1), should be used in 
future studies to cover all possible alternative clustered Pcdh isoforms.  
 
Overall, our knowledge of the molecular mechanism involving Smchd1 that regulates the 
random combinatorial monoallelic expression of the clustered Pcdh is far from complete. For 
example, it is not known whether loss of Smchd1 results only in more clustered Pcdha and 
Pcdhb isoforms being expressed, or whether there is also loss of the monoallelic expression 
of the isoforms. Additionally, it seems that the presence of Smchd1 is important during or 
before choosing the isoforms of clustered Pcdh to be expressed, but that it is dispensable once 
the pattern is epigenetically stable. However, it is unknown whether Smchd1 is directly 
involved in this choice process. Finally, it is likely that there are additional layers of 
epigenetic modifications and modifiers (e.g. the possible involvement of lncRNA or crosstalk 
between the clustered Pcdh alleles) that are involved in the initiation and/or maintenance of 
the chosen pattern of Pcdh isoform expression. Such players have been identified in other 
model systems where Smchd1 plays a role (e.g. XCI and genomic imprinted gene clusters) 
and these are all yet to be investigated at the clustered Pcdh locus. HOTAIR lncRNA has been 
shown to be associated with clustered Pcdh expression in several cancer related studies 
(Novak et al., 2008, Bhan et al., 2013, Gupta et al., 2010). Therefore, it is highly possible that 
lncRNA (such as HOTAIR) could be involved in the regulatory mechanisms of clustered 
Pcdh expression. In addition, Smchd1 interacts with Xist lncRNA associated H3K27me3, and 
in association with Lrif1, establishes the highly compact heterochromatin that is characteristic 
of the Xi (Nozawa et al., 2013). Biochemical analysis of recombinant Smchd1 protein has 
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shown that Smchd1 has high affinity for binding both RNA and DNA (Chen et al., 2015). 
Assuming lncRNA is involved in regulating clustered Pcdh expression, it is possible that 
Smchd1 interacts with lncRNA in this regulatory mechanism. 
 
This study has made a significant contribution to our knowledge of the role of Smchd1 at the 
clustered Pcdh locus. The findings are summarised in the following points. 
 
(1) The transcription levels of most of the clustered Pcdha and Pcdhb isoforms were up-
regulated in Smchd1MommeD1/MommeD1 NSCs and, at the individual cell level, more 
Smchd1MommeD1/MommeD1 NSCs expressed more individual Pcdha and b isoforms per cell than 
was found in Smchd1+/+ NSCs.  
 
(2) Compared with Smchd1+/+ Purkinje cells, the dendrites of Smchd1MommeD1/MommeD1 
Purkinje cells display “loss of self-avoidance”.  
 
(3) Once the expression pattern of PCDHA isoforms has been choosen and epigenetically 
stabilised, the loss of SMCHD1/SMCHD1 (in combination with loss of some DNA 
methylation) in human neuroblastoma cell lines was not sufficient to alter that fixed 
expression pattern to any great extent. 
 
. 
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Appendices 
 
Appendix 1. Original image of bulk cell Surveyor assay.  
 
The image is the original bulk lentiCRISPR SMCHD1 knockout cell surveyor assay. Control 
sample represents no virus infected SK-N-SH or SH-SY5Y cells. V stands for virus (i.e. V4 
means virus No.4), W stands for well (i.e. W1 means well No.1). 
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Appendix 2. Original image of single clones Surveyor assay 
 
The images are original images of single clones Surveyor assay. The number on each well 
represents the name of the single clone. 
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Appendix 3. Off-target Surveyor assay 
 
The top three off-target sequences in the human genome GRCh38/hg38 for both SMCHD1 
Exon3 No.1 and No.2 were identified using the Zhang lab online tool, which were named 311, 
312 and 313 (three off-target sequence for Exon3 No.1), and 321, 322 and 323 (three off-
target sequence for Exon3 No.2). Single clone 416 and 511 were used to perform off-target 
Surveyor assay for Exon3 No.1 and Exon3 No.2, respectively. DNA isolated from no virus 
transduced SH-SY5Y was used as control (C in the image).  
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Appendix 4. Original image of western blot 
 
A, B, C and D are four different images for western blot results of single clones. Note: Part of 
image (A) the membrane was cut in half and swapped over for the photograph, therefore the 
SMCHD1 is located at the bottom part of the image while the GAPDH is located at top part 
of the image.  
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Appendix 5. PCDHA expression level in single clones 
 
 
The image shows the qRT-PCR result for PCDHA expression in different single clones. The 
main pattern is still maintained and the changes are not consistent between different clones. 
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Appendix 6. PCDHA expression level in single clones (5’-AZC treated) 
 
The image shows the PCDHA expression analysis in different single clones (SMCHD1 
knockout and 5’-AZC treated). The control (RALA gene) was only detected in these four 
clones after 5’-AZC treatment. 
 
  
Appendices 
194 | P a g e  
 
Appendix 7. SK-N-SH STR profiling report 
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Appendix 8. SH-SY5Y STR profiling report 
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Appendix 9. HEK293T STR profiling report 
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Appendix 10. Confirmation of PCDHA PCR product 
 
The left image is the gel result for PCR products PCDHA8, A11, AC1 and AC2. It is showing 
only one band in lane PCDHA11, which indicates that only one PCR product has been 
amplified by this pair of primers. The right hand side image is the sequencing trace for 
PCDHA11. It confirms that only one PCR product has been amplified and is an exact match 
for the sequence of PCDHA11. 
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Appendix 11. ENCODE data in UCSC (PCDHA) 
 
UCSC track showing the PCDHA gene cluster, and ENCODE data showing H3K4me3 ChIP-
seq and RNA-seq for the SK-N-SH. There is peak corresponding to PCDHA11 in RNA-seq 
data, however, there is no peak at PCDHA11 loci in H3K4me3 ChIP-seq data. 
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Appendix 12. CRISPR design tool output for hSMCHD1 Exon 3 
 
LOCUS       hg19                     162 bp    DNA              UNK 01-JAN-1980 
 DEFINITION  guides analysis for job hSMCHD1 Exon 3, by 
              Graham.Kay@qimrberghofer.edu.au on the web at 
              crispr.mit.edu/job/7499852079800188 
   ACCESSION   7499852079800188 
    VERSION     7499852079800188 
     KEYWORDS    . 
      SOURCE      . 
        ORGANISM  . 
                  . 
       FEATURES             Location/Qualifiers 
         protein_bind    complement(25..47) 
                         /bound_moiety="CRISPR reverse-strand guide 
#10218406 
                      GACCGACTGTAGCAGGTATAAGG" 
                        /note="{"n_genic_offtargets": 4, "n_offtargets": 58, 
                       "score": "88%", "sequence": "GACCGACTGTAGCAGGTATAAGG"}" 
     protein_bind    complement(32..54) 
                         /bound_moiety="CRISPR reverse-strand guide 
#10218405 
                      ACTGATTGACCGACTGTAGCAGG" 
                        /note="{"n_genic_offtargets": 8, "n_offtargets": 43, 
                       "score": "94%", "sequence": "ACTGATTGACCGACTGTAGCAGG"}" 
     protein_bind    complement(93..115) 
                         /bound_moiety="CRISPR reverse-strand guide 
#10218404 
                      TTAACCAGTGTGTCATAGTGAGG" 
                        /note="{"n_genic_offtargets": 11, "n_offtargets": 161, 
                      "score": "74%", "sequence": "TTAACCAGTGTGTCATAGTGAGG"}" 
     protein_bind    complement(139..161) 
                         /bound_moiety="CRISPR reverse-strand guide 
#10218403 
                      CAAAGGATTTTGTCCTTCACTGG" 
                        /note="{"n_genic_offtargets": 25, "n_offtargets": 284, 
                      "score": "60%", "sequence": "CAAAGGATTTTGTCCTTCACTGG"}" 
     protein_bind    23..45 
                          /bound_moiety="CRISPR forward-strand guide 
#10218399 
                      CACCTTATACCTGCTACAGTCGG" 
                        /note="{"n_genic_offtargets": 8, "n_offtargets": 119, 
                      "score": "74%", "sequence": "CACCTTATACCTGCTACAGTCGG"}" 
     protein_bind    89..111 
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                     /bound_moiety="CRISPR forward-strand guide 
#10218400 
                      CTTACCTCACTATGACACACTGG" 
                        /note="{"n_genic_offtargets": 17, "n_offtargets": 119, 
                      "score": "79%", "sequence": "CTTACCTCACTATGACACACTGG"}" 
     protein_bind    99..121 
                          /bound_moiety="CRISPR forward-strand guide 
#10218401 
                      TATGACACACTGGTTAAAAGTGG" 
                        /note="{"n_genic_offtargets": 16, "n_offtargets": 282, 
                      "score": "55%", "sequence": "TATGACACACTGGTTAAAAGTGG"}" 
     protein_bind    126..148 
                          /bound_moiety="CRISPR forward-strand guide 
#10218402 
                      TATGAATATTATGCCAGTGAAGG" 
                        /note="{"n_genic_offtargets": 22, "n_offtargets": 349, 
                      "score": "55%", "sequence": "TATGAATATTATGCCAGTGAAGG"}" 
ORIGIN 
               1 atgaaactgt taaagatgga gtcaccttat acctgctaca gtcggtcaat 
cagttactac 
        61 tgacagctac gaaagaacga attgacttct tacctcacta tgacacactg 
gttaaaagtg 
       121 gcatgtatga atattatgcc agtgaaggac aaaatccttt gc 
  // 
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Appendix 13. The primers used in this thesis (Table 2 to 7) 
Table 2. Mouse clustered Pcdh primer list 
Group Name Forward primers Reverse primers 
Pcdha Pcdha1 CGCAGAAGTAAATTCAGATCTTTCTGG CGTATTTAAAGGTCCAGCTGTTGC 
 Pcdha2 CGGAATCAGCAGAAGAGAGACAACC Same as above 
 Pcdha3 GGTTGGAGACATTGATTTCTCCATC Same as above 
 Pcdha4 GCCCCAGTTTATCTGATTCAAGG Same as above 
 Pcdha5 TCAGGGACCCAGCTCTACAGAG Same as above 
 Pcdha6 TCCTCCTTGTCCGGTTGTGG Same as above 
 Pcdha7 TCAGGGTCCCAGCTCTACAGATAAC   Same as above 
 Pcdha8 CCCGGTCTACCTCCATGTCC Same as above 
 Pcdha9 TGGCCGAAGTGGGAATGG Same as above 
 Pcdha10 CCTCCTGGTTTGGGTTCTGG Same as above 
 Pcdha11 CCCAGCCTACCTCCCAACC Same as above 
 Pcdha12 GAAAGGCAGGTAGAACATTTGAAAGAG Same as above 
 PcdhaC1 CATTCAAATGTGGAAGCCGTG Same as above 
 PcdhaC2 ACACAGGGGCCCAGACAGG Same as above 
Pcdhb Pcdhb1  AGGTCTGCAGAGGCAGGATACC GTGAGGCCGTAGTGGAGAGAGC 
 Pcdhb2  GGGCACACCCAGGCTAACAG GGAATGGAGGGCCAACTGTG 
 Pcdhb3  CGGTCCGTGAGAACAACAGC GCCCACATGGAACTCGAAGG 
 Pcdhb4  ATCCTCACCGCTCTGGATGG GGGGGAAATTCTCGGGAACC 
 Pcdhb5  ATGATCCGGATGTGCTCACG AGCCACCCAGAGAGGGTTCC 
 Pcdhb6  GGCTACTTGGTGGCTCACTTGG CACATAGTGCTTCGCGATCTGG 
 Pcdhb7  GCCGGGCACTCTGTTACCAC TCCTGACCTCGGTGGAGACC 
 Pcdhb8  TCAGGGTTGGGGAACTGACC CACAGTGCTTCGCGATCTGG 
 Pcdhb9  GTGCAGAAGGGCCAGAGAGG AGTCGCCCCTCAGACACACC 
 Pcdhb10  TCGTGCTCTACCCGTTGCAG TGGGTGCATCTCGCTCACTC 
 Pcdhb11  AGGACAATGGCGAGCCTCAG CGAAGACACGGAAGCCAAGG 
 Pcdhb12  ACCCAGAGCTGGTGCTGGAC TCCGTGGCAGAGACCATGAC 
 Pcdhb13  ATGCTGAAGATGCGCTCACG CCGCTGACATCCACCAGATG 
 Pcdhb14  CTTCCAGGTGCCGTGTTTCC CTGTTCCTCCCGGTCCAGTG 
 Pcdhb15  TTCCAGGGAGCTGCTTGAGG CCAGCCCCAAATCCTTTGC 
 Pcdhb16  GACGCTGGGACCTTTTCTGG ATGGGACTCCCCATGTCTGC 
 Pcdhb17  CAGTCCCACCGGTTCTCTGG CTGGGGCATTGTCATTCACG 
 Pcdhb18  TCAGCCCTACCTGCCTCTGC TACCGCTGACGTCCACAAGG 
 Pcdhb19  GGACAAGGCGCTGGATTACG CAAACTCGGGGGAGTTGTCG 
 Pcdhb20  CATCACTGCCTCCGACATGG TCTGGGTCCTGAGCCGGTAG 
 Pcdhb21  GAATGCCTGGCTGTCGTTCC GGGTAGAGTCGTGCGCAACC 
 Pcdhb22  CCACGTGAGTGCCACAGACC TGAGCAGCTGGAACGACAGC 
Pcdhg Pcdhga1 GCTTGAAGATAAAGAGGAAATATTTTCTCAG CAGGGTAGAGCTCCCATCAGC 
 Pcdhga2  CTTGATGATAAAAGAGAAGAAACCCCTC Same as above 
 Pcdhga3  AGAAGACCCCACGCTGCC Same as above 
 Pcdhgb1  ACGTGGCACCAGAGGTTGC Same as above 
 Pcdhga4  TGATCCTCTCCTGGTATCTCAAGAC Same as above 
 Pcdhgb2  GCTCCTCAGGACCTCCTCTGC Same as above 
 Pcdhga5  CAAAGAAGAGCCCGGAGATGC Same as above 
 Pcdhga6  GCAAAGAGGAAGACTCTCTTGATCAG Same as above 
 Pcdhga7  AGGGTGAAGCCCCAAGTTCC Same as above 
 Pcdhgb4  AGCGGGGGCCTTGTTTCC Same as above 
 Pcdhga8  TTTCCGCAGCCCAACTATGC Same as above 
 Pcdhgb5  GTCATCTGGGGCCTTGTTTCC Same as above 
 Pcdhga9  CTATTGATGACACTCCTTTGGTTCC Same as above 
 Pcdhgb6  GTTGGGCAAACGGGAAAGG Same as above 
 Pcdh-γa10  AAGACGCTCCTTTGGTGCC Same as above 
 Pcdh-γb7  CTCCTGGTGTTGAAGCAGACG Same as above 
 Pcdhga11  TAGGCAAATGTGAACCGACAG Same as above 
 Pcdhgb8 TCCGCGAGACCTTTGTACGG GGCCAGGTGCCAGTTTCATC 
 Pcdhga12  AGCCTCTTTTACCATCGGGTG CAGGGTAGAGCTCCCATCAGC 
 Pcdhgc3  CACGCTGCGAAGTTGTGATCC Same as above 
 Pcdhgc4  TTGGCTTCTGCGCCTACTCG Same as above 
 Pcdhgc5 TTCAGCAGCCCTCAGCCTTG GGCCAGGTGCCAGTTTCATC 
 Actb ACCCAGGCATTGCTGACAGG ATGGAGCCACCGATCCACAC 
 Rala1 GGTCAAGGAGACACTCAGGCATT GGCTGGGGTTACACAGGGAACTC 
 Rala3 AAACAGAGCTGACCAGTGGAACG TCCATCTTTCTGGCTCGTATT 
 Pcp2 GTGGCCCTGCTCCAGAGATG TGAGGGTCCCAGGTCGTTTC 
 Smchd1  CAGTATCGCACTGCTCGTTACAGGC TGCGCACAGGAGTCATTCCG 
 Cre CACCCTGTTACGTATAGCCG CTAATCGCCATCTTCCAG 
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 Smchd1SNP GGAAGTTGTGGATGAGTCAGACA ACCTCACCTTACAGTGGACGAT 
 
Table 3. Human PCDHA primer list 
Group Name Forward primers Reverse primers 
PCDHA PCDHA1 TTCAGCCCAGGCCTATCTCC TGCTGTTGACACCCGCACCG 
 PCDHA2 CGGAATCAGCAGAAGAGAGACAACC TGCTGTTGACACCCGCACCG 
 PCDHA3 GCCCTAGCCTTCCTCCTTGTCC TGCTGTTGACACCCGCACCG 
 PCDHA4 GGCCTTCAGCCCCAGTTTACC TGCTGTTGACACCCGCACCG 
 PCDHA5 AGGGTGTGCTCTGGGGAAGC TGCTGTTGACACCCGCACCG 
 PCDHA6 CCCCAGCCTTTCACCTTGTCC TGCTGTTGACACCCGCACCG 
 PCDHA7 GCCTTCCTCAGGGTCCATCC TGCTGTTGACACCCGCACCG 
 PCDHA8 CCTGCCTTCCTCCTGATCTGGG TGCTGTTGACACCCGCACCG 
 PCDHA9 CGGGAGAACCCTCTGCTTCC TGCTGTTGACACCCGCACCG 
 PCDHA10 GACGGGGAAGATCAGTCTATTGG TGCTGTTGACACCCGCACCG 
 PCDHA11 GGGGAAAGACAGGAGCCAGGG TGCTGTTGACACCCGCACCG 
 PCDHA12 CCAAGCCTTCAGCTGTCTCG TGCTGTTGACACCCGCACCG 
 PCDHA13 GCAGAGGGAACAGGCCAGAGG TGCTGTTGACACCCGCACCG 
 PCDHAC1 ACCTGCGAAATCTTGCCACTGG TGCTGTTGACACCCGCACCG 
 PCDHAC2 GACAGGACCAGGGCCTTCGG TGCTGTTGACACCCGCACCG 
Control RALA TGGGGAGGAAGTCCAGATCG TGCTGTTGACACCCGCACCG 
 SMCHD1  TTCACCAAAGGTTGAGACGAC TGGCCTCTTCTCTCTGTCACC 
 
Table 4. PrimeTime and Taqman probes 
name sequence 
Pcdha /56FAM/ACCTGAGGC/ZEN/AGGAGAGGTG/3IABkFQ/ 
Pcdhg /56FAM/TGCAAGCCA/ZEN/TGATCTTGGCC/3IABkFQ/ 
Rala1 /56FAM/TTCACAGAC/ZEN/TAGGCCATGTG/3IABkFQ/ 
Rala3 /56FAM/AGACGTCTG/ZEN/CTAAAACGC/3IABkFQ/ 
Actb /56FAM/CAAGATCAT/ZEN/TGCTCCTCCTG/3IABkFQ/ 
Pcp2 /56FAM/CCGCATGGA/ZEN/CGACCAGCGT/3IABkFQ/ 
RALA /56FAM/TGGGCAGGA/ZEN/GGACTACGC/3IABkFQ/ 
PCDHA /56FAM/ACGGGCTGG/ZEN/TCCAGGAGGG/3IABkFQ/ 
Smchd1 MOMF /56FAM/ACCTCACCTTACAGTGGACGAT/3MGBNFQ/ 
Smchd1 MOMF1 /56VIC/CAGCTTGGTTGTGCTGT/3 MGBNFQ / 
Smchd1 MOMF2 /56FAM/CAGCTTTGGTTATGCTGT/3MGBNFQ/ 
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Table 5. Guide sequence for CRISPR knockout of SMCHD1 
 
Guides in Exon 3 of SMCHD1 
Guide #1 93 ACTGATTGACCGACTGTAGCAGG 
Guide #2 88 GACCGACTGTAGCAGGTATAAGG 
 
Guide #1 oligos 
SMCHD1 Ex3 No1 F 5’-CACCGGCTGATTGACCGACTGTAGC-3’  
SMCHD1 Ex3 No1 R 5’-AAACGCTACAGTCGGTCAATCAGCC-3’ 
 
Guide #2 oligos 
SMCHD1 Ex3 No2 F 5’-CACCGGACCGACTGTAGCAGGTATA-3’ 
SMCHD1 Ex3 No2 R 5’-AAACTATACCTGCTACAGTCGGTCC-3’ 
 
Table 6. Surveyor assay primer list 
Group Name Forward primers Reverse primers 
Human Exon 3 Target 1 TGAATGGAAGGAAGTATTTGTGC GAAGGAATGGGATACGTAATCAGG 
 OFF 1 No.1 TCCATGGCCCACTCAAGACC ACCGAAACAACTTCCAGCCC 
 OFF 1 No.2 TCGGCACTTGAATTCCTGGC AACTCCCTTCCACCCTTGCC 
 OFF 1 No.3 GTGGGGATGAGACTTGGGGC TCTCCCTGGTTTCCTCCTGC 
 Target 2 TGAATGGAAGGAAGTATTTGTGC GAAGGAATGGGATACGTAATCAGG 
 OFF 2 No.1 CATTTGGTGTGCTTCAGTCTTG TGCCAACAGTTTCATAGTGCTAG 
 OFF 2 No.2 ACCTCACCCACTTCTCCAGC GCTAGATCTGACAGTTCCTTGGG 
 OFF 2 No.3 GCTCACATCATCTGCTGCCC CACTGCAAGGGAAGGTGTTATGG 
 
Table 7 Primers for 5C assay  
Forward primers 
Name Sequence 
PCDH_ECORI_1 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGATATAGTGTGGCCCTGCAGGTACAGGAA 
PCDH_ECORI_2 CCATCTCATCCCTGCGTGTCTCCGACTCAGCGTTCCGGACCGTCAGGCGACGCTTTCGAA 
PCDH_ECORI_3 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGGTTTCCCAACACTCACACACTGGTAGAA 
PCDH_ECORI_4 CCATCTCATCCCTGCGTGTCTCCGACTCAGAACCAACTCAAACTGGCTCAACTAATTGAA 
PCDH_ECORI_5 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTGTAGAAAAGGTTTCCTCTAGAACTGAA 
PCDH_ECORI_6 CCATCTCATCCCTGCGTGTCTCCGACTCAGATAGAAAATGCTTGAGTGTACATTGGAGAA 
PCDH_ECORI_7 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGGTATAATCATAGTGGCAACAGCCTTGAA 
PCDH_ECORI_8 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCATCTAGGGAGCCATGTGATGAGAAAGAA 
PCDH_ECORI_9 CCATCTCATCCCTGCGTGTCTCCGACTCAGGATAGACCACAACAGCCTTTGGACCCAGAA 
PCDH_ECORI_10 CCATCTCATCCCTGCGTGTCTCCGACTCAGCAATTTAGTCCTTATCACAGACATAGTGAA 
PCDH_ECORI_11 CCATCTCATCCCTGCGTGTCTCCGACTCAGTGTCTGGACACATTGCTCAATATCAGAGAA 
PCDH_ECORI_12 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTTGGTGCCCTCCCTGTGGTAATAAATGAA 
PCDH_ECORI_13 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTGGATGCCCAGTGATTTTACATGTCAGAA 
PCDH_ECORI_14 CCATCTCATCCCTGCGTGTCTCCGACTCAGAATATTTATTCCTGAATCTAGACTCCTGAA 
PCDH_ECORI_15 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAACAATTTCCTGATGCCATTAACCTTGAA 
PCDH_ECORI_16 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTGACCGTTAAGCAGATTAGATAACTTGAA 
PCDH_ECORI_17 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAAACGCCCACTTCCAAATGCGGCGAGAA 
PCDH_ECORI_18 CCATCTCATCCCTGCGTGTCTCCGACTCAGATATTACAAATGAAATGGGTGAAAATGGAA 
PCDH_ECORI_19 CCATCTCATCCCTGCGTGTCTCCGACTCAGGACAACAACGATAATGTCCCAGATTTGGAA 
PCDH_ECORI_20 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCTAGGCCACTGTCAAAGTCATTGATTGAA 
PCDH_ECORI_21 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTCTCATGATTACTTCATGCTAGATGTGAA 
PCDH_ECORI_22 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGGGAATGAACGATTTCTGGGACTCTGAA 
PCDH_ECORI_23 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGCATTATATGTATGCATGATAAATGTGAA 
PCDH_ECORI_24 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCTATTTCGAGCCATATGGGAGATTCTGAA 
PCDH_ECORI_25 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAACATTACCCTTATGAATTTAGATGAGAA 
PCDH_ECORI_26 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCTACATACAAGATAAAACTCTTCATGGAA 
PCDH_ECORI_27 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAAACCCTGTCCTACTTTATGGTGCTGGAA 
PCDH_ECORI_28 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTTTTTCATGAGGCCACCTTAACAACTGAA 
PCDH_ECORI_29 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTTTAAGGATCCTTTGAAACTTCTTAAGAA 
PCDH_ECORI_30 CCATCTCATCCCTGCGTGTCTCCGACTCAGGCTCTACAGCTCTGGCTTCTCCTCCTCGAA 
PCDH_ECORI_31 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTGTAGCCTGGAACTGCTAAGCTCAAAGAA 
PCDH_ECORI_32 CCATCTCATCCCTGCGTGTCTCCGACTCAGATATTCTTTGTCTTAAAGTTCTGCATGGAA 
PCDH_ECORI_33 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTTGTCACTTTTCTTTTACCGTTTTTAGAA 
PCDH_ECORI_34 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAAAATTCAGCACAATATGTATCAGTGGAA 
PCDH_ECORI_35 CCATCTCATCCCTGCGTGTCTCCGACTCAGGATGATGGGGAACATGTAAAGACCAGTGAA 
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PCDH_ECORI_36 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATACTATCCCTCTAGGTGCAGCTCAGAA 
PCDH_ECORI_37 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAATTAAGAGTGAAATTTATAGGCCTAGAA 
PCDH_ECORI_38 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTTAATTTGTTGATCTGAGTGGGGCTGAA 
PCDH_ECORI_39 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTATTTATCTTCCATTTGAATGATATAGAA 
PCDH_ECORI_40 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGAGTGGATCCCTGTAGTCCCCATTAGAA 
PCDH_ECORI_41 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGAAGGGATGTGCTAGTTCAGGCCTTTGAA 
PCDH_ECORI_42 CCATCTCATCCCTGCGTGTCTCCGACTCAGTACATTCAGAGGAAAGTATTCCACCCAGAA 
PCDH_ECORI_43 CCATCTCATCCCTGCGTGTCTCCGACTCAGATTATGATTTAGAGTCAGATTTGAGTTGAA 
PCDH_ECORI_44 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCACAAGGCTGATAGCCTGGTGGCCAGAA 
PCDH_ECORI_45 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCGGTGTGCGCCTGGCCTCACTGATGAA 
PCDH_ECORI_46 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTTGCTTGGGAGTCAGTGACCCTTTCTGAA 
PCDH_ECORI_47 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTACCAATAATTTAGCGTGCATCTTCAGAA 
PCDH_ECORI_48 CCATCTCATCCCTGCGTGTCTCCGACTCAGCAATTCCCCTAAACTCTCCTCAAAAGAGAA 
PCDH_ECORI_49 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGTTTATTCCATTCTCTATGGCTAATAGAA 
PCDH_ECORI_50 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCCCCAGAGGACTGTGGGTAGGAAGGAGAA 
PCDH_ECORI_51 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAGAAGGAAGTCTTTTAAGGTTTCCCAGAA 
PCDH_ECORI_52 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCCTTTAGAAACTAACAGTCTAAAAATGAA 
PCDH_ECORI_53 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCAGTTTTAGCTAAGCGAGAGCCCCAGAA 
PCDH_ECORI_54 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGTTTCTCCATGTTTATGCTAGGCTTTGAA 
PCDH_ECORI_55 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTATGGTAAATCGCTCACTTTCCTTAGAA 
PCDH_ECORI_56 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTTACTAGTTTGAAACCGAGTTAGACGAA 
PCDH_ECORI_57 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCCCTTTGTAATCAAACCTACATTTGGGAA 
PCDH_ECORI_58 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCACGCTGTGGATGGTGACTCAGGTCAGAA 
PCDH_ECORI_59 CCATCTCATCCCTGCGTGTCTCCGACTCAGATATATCTATAACCCTTTCTCCAGTTGGAA 
PCDH_ECORI_60 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGGCTATGAGACAGTAGTGATTAACTGGAA 
PCDH_ECORI_61 CCATCTCATCCCTGCGTGTCTCCGACTCAGTAAGGAACCTTTTCAGGTATTCACTGAGAA 
PCDH_ECORI_62 CCATCTCATCCCTGCGTGTCTCCGACTCAGTGAACACACTGATCATGAGTTATTAGGGAA 
PCDH_ECORI_63 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCCAGCAGTCTATCAATAAATCCACTGAA 
PCDH_ECORI_64 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCTGTTCCTAAACATTAAACTTAATTAGAA 
PCDH_ECORI_65 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAGAAGTAATTAAAACTCAAGAGGTGAGAA 
PCDH_ECORI_66 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAGTAAATAATTATGAATCGGCTCTCAGAA 
PCDH_ECORI_67 CCATCTCATCCCTGCGTGTCTCCGACTCAGATGTACCATTCAGGATACTGAACTGCAGAA 
PCDH_ECORI_68 CCATCTCATCCCTGCGTGTCTCCGACTCAGATTTGTCAAAGGAACTTGAGTGAGTGTGAA 
PCDH_ECORI_69 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTTAGGCTAGTGTAAATTCTATCCTGTGAA 
PCDH_ECORI_70 CCATCTCATCCCTGCGTGTCTCCGACTCAGCAGCCTCCAAAACTACACTATCACTCCGAA 
PCDH_ECORI_71 CCATCTCATCCCTGCGTGTCTCCGACTCAGGCAAATCCCAGTTTCAGGAAGAGCTTTGAA 
PCDH_ECORI_72 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTCCATGAATATCAGGAAAAGGCATAGAA 
PCDH_ECORI_73 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTACTAACTAGTGTTGCCACGTTTTGGAA 
PCDH_ECORI_74 CCATCTCATCCCTGCGTGTCTCCGACTCAGTGGACTCCAACATGAAGAAGCTAGGGAGAA 
PCDH_ECORI_75 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTCCTGAGACGGTAGTCTCTATCTTCCGAA 
PCDH_ECORI_76 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCCTGAAAGAAAATTACTACCAGGTTAGAA 
PCDH_ECORI_77 CCATCTCATCCCTGCGTGTCTCCGACTCAGAACCTTCCCACTCTAATTCACAGCAGTGAA 
PCDH_ECORI_78 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTCAGAGATATAAATGACCACGCCCCGGAA 
PCDH_ECORI_79 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTCCAAGATGTAAATGACCATGCCCCAGAA 
PCDH_ECORI_80 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCTGACAACAGGTCGTGATAAATCATAGAA 
PCDH_ECORI_81 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCAGCCTTGCTTCGCTGAGTAGGAAAGGAA 
PCDH_ECORI_82 CCATCTCATCCCTGCGTGTCTCCGACTCAGGCAAAAGTAAGTAACCATCTAAATATTGAA 
PCDH_ECORI_83 CCATCTCATCCCTGCGTGTCTCCGACTCAGTACCGGGGACAAATCATTCTTGTTGCAGAA 
PCDH_ECORI_84 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCTATGCATTTTCTTACGCCACTGAAAGAA 
PCDH_ECORI_85 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGGTGTGAACCGTCCTCCCAGGAAGCTGAA 
PCDH_ECORI_86 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCTCTCATTTCCGGGTTCTAATCCATGAA 
PCDH_ECORI_87 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCATCATTTTCCAACTCTGTTGCTGAGAA 
PCDH_ECORI_88 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCTCTGTATGATGGTGAAAAGACCAGAGAA 
PCDH_ECORI_89 CCATCTCATCCCTGCGTGTCTCCGACTCAGATTTACTTATGTATTCTTAGTCTTTGTGAA 
PCDH_ECORI_90 CCATCTCATCCCTGCGTGTCTCCGACTCAGACTCTGACGGGAGGTTCCGAGACAAATGAA 
PCDH_ECORI_91 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGCTTACAATTGTCTCAGAAACACTATGAA 
PCDH_ECORI_92 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAGGACTTTTTGGAAAATCTACAGTCAGAA 
PCDH_ECORI_93 CCATCTCATCCCTGCGTGTCTCCGACTCAGCATTAGATTCCTCATGTTTAAGGTGGGGAA 
PCDH_ECORI_94 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTAGTCTTTAAAATACTCTCTGAGTCTGAA 
PCDH_ECORI_95 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGTGACCATATCGTCGATTACAAAGAGAA 
PCDH_ECORI_96 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAAGACTGGCGAGGCTCCGGGACAAATGAA 
PCDH_ECORI_97 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTCATCACTTACCAGCCCTATTCCCGAGAA 
PCDH_ECORI_98 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTTTTTTTTAACCCTTTAGTAATCTTGAA 
PCDH_ECORI_99 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCCTCAGCAGCTTCAGCTTATGCCCCAGAA 
PCDH_ECORI_100 CCATCTCATCCCTGCGTGTCTCCGACTCAGGCTGTCTAATAACACCTGATTGCCCTTGAA 
PCDH_ECORI_101 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTATGGTAACAGTGATGGCTACAATTGGAA 
PCDH_ECORI_102 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGAACTCATGCTGCAGGGAAATTATGTGAA 
PCDH_ECORI_103 CCATCTCATCCCTGCGTGTCTCCGACTCAGAATCATGAAAAATTTCACACTGGAGAAGAA 
PCDH_ECORI_104 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTTCCACGGAGGATTGCTCCAGGCTGGGAA 
PCDH_ECORI_105 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTGGTGATTACTTTTGACTGCAATCGAGAA 
PCDH_ECORI_106 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGTACGCTCCGCAAGGGTCTTTGTGCGAA 
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PCDH_ECORI_107 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTTCACTGGTGGTGAACTGGGATAGTGAA 
PCDH_ECORI_108 CCATCTCATCCCTGCGTGTCTCCGACTCAGACACACTAAGTTAAATCAAAATAACCAGAA 
PCDH_ECORI_109 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTGTATTGTAAGAACTATCATAACAGGGAA 
PCDH_ECORI_110 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATCTAAGATGTAAATTATGGGTAATGAA 
PCDH_ECORI_111 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCCTTCTTACTGACTTTTTGGAATCCTGAA 
PCDH_ECORI_112 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCGAAAGCAAGCTGCTGCGAGCACTCTGAA 
PCDH_ECORI_113 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGGATTAGCTCCAACCAAGTCCAGAAGGAA 
PCDH_ECORI_114 CCATCTCATCCCTGCGTGTCTCCGACTCAGTAATTCGTTCAGTATATCATATGTCTGGAA 
PCDH_ECORI_115 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAAGATGCCCTCACTTGAATAGACCCTGAA 
PCDH_ECORI_116 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTAGCATGTAACTTTTTCTGATCTATGAA 
PCDH_ECORI_117 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAACAGCTCTGCTTTCCTCTCCTTGTGGAA 
PCDH_ECORI_118 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCCTACTTCTGGATGACTCTCCAGTCAGAA 
PCDH_ECORI_119 CCATCTCATCCCTGCGTGTCTCCGACTCAGACCAGTCCGTCGTAGGAAACTGGAACCGAA 
PCDH_ECORI_120 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGCGGAAGGAAACTTGAGTGTGCACTAGAA 
PCDH_ECORI_121 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGACAAAATATCACAGCTATTTCAGTTGAA 
PCDH_ECORI_122 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTTTGTGCTTTCATTTAGGTTCTGTGAGAA 
PCDH_ECORI_123 CCATCTCATCCCTGCGTGTCTCCGACTCAGATAAAGGTGACAATGAGTGTCTGTCTAGAA 
PCDH_ECORI_124 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCCAGGAAGCCAAATAGACTTTACATAGAA 
PCDH_ECORI_125 CCATCTCATCCCTGCGTGTCTCCGACTCAGACAAATAGAATTTAACTCCAGTTTACAGAA 
PCDH_ECORI_126 CCATCTCATCCCTGCGTGTCTCCGACTCAGCAGCCAATCCATTATCCAGTTTCTTATGAA 
PCDH_ECORI_127 CCATCTCATCCCTGCGTGTCTCCGACTCAGACATAGGCAATTACATGTTTTAACAGAGAA 
PCDH_ECORI_128 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTACAGAACCGGGCAAATCTTTAGTCTGAA 
PCDH_ECORI_129 CCATCTCATCCCTGCGTGTCTCCGACTCAGGATTGCCTATGACCCTGATAGCAATGAGAA 
PCDH_ECORI_130 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCGAAGAATATATACATTTCGGAGACCGAA 
PCDH_ECORI_131 CCATCTCATCCCTGCGTGTCTCCGACTCAGCACTTCTCTCTCTGATCAGATTTTGGAGAA 
PCDH_ECORI_132 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTCAACGTGTCCAGTGAGGACTTTGCAGAA 
PCDH_ECORI_133 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTCTGCAGAAGATCCTGATATTAGTATGAA 
PCDH_ECORI_134 CCATCTCATCCCTGCGTGTCTCCGACTCAGCATCTAGGGATAGGATTTATACTTGTGGAA 
PCDH_ECORI_135 CCATCTCATCCCTGCGTGTCTCCGACTCAGTGCTACCTGGGTATTGGCTTCTAAAAGGAA 
PCDH_ECORI_136 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTACATATGCAGTATATCTTTGGGATGAA 
PCDH_ECORI_137 CCATCTCATCCCTGCGTGTCTCCGACTCAGATCTAAAATTTTACTTGCCAACATATAGAA 
PCDH_ECORI_138 CCATCTCATCCCTGCGTGTCTCCGACTCAGCATTTTCCAGCCCTATGTGACCATCAAGAA 
PCDH_ECORI_139 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTTGACAGTGCCATTCACAGAGACAGTGAA 
PCDH_ECORI_140 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTGAATAAATTCATTCTAGGGCTGGTAGAA 
PCDH_ECORI_141 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCCCAGCTGCTCATTTCAATCTGGTATGAA 
PCDH_ECORI_142 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGCAGGCCATACACTGGCTTTGAAGCAGAA 
PCDH_ECORI_143 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTCGACGAGCCTCAGTTTCCCCATCTGGAA 
PCDH_ECORI_144 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTTTCCTATCATTTTATTATTTCTTTGAA 
PCDH_ECORI_145 CCATCTCATCCCTGCGTGTCTCCGACTCAGTAGTTCCACAGGAAGAGGCTTAAAAGGGAA 
PCDH_ECORI_146 CCATCTCATCCCTGCGTGTCTCCGACTCAGATTCAAGAGAATTAAAAATTCTTAAAAGAA 
PCDH_ECORI_147 CCATCTCATCCCTGCGTGTCTCCGACTCAGTATTAATTCTTCATTAAATGTTGGGTGGAA 
PCDH_ECORI_148 CCATCTCATCCCTGCGTGTCTCCGACTCAGGCTACTGATAACATGATACAATGTGGAGAA 
PCDH_ECORI_149 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAATGAAAAACAATAAGACTGACAGTGGAA 
PCDH_ECORI_150 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTAGGATAGAGGACAAAATCAGTAGAAGAA 
PCDH_ECORI_151 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAAAAGGTTTTGCCAGTAATGGACCATGAA 
PCDH_ECORI_152 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGACTTTGGAGTCACTGTTTGGAGTCTGAA 
PCDH_ECORI_153 CCATCTCATCCCTGCGTGTCTCCGACTCAGTTTTACAGAACAATCTTTGAATTTAAGGAA 
PCDH_ECORI_154 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCAAATGAATTTAAGTCTGTCCATCTTGAA 
PCDH_ECORI_155 CCATCTCATCCCTGCGTGTCTCCGACTCAGATATTAAAAAGTTCCATGTTAAGCCTGGAA 
PCDH_ECORI_156 CCATCTCATCCCTGCGTGTCTCCGACTCAGTAAAGGCCAACATCCAGGATAAGAAAGGAA 
PCDH_ECORI_157 CCATCTCATCCCTGCGTGTCTCCGACTCAGGAGGCTCCCTCTGTTTGCTTAGTAACAGAA 
PCDH_ECORI_158 CCATCTCATCCCTGCGTGTCTCCGACTCAGGGCAACAGAGGGTCATAATAGGATCTTGAA 
PCDH_ECORI_159 CCATCTCATCCCTGCGTGTCTCCGACTCAGCCTTTGTTCTACTGCTCCCCATCTCATGAA 
PCDH_ECORI_160 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCGCTCTGGAGTTTAATTTCCTAGTTCGAA 
PCDH_ECORI_161 CCATCTCATCCCTGCGTGTCTCCGACTCAGTCCACCAGAGGAGAGATTCGGAGGCCTGAA 
PCDH_ECORI_162 CCATCTCATCCCTGCGTGTCTCCGACTCAGCACAGGCATCTTTTTTAACTCTCATAAGAA 
PCDH_ECORI_163 CCATCTCATCCCTGCGTGTCTCCGACTCAGCTGTGGAGGGGTCAGGGCAAGAGCAGAGA 
PCDH_ECORI_164 CCATCTCATCCCTGCGTGTCTCCGACTCAGAAGAACTGAATCATAGGTTGGGTCTGAGAA 
PCDH_ECORI_165 CCATCTCATCCCTGCGTGTCTCCGACTCAGAGGCCAGTGACCTCCAATTCCAAGGGTGAA 
PCDH_ECORI_166 CCATCTCATCCCTGCGTGTCTCCGACTCAGAATGAAGCAATGAGGAGATGTGGAAGGGAA 
PCDH_ECORI_167 CCATCTCATCCCTGCGTGTCTCCGACTCAGGTGACCCTCTCCCTTCGTTCCCTTCCTGAA 
Reverse primers 
PCDH_ECORI_REV_1 /5Phos/TTCCTTTTGGTTAAGAGCACTCAAGACACTATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_2 /5Phos/TTCAGTAAATGGTATCACATATGGGCAATTATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_3 /5Phos/TTCCCACCACCTCTTACCAATTCCTAAATAATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_4 /5Phos/TTCCATCTGTGAGTATCTGACAAAGAGTCAATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_5 /5Phos/TTCCCCTCCAGCTGAGATGTCTCTTCTGAGATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_6 /5Phos/TTCCTGGCCTCAAGTGATCTGCCTGGGAGTATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_7 /5Phos/TTCCTGGGGAAGTGCAGGCTATAGCCCACCATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_8 /5Phos/TTCTGCAGTTTACTCAGTATTTATTTAGGTATCACCGACTGCCCATAGAGAGG 
PCDH_ECORI_REV_9 /5Phos/TTCCCCTGGTCTAACTTGGATAGAATATGCATCACCGACTGCCCATAGAGAGG 
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PCDH_ECORI_REV_10 /5Phos/TTCTGTCTTCCTCTGTTACCATGGTCCTGTATCACCGACTGCCCATAGAGAGG 
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